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Chapter I Aim of the Thesis 
The objective of this thesis was to investigate the suitability of vibrating mesh (VM) nebulization 
for the pulmonary delivery of sensitive pharmaceutical proteins.  
Vibrating mesh nebulization has proven to enable efficient, fast and  with the latest generation 
of inhaler devices  highly reproducible pulmonary delivery of small molecular drugs. These 
performance properties are very interesting for the pulmonary delivery of costly 
biopharmaceuticals and VM nebulizers have been used to nebulize a range of proteins. Detailed 
studies on the possible impact of VM nebulization on protein stability  an obligatory 
requirement and a major issue concerning all aerosol generating methods  have not yet been 
published though. Many of the proteins successfully nebulized with VM devices so far, can be 
considered rather stable (DNase, α1-AT, IL) [1]. Hence, the suitability of VM nebulization for 
the pulmonary delivery of more delicate pharmaceutical proteins has not been conclusively 
assessed. 
A major aim of this thesis was therefore a thorough characterization of VM nebulization in order 
to evaluate its feasibility to aerosolize liquid formulations of delicate pharmaceutical proteins. 
This included an investigation to identify forces causing protein degradation encountered during 
VM nebulization. Furthermore the influence of proteins and their formulations on nebulizer 
performance was examined. Based on the gathered data, procedures to mitigate respective 
detrimental forces were developed and evaluated for their efficiency (Chapter IV). 
Another objective was the integration of the nebulization process into formulation development 
in a high throughput fashion. A surrogate screening method was developed to predict protein 
stability after VM nebulization while consuming only a fraction of valuable time and API 
material necessary for actual nebulization. The method was evaluated for three different proteins 
(Chapter V). 
The initial stimulus and the pivotal and connecting element of this work was the assessment of 
feasibility for the local pulmonary delivery of the biopharmaceutical SM101 via nebulization and 
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the development of a respective formulation. SM101 is a soluble human FcγRIIB receptor 
currently in development by SuppreMol (Martinsried, Germany) for the treatment of primary 
immune thrombocytopenia and systemic lupus erythematosus and potential candidate for topical 
pulmonary delivery. A final objective was the evaluation of SM101 in vivo efficacy for the 
treatment of pulmonary type III hypersensitivity reaction. This included the identification of 
suitable aerosol delivery methods for administration to small laboratory animals and the 
development of a disease model applicable for SM101 efficacy testing (Chapter VI). 
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Chapter II Introduction 
1 Rationale for pulmonary delivery of biopharmaceuticals 
The rationale for pulmonary delivery of biopharmaceuticals can be ascribed to two different aims. 
On the one hand, systemic delivery through the lungs has been suggested to be a very promising 
non-invasive alternative to intravenous delivery of biopharmaceuticals featuring the unique 
combination of a highly disperse dosage form and a huge absorptive area directly interfacing with 
the blood circulation system [2, 3]. Additionally the level of metabolizing enzymes is reduced 
compared to the GI tract [4] and absorbed molecules do not undergo a first pass effect [5]. 
Accordingly, bioavailability for proteins was reported to be the highest for any non-invasive route 
[6]. While insulin has been a driving force for research in the field, the withdrawal of Exubera® 
has also demonstrated some of the difficulties accompanying this approach [7-9]. 
On the other hand, motivation for biopharmaceutical delivery to the lungs is the topical 
treatment of respiratory diseases. Direct access to the site of action allows for high local API 
concentrations while minimizing systemic exposure to the drug [10-12], making therapies more 
effective and safe. In 1996 Pulmozyme® (Dornase alfa, DNase) became available for the 
treatment of cystic fibrosis as the first inhaled biopharmaceutical. Unlike Exubera® it is also a 
market success with annual sales topping $600 million in 2011 and 2012 [13]. Local pulmonary 
delivery is an interesting opportunity for the treatment of respiratory diseases like CF, COPD, 
asthma or pulmonary fibrosis [14]. Various peptides and proteins are under development for the 
treatment of lung malignancies [15], lung transplant rejection [16], α1-antitrypsin deficiency 
(genetic emphysema) [17-20] or for pulmonary vaccination. An inhalative measles vaccination 
was reported to be superior to a parenteral vaccination in 4 million children [21]. 
Despite the advantageous biological situation and the successful example of Pulmozyme®, no 
other inhaled biopharmaceutical is approved to date. A selection of biopharmaceuticals in 
development for inhalation is listed in Table II-1. Many of the challenges of successful inhalation 
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probability of aerosol deposition in the lungs is determined by the diameter (d) of the generated 
aerosol particles and the breathing maneuver performed by the patient [74] (v = speed ~ 
respiratory flow rate; t = time ~ breath holding time), which both influence the forces relevant 
for aerosol deposition mechanics [10, 22, 75, 76]: 
 Inertial Impaction ~ d2 * v 
 Gravitational Sedimentation ~ d2 * t 
 Diffusion by Brownian motion ~ t / d 
Since breathing patterns differ substantially among individuals but are beyond control of common 
inhalers, pulmonary deposition of an aerosol is commonly predicted based on its particle size 
distribution [77-79] which is easily accessible by in vitro analytics. According to deposition 
models, it is assumed that particles in a range of 1-5 µm deposit in the small respiratory airways, 
while larger droplets deposit on the throat and conducting airways and smaller aerosol particles 
may be exhaled. These predictions might not be very accurate though [10] since they are based 
on deposition models of monodisperse environmental aerosols in healthy male subjects instead of 
more polydisperse pharmaceutical aerosols of higher density [10]. 
Various inhaler types have been developed to achieve pulmonary delivery and with them 
pulmonary delivery has been established for the treatment of respiratory diseases with small 
molecule drugs. Indications include asthma, chronic obstructive pulmonary disease (COPD) and 
other respiratory ailments like cystic fibrosis or emphysema. Apart from these common inhalation 
therapies, pulmonary delivery is also used in the treatment of RSV infections, tuberculosis, croup, 
primary pulmonary hypertension, influenza and schizophrenia [80]. Metered dose inhalers (MDI) 
and especially dry powder inhalers (DPI) are the dominant devices types for small molecule drug 
administration to the lungs. In contrast the only marketed inhaled biological  Pulmozyme®  is 
exclusively available for nebulization. Likewise, with a few exceptions, biopharmaceuticals in 
development for inhalation are designated for nebulization (see Table II-1). Otherwise, nebulizers 
are confined to treatments requiring frequent administration of large doses, e.g. in cystic fibrosis 
or for aerosol delivery to children and elderly patients. Nebulizers are employed during stationary 
treatments in hospitals and are the only possibility to administer aerosols to intubated patients. 
All prevalent device types have been available for 50 years or more and each type has its eligibility  
Introduction 
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Table II-2: Attributes of an ideal medical inhaler, taken from [81]. 
Reliable, reproducible and accurate dosing and particle generation 
Generation of small particles of 1-5 µm 
Simple use and handling 
Multiple dose capability 
Resistance to bacterial contamination 
Durability 
Cost effectiveness 
Product stability 
 
while none can combine all the properties proposed for an ideal medical inhaler by Wolff and 
Niven [81] (Table II-2).  
The shortcoming with respect to exact dosing is tolerated for treatment with small molecular 
drugs, as they usually possess a large therapeutic index and can achieve a safe and effective 
therapeutic treatment even if the pulmonary delivered dose is variable and contains only a 
fraction of the charged amount [10, 82]. Biopharmaceutical inhalation may require stricter rules 
in order to be successful. Especially the high costs of biopharmaceuticals call for a more efficient 
and less wasteful delivery. High potency and specificity may also make a better control over the 
deposited dose and the spatial distribution within different lung regions mandatory.  
An aspect of paramount importance for biopharmaceuticals is their delicate stability whose 
conservation is essential for biologic activity. Protein degradation can occur at any given stage 
including production, processing, formulation or shipping and storage. Many excellent and 
comprehensive reviews have been published that describe the diverse manifestations of protein 
degradation and elucidate various factors and influences provoking such [83-88]. These include 
elevated temperature, extreme pH, shaking and shearing stress, light exposure, freezing or drying 
which may results in physical or chemical protein degradation. Chemical degradation relates to 
alterations in the primary structure of protein, which among other mechanisms may be caused 
by deamidation, oxidation or hydrolysis. Physical degradation on the other hand, manifests as 
aggregation, adsorption or loss of secondary, tertiary or quaternary protein structure. 
Chapter II 
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Given the relative robustness of small molecular drugs, the impact of aerosol generation on 
molecular integrity has not been a major focus during the development or optimization of aerosol 
delivery devices but is of utmost importance for successful inhalation of biopharmaceuticals. 
3 Metered dose inhalers and dry powder inhalers 
The currently available inhaler device classes differ significantly in the requirements for the 
formulation of the biopharmaceutical to be delivered.  
In MDIs, the API is dissolved or suspended in a propellant such as HFA 134a which raises 
concerns regarding protein solubility and especially protein stability. Consequentially this 
approach is less promising for biopharmaceutical inhalation than DPI or nebulizer based delivery. 
Nevertheless, the feasibility of MDI suspensions for biopharmaceutical delivery was demonstrated 
with spray-dried [89] or lyophilized [90] BSA formulations as well as lyophilized nanoparticles 
containing lysozyme [91] or thymopentin [92]. Considering the high cost of biopharmaceuticals, 
a further disadvantage of pMDIs is their low lung deposition efficiency in the range of 10-20% of 
the metered dose [93, 94] and the significant inter- and intra-individual dose variability in the 
range of 40-80% [95-97]. When used without a spacer, up to 75% of the metered dose deposit on 
the oropharynx and may be swallowed. Furthermore, the complicated handling of pMDIs has 
been documented with reports of 76% of patients making at least one error in MDI handling [98]. 
Unlike MDIs, DPIs do not require coordination of breathing and actuation by the patient since 
particle disaggregation relies on the patients inspiratory flow rate instead of a propellant [1, 7]. 
This may prove unfavorable though for young children, elderly patients or patients with severe 
conditions or acute exacerbations when inspiratory flow may be too low for powder 
deagglomeration. Consequently, handling problems observed in 4-94% of the patients, depending 
on the DPI model used, were especially prevalent with young children [99]. Lung doses range 
between 10-30% [93, 100] and also underlie individual variations in a range of 8-47% [95-97].  
Biopharmaceutical delivery via DPIs requires the precedent drying of the API since it is usually 
initially available as a liquid drug substance. Protein stability is usually improved in the solid 
state wherefore DPI is considered a promising approach for biopharmaceutical delivery to the 
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lungs with some drug candidates being in clinical development (see table 1). Various techniques 
for protein drying and particle generation have been reviewed for pulmonary delivery [12, 101]. 
These include spray drying and lyophilization as were used for the insulin formulations of 
Exubera® and AFREZZA® respectively. Prior to its withdrawal, Exubera® was the first and 
only approved and marketed DPI for biopharmaceutical inhalation. AFREZZA® is one of only 
two inhalable insulin developments still active after Pfizer stopped Exubera® sales (the second 
being Adagio™ by Dance Biopharm based on nebulization). In the aftermath additional data on 
AFREZZA® was demanded by the FDA. In October 2013 Mannkind Corporation submitted the 
third new drug application (NDA) for AFREZZA®. A decision is expected in July 2014, after an 
FDA advisory committee had recommended to grant AFREZZA® approval in April 2014. 
On the downside, DPI development and manufacture is more complex and costly [1]. The 
formulation is a crucial determinant of deposition efficiency. Particles must be small for optimum 
lung deposition while at the same time the powder must be free flowing for disaggregation during 
inhalation [94]. However fine powders are cohesive and have poor flow properties [94]. The conflict 
is usually solved by the addition of large inert carrier particles which improve powder flowability. 
As a consequence, the maximum amount of API deliverable in a single inhalation is significantly 
reduced [102]. The amount of powder inhaled is limited since high powder doses may induce 
cough [1]. Humidity poses a problem for particle disaggregation and protein stability [103]. 
Several proprietary particle formulation technologies have addressed these problems by means of 
large porous particles that have advantageous aerodynamic properties and can significantly 
enhance the lung dose of a single inhalation [7] with reported lung deposition of 50% [104]. The 
already mentioned AFREZZA® is built on Technosphere® microparticles, made from fumaryl 
diketopiperazine (FDKP). Arcus® formerly known as AIR® are large porous particles made from 
PLGA generated by spray drying [104]. They were originally intended for the pulmonary delivery 
of insulin (Alkermes in cooperation with Eli Lilly) and are now developed as a pulmonary 
delivered Parkinson therapy by Civitas therapeutics. Finally the PulmoSphere® technology has 
gained FDA approval as part of Novartis’ TOBI podhaler in March 2013. These large porous 
particles are based on long-chain phospholipids [105]. Besides insulin, these large porous particle 
platforms have also been employed for the pulmonary delivery of other biopharmaceuticals like 
PTH [106], hGH [107], sCT [108], GLP-1 [109] and immunoglobulins [110, 111].  
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4 Nebulizers 
If protein stability permits the use of a liquid formulation, nebulizers are the device of choice for 
atomization, while the API may be formulated either in solutions or in a suspensions. Liquid 
formulations are usually available in early stages of biopharmaceutical development and 
nebulizers are readily available to atomize virtually any liquid formulation. Avoiding additional 
process steps like drying, formulation development for nebulization is usually simpler, less 
expensive and faster than for dry powder formulations, allowing for a faster progression to clinical 
trials. Nebulizers can be categorized according to the mechanism of atomization into jet, 
ultrasonic or vibrating mesh nebulizers. Factors relevant for protein degradation and inactivation 
depend on the underlying mechanism of aerosol generation. 
4.1 Proteins and the Air-liquid interface 
A feature inherent for any nebulizer regardless of its atomization principle is the generation of a 
huge air-liquid interface during dispersion of the bulk liquid into micron-sized aerosol droplets. 
Since proteins are amphiphilic molecules they have the tendency to interact with interfaces, 
which is often associated with protein adsorption, (partial) unfolding and aggregation.  
The very hydrophobic air-liquid interface is ubiquitous during protein manufacturing, processing, 
handling or storage [85, 112, 113] and stress testing involving a forced exposition to the air-liquid 
interface by agitation is routinely conducted during formulation development to predict protein 
stability. The extent of interface generated during such agitation experiments can be sufficient 
to provoke severe protein aggregation. Shaking of insulin elicited distinct aggregation [114]. IgG1 
antibody agitation led to the formation of soluble aggregates and subvisible particles [115, 116]. 
After shaking of recombinant factor XIII [117] and vortexing of human growth hormone [118] 
non-covalent, insoluble aggregates were formed to a large extent. 
Protein interaction with the air-liquid interface does not always result in protein degradation 
though [119]. The extent of protein aggregation and the formed species rather depend on 
individual protein characteristics determining its aggregation propensity and the probability and 
intensity of interface interaction. Aggregation propensity is ultimately governed by the primary 
structure [83], e.g. the proportion and distribution of hydrophobic residues and charge [120] in 
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the amino acid sequence, as well as secondary structure motifs [121]. The probability and 
intensity of interaction with interfaces is determined by the surface area available, surface tension 
and the surface activity of the protein [86, 122], which is influenced by various properties 
including molecule size, charge, hydrophobicity, stability and structural features [123]. 
 
Figure II-1: Mechanism of air-liquid interface induced aggregation. Protein models are reprinted (adapted) with 
permission from [124](Copyright (2012) American Chemical Society). 
Air-liquid interface induced aggregation is a mechanism involving multiple phases [87, 125] 
(Figure II-1). Initially monomer is adsorbed to the interface. Upon contact, molecules align to 
the interface thereby taking a flat confirmation [125, 126]. This involves at least partial unfolding 
of the monomer and hydrophobic residues which are normally buried within the native structure 
[127, 128] now interact with the gaseous phase. A monolayer of partially unfolded molecules is 
formed until allocation of the entire surface area available. This step proceeds fast [129, 130], 
occurring within one second for lysozyme [131] and can be speeded up with increasing protein 
concentration [125]. The exposition of hydrophobic residues is associated with an increase in 
surface activity and a decrease in biological activity [129]. 
In a subsequent step occurring at a much slower rate [129, 130], molecules may undergo changes 
in their secondary structure depending on the protein [125, 129, 132] and on the layer of 
adsorption. While lysozyme molecules located in the primary layer with direct contact to the 
interface take mainly antiparallel beta-sheet conformation, molecules in the secondary and 
additional layers interact with the hydrophilic residues of the unfolded molecules and assume a 
loose confirmation dominated by random coil [125]. 
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Aggregation may occur directly in the interface where the proximity of hydrophobic residues 
increases the probability of inter-molecular interactions. Additionally, non-native protein 
molecules may serve as nuclei for aggregation in the bulk solution after desorption from the 
interface [86, 87]. Aggregated species may be detected as oligomers and soluble aggregates or 
grow further to form insoluble aggregates including subvisible and visible particles. The respective 
pathways are very complex and differentiate from protein to protein and for different 
formulations [117, 133]. 
Partial unfolding in the interface also impacts on thermal protein degradation. Instead of the 
sharp transition between the folded and unfolded state observable during Tm measurements of 
bulk solutions, thermal unfolding of protein adsorbed to an interface occurs over a broad range 
of temperatures lower than the bulk Tm [128].  
It has been estimated that the nebulization of 10 mL solution with a jet nebulizer is associated 
with the generation of air-liquid interface greater than 24 m2 [134] or even 1500 m2 [135]. The 
plentiful emergence of air-liquid interface during nebulization is therefore presumably a major 
detrimental impact on protein stability.  
The actual extent of protein degradation by air-liquid interface effects or other detrimental 
factors present during nebulization also depends on the nebulizer type used. While dedicated 
studies are available for jet and US nebulizers, less information is available for VM devices. 
4.2 Aerosolization of Proteins by Jet Nebulizers 
Jet nebulizers apply the energy of a compressed gas  usually air  to atomize a liquid. The liquid 
is forced through a nozzle by means of a high-velocity air-stream (Venturi effect; see Figure II-2). 
The liquid entrained into the stream is sheared into a thin film which breaks up into primary 
aerosol droplets. This primary aerosol has a very broad droplet size distribution ranging from <1 
to 600 µm [134]. An array of baffles is used to filter all droplets of inadequate size so only droplets 
in the desired size range are delivered to the nebulizer’s mouthpiece. Larger droplets, which make 
up more than 97% of the primary aerosol [1, 26], are recycled into the fluid reservoir and undergo 
repeated atomization. On average each API molecule undergoes the process 10 to 15 times before 
leaving the device in an aerosol droplet [1, 136, 137].  

Chapter II 
14 
degradation observed during normal nebulization [134]. On the other hand, careful bubbling of 
air at 0.5 psig through G-CSF solution resulted in the aggregation of 10% of the protein. The 
detrimental impact of interface generation by bubbling was also reported by Maa et al. for hGH 
[119]. 
Applying DoE to examine the impact of jet nebulizer settings on protein degradation, Fängmark 
et al. found that low liquid feed rates and low relative humidity of the atomizing gas were 
negative influences on the stability of urease [144]. Decreasing the relative humidity of the 
atomizing gas from 70% to <5% increased urease degradation, which was attributed to an 
increased extent of solvent evaporation and resulting up-concentration of the protein and 
excipients. A low liquid feed rate, i.e. a low ratio of liquid volume per gas volume amplified both 
evaporation and generation of air-liquid interface as it was responsible for the formation of smaller 
aerosol droplets. 
Increased operating air pressure, which Niven et al. [135] associated with higher shear forces did 
not alter the extent of urease degradation in the primary aerosol [144] when there was no aerosol 
recirculation. The interaction of shear and air-liquid interface during protein denaturation was 
examined by Maa et al. [119]. Shearing experiments were performed with a rotor stator 
homogenizer. In the absence of any air-liquid interface, hGH remained intact even if homogenized 
at the highest shear rate. In the presence of an air-liquid interface, the extent of hGH aggregation 
increased with higher shear rates during homogenization. At the highest rate all hGH monomer 
content was lost after less than 20 minutes shearing. Higher shear generated more surface area 
by finer dispersion of the air in the liquid phase.  
Fängmark et al. also investigated the impact of aerosol recirculation for an IgG antibody and 
found that in the investigated range of up to 9 cycles, aerosol recirculation was the most 
detrimental factor of jet nebulization [34]. Repeated atomization multiplies all other stress 
encountered during jet nebulization.  
Solvent evaporation is a common phenomenon in jet nebulization [145, 146] and protein up-
concentration of up to 33% has been reported [25]. In parallel an up-concentration of excipients 
added for protein stabilization has to be expected. A detrimental impact of oxidation as could 
be promoted by radical formation from cavitation was ruled out [144]. 
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Figure II-3: Degradation profile of LDH (circles) and G-CSF (diamonds) during jet nebulization. Taken from [135]. 
Two different time profiles of protein degradation were observed for jet nebulization. For LDH 
[135] and urease [144] a log-linear degradation was reported, i.e. an equal fraction of protein is 
degraded with every recirculation (Figure II-3). In contrast, the time course of IgG [34] and 
G-CSF [135] degradation was marked by a rapid initial decline in native protein reaching a 
plateau after 5 to 10 minutes. Niven proposed that G-CSF aggregates formed at the air-liquid 
interface may saturate the interface and prevent migration of native molecules to the interface. 
Fängmark observed that the IgG degradation profile (compare G-CSF in Figure II-3) matched 
well with the temperature profile in the medication reservoir. He concluded that IgG degradation 
was mainly influenced by evaporation effects, apparently assuming that the extent of evaporation 
followed the same profile as the reservoir temperature. While a comparable temperature drop 
within the initial 2-4 minutes before reaching a plateau was also observed in two further studies 
[147, 148], neither found a corresponding plateau in concentration change. Instead concentration 
increased linearly throughout the entire nebulization. 
Beyond that, rhDNase did not show any signs of degradation during shear and interfacial stress 
[119] or jet nebulization [25], demonstrating that interfacial protein degradation does not only 
depend on the available surface area but also on properties of the protein like surface activity. 
Surface tension measurements affirm this suggestion as the less stable rhGH (<50 mN/m; [119]) 
and G-CSF (~48mN/m;[134]) are more surface active than the more stable rhDNase (68 mN/m; 
[119]). Jet nebulization has also been reported for other proteins, including hGH [149], alpha1-
antitrypsin (α1-AT) [150, 151], insulin [149], interleukin 2 (IL-2) in lung metastases [48, 152] and 
interferon-γ [153, 154]. 
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4.3 Aerosolization of Proteins by Ultrasonic Nebulizers 
Ultrasonic (US) nebulizers are second generation inhalers invented in the 1960s. While they were 
developed to eliminate the weaknesses of jet nebulizers, a gentler mode of aerosol generation was 
not an objective at that time. Instead, US nebulizers are more portable and operate quietly. 
Treatment times are reduced since output rates are usually higher with ultrasonic nebulizers 
[155-157] but pulmonary deposition efficiency remains comparable to jet nebulizers. A substantial 
amount of material is lost as residual “dead” volume which is equal [155] or slightly lower [156, 
157] than for jet nebulizers. Atomization relies on high frequency ultrasonic vibration. A piezo-
electric crystal oscillating at frequencies usually above 1 MHz is embedded in the bottom of the 
medication reservoir. The ultrasonic vibration is transmitted through the liquid in the reservoir 
and creates a geyser or standing wave (Figure II-4). Two different mechanisms are assumed to 
be responsible for primary aerosol generation [158]. Capillary waves form on the liquid surface 
and create droplets on their crest. Another theory attributes droplet emission by cavitation effects 
of collapsing microscopic air bubbles. Both phenomena have been observed and fascinating photos 
and videos are available [159, 160]. Comparable to jet nebulization, the primary aerosol is more 
polydisperse than desired (Figure II-4) entailing the use of an internal baffling system to deliver 
adequately sized droplets to the mouthpiece and recirculate larger droplets into the medication 
reservoir. 
 
Figure II-4: Standing wave as generated inside an US nebulizer (A). The fine mist is delivered to the mouthpiece 
while the larger droplets are recycled into the medication reservoir by baffles. Still frame taken from [160]. 
Schematic drawing of an US nebulizer (B) modified from patent US6357671 [161].  
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As observed for jet nebulizers, aerosol recirculation plays a pivotal role in biopharmaceutical 
degradation during US nebulization. Besides the aerosol inherent air-liquid interface, additional 
detrimental influences were suggested in relation to ultrasound and cavitation [162-164]. A 
byproduct of ultrasonic radiation is the heating of the inhaler solution. A large part of the 
introduced energy is dissipated as heat and does not contribute to aerosol generation. 
Temperature in the medication reservoir has been reported to rise with ongoing nebulization 
[147, 165]. Temperatures reaching above 50°C in the medication reservoir and up to 75°C within 
the geyser pose a significant limitation for the nebulization of thermolabile proteins [166]. 
Together heating and aerosol recirculation invoke evaporation that may be less [167, 168] or more 
pronounced than by jet nebulization [147]. 
Niven et al. conducted a detailed investigation of factors relevant for LDH degradation during 
US nebulization [166]. The kinetic of LDH activity loss during US nebulization differed from the 
apparent first order kinetic observed during jet nebulization [135]. Degradation followed a 
sigmoidal progression instead, indicating that more than one factor was involved in LDH 
degradation (Figure II-5 A). To identify the involved factors, Niven applied three different modes 
of operation (apart from normal operation) for US nebulization of LDH (Figure II-5 B). One 
modification was to maintain the temperature inside the medication reservoir at 25°C throughout 
nebulization by means of a cooling coil. In the absence of heating, LDH activity declined in a 
log-linear  jet nebulizer like  fashion. In a second experiment, normal heating was allowed but 
generation of new air-liquid interface was minimized by blocking the geyser with a baffle. LDH 
remained stable for ten minutes but suddenly lost most of its activity within just a few minutes 
presumably when the temperature within the geyser approached the unfolding temperature (Tm) 
of LDH at 56°C. Additionally the device was operated while both, heating and interface 
generation were prevented. Over a time span of 40 minutes, no more than 15% of LDH activity 
was lost. In a different study, formation of hydroxyl radicals resulting from cavitation increased 
as a function of nebulization time, which may furthermore induce protein oxidation [163]. 
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A)  B)  
Figure II-5 A: LDH degradation profile after jet (filled squares) or ultrasonic nebulization (empty circles). B: 
Isolation of individual factors for LDH inactivation during US nebulization. LDH activity during nebulization at 25°C 
(filled circles), during normal heating but without aerosol production (empty circles) or operated at 25°C without 
aerosol production (empty squares) are shown. Taken form [166]. 
Protein degradation by US nebulization can be predominantly attributed to thermal and 
interfacial stress. Additional factors like cavitation are of minor importance. The use of the 
unfolding temperature to predict susceptibility to degradation during nebulization has been 
suggested [169]. It should be noted though, that proteins absorbed to the air-liquid interface 
exhibit onset temperatures for unfolding that are significantly lower compared to bulk solutions 
[128]. Tm values determined for bulk solutions may thus not be appropriate for the definition of 
threshold temperatures in nebulization but rather serve to roughly categorize proteins into more 
or less susceptible to the encountered thermal stress. For example Steckel et al. had to realize 
that US nebulization significantly destabilized aviscumine although the temperature inside the 
medication reservoir was not allowed to rise above 35°C and was thus kept well below the Tm of 
aviscumine at 50°C [145]. 
Niven et al. found that nebulizer cooling did not only reduce protein degradation but also 
markedly reduced the output rate [166]. He concluded that cooling was not feasible for routine 
operation as already long treatment times would be further extended, which is inacceptable as 
prolonged treatment times may have a negative impact on life quality of chronically ill patients 
and are associated with reduced compliance [75, 170]. In general US nebulizers are considered 
not suitable for the pulmonary delivery of proteins [1].  
Contrary to this notion, Ip et al. have compared one jet and three different US nebulizers for the 
nebulization of rhConINF and found that the extent of rhConINF degradation varied greatly 
among the tested US nebulizers [165]. A Microstat nebulizer caused complete monomer loss 
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within 10 minutes of nebulization, while nebulization with a DeVilbiss Aerosonic® device resulted 
in 75% monomer recovery. Contrary to the Aerosonic® which automatically stopped operation 
when TRES rose above 52°C to cool down, temperature rise in the Microstat was unrestricted and 
topped 80°C within 10 minutes of nebulization. A third device, the Medix Easimist nebulizer did 
not negatively affect rhConINF monomer content or in vitro activity. This device is equipped 
with an internal fan to remove aerosol from the reservoir and cool the solution. Similarly Khatri 
et al. tested jet and US nebulizers with the model protein LDH and also reported a significant 
difference between two US nebulizers regarding heating and protein degradation [171]. While the 
Sonix 2000® nebulizer exhibited the expected temperature rise and 80% loss in LDH activity 
within the medication reservoir, the reservoir temperature only negligibly changed for the Omron 
U1 and LDH activity was mostly recovered. This US nebulizer operates at only 67 kHz to prevent 
heating. On the other hand, the aerosol performance of the Omron U1 was poor which was also 
observed by Munster et al. during urokinase plasminogen activator nebulization [172]. 
Nebulization of an equal volume took twice as long with the Omron U1 compared to a Sonix 
2000® and the aerosol droplet diameter was also 40% larger for the Omron device. 
Parallel to the determination of LDH activity inside the medication reservoir, Khatri et al. also 
collected the aerosol in the two stages of a twin-stage glass impinger. The cutoff diameter between 
the upper and the lower stage is 6.4 µm so that all aerosol deposited in the lower stage may be 
considered as the respirable fraction. Interestingly, while the LDH activity of the residual volume 
remaining in the medication reservoir after nebulization with the OMRON U1 was close to 100%, 
so was the result for LDH deposited in the upper stage but in the lower stage only 3% of the 
LDH activity could be recovered although 30% of the protein had deposited there. Khatri et al. 
attributed the pronounced LDH deactivation to the smaller aerosol size and the hence larger air-
liquid interface. Such a distinct effect of droplet size with 100% LDH activity remaining in 
droplets greater 6.4 µm compared to only 10% LDH activity remaining in droplets below 6.4 µm 
seems rather unlikely and has not been reported elsewhere. Instead, the aerosol collection 
conditions significantly differ for the upper and the lower stage of the twin-stage impinger. Only 
in the lower stage does aerosol collection involve bubbling of the aerosol through a buffer solution. 
The disruptive effects of bubbling on protein stability have been laid out above, indicating that 
Chapter II 
20 
the results may be corrupted by unsuitable aerosol collection conditions. A critical evaluation of 
methods used for aerosol collection is not yet available in literature. 
Besides the already mentioned proteins, ultrasonic nebulization has also been reported for platelet 
activating factor [173], G-CSF and PEG-G-CSF [61], rh-SOD [174] and alpha1-protease inhibitor 
[20]. G-CSF and PEG-G-CSF remained active when the US nebulizer was cooled with a coil. Rh-
SOD exhibited 97% activity after nebulization with a modified US neb.  
4.4 Aerosolization of Proteins by Vibrating Mesh Nebulizers 
In the early 2000s a new class of nebulizers became available, so called vibrating mesh (VM) 
nebulizers (also called vibrating membrane nebulizer, Figure II-6). Since then, various reviews 
about VM nebulizers have been published [10, 157, 175-178]. The VM technology is an 
advancement of the ultrasonic nebulization principle, developed to improve the efficiency and 
speed of nebulization as well as device handling whereas optimized protein stability was no 
primary concern. Vibrating mesh nebulizers are small, battery powered and portable. Operation 
is silent [179, 180]. VM nebulization is reported to be more efficient and faster than nebulization 
with other types [27, 140, 179, 181]. Treatment times could be reduced 3-4 fold compared to a 
jet nebulizer [179, 181, 182]. In direct comparison to jet nebulizers, lung deposition was found to 
be doubled [181-183] or more than quadrupled in 3-year old children [184]. The residual volume 
of usually < 0.3 mL is a major reason for the observed efficiency increase. VM nebulizers employ 
a piezoelectric actuator coupled to a mesh that is set into vibration by the high frequent 
oscillation of the actuator. The liquid in the reservoir is forced through thousands of micron sized 
holes in the vibrating mesh, which has been described as a “micro-pump action” [185]. This 
generates a slow moving primary aerosol that is characterized by a narrow size distribution and 
thus does not require a baffling system to deliver an aerosol of the desired size range. Aerosol 
recirculation is therefore not necessary and even ruled out by design [186] which is a major 
improvement over jet and ultrasonic devices. While the generated air-liquid interface is still huge, 
it is greatly reduced compared to the repeatedly recirculated aerosols of jet or US nebulizers. 
This eliminates the main cause of solvent evaporation and the resulting solute up-concentration. 
Accordingly, no significant changes in solvent concentrations during VM nebulization were 
reported [27, 148].  
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to SEC analysis. Insoluble aggregate formation was not addressed in the study [191]. Many 
studies rely on pulmonary delivery of AAT by jet nebulization [17], but data on biologic activity 
or aggregation are not available. Short treatment times and efficient AAT deposition have been 
reported for the AKITA2 [32] and the i-neb AAD [31] VM nebulizers. 
Maillet et al. investigated the feasibility of local pulmonary administration of the antibody 
Cetuximab® for lung cancer treatment and directly compared the impact of jet, US and VM 
nebulization regarding aggregation and biologic activity [15]. They found that subvisible particle 
formation was distinct for US and jet nebulization. The particle count after US nebulization was 
approximately twice as high as that after jet nebulization, whereas VM nebulization with an 
Aeroneb® Pro resulted in negligible subvisible particle counts. Cetuximab® binding activity and 
inhibitory action analyzed in cell assays was preserved after jet and especially VM nebulization. 
Data variability was very high for the US nebulized sample, which was attributed to the 
sedimentation of protein aggregate particles onto the cells. Maillet et al. claim that protein 
aggregation observed during US nebulization was not caused by the noted temperature increase 
since no aggregation occurred during still storage at comparable conditions. This does not take 
into account a possible reduction of the unfolding temperature [128] by interface adsorption.  
A direct comparison of jet and VM nebulization was also performed by Germershaus et al. for 
insulin-like growth factor-I, finding no difference in protein stability for a PARI LC® Sprint jet 
nebulizer and the PARI eFlow® nebulizer [59]. After nebulization a 7% decrease in IGF-I peak 
was observed after nebulization with either device. The formation of aggregates or particles was 
suggested to be responsible for the loss. While no covalent aggregation was observed via non-
reducing SDS PAGE, non-covalent aggregation or particle formation was not analyzed in this 
study. Besides protein stability, nebulizer performance significantly differed. Output rate with 
the eFlow® increased more than fourfold compared to the jet nebulizer. On the other hand the 
FPF reached more than 80% for the jet nebulizer but remained below 60% for the eFlow®. 
Preservation of binding potency and no soluble aggregation or degradation were also reported for 
eFlow® nebulization of a formulation of PA401 (IL-8 decoy chemokine) [192]. While providing 
no detailed information on the impact on API stability, successful VM nebulization has further 
been reported for GM-CSF [62], IL-4 mutein [193] and INF-γ [46], for liposomal formulations of 
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rh-Cu/Zn SOD [53] and for the Fc-fusion proteins EPO-Fc [67, 68], INF-β-Fc [70], INF-α-Fc [69] 
and FSH-Fc [71]. 
5 Aerosolization of Proteins by Metered Dose Liquid 
Inhalers 
Within the last decades, a number of delivery device technologies emerged which generate aerosol 
from pre-metered liquids without the application of a propellant gas. Their different underlying 
principles of aerosol generation are covered in a number of reviews [10, 22, 157, 176, 178]. For 
the AERx® system and the Respimat® device aerosolization of proteins has been reported. 
   
Figure II-8 A: Respimat® by Boehringer Ingelheim [194]; B: Aradigm’s AERx® inhaler system [10] 
The AERx® system is a hand held device generating a fine aerosol cloud by mechanically 
extruding a pre-metered solution through an array of micron sized nozzles (Figure II-8 B). Each 
pre-metered dose is contained in the medication reservoir on a disposable strip that also hosts 
the nozzle array. The technology had been licensed to Novo Nordisk for pulmonary insulin 
delivery [195, 196] but the partnership was discontinued after Pfizer’s withdrawal of Exubera®. 
The feasibility of pulmonary biopharmaceutical delivery with the AERx® inhaler has also been 
demonstrated for INF-α-2b [45] and the superior delivery efficiency of the AERx® over a common 
jet nebulizer has been demonstrated for DNase [30] and rh-IL-4 receptor [40]. Comparing AUC 
data after rh-IL-4 receptor delivery with the AERx® or a PARI LC STAR® jet nebulizer revealed 
significantly higher systemic delivery after AERx® inhalation, which was attributed to a higher 
respirable dose and better peripheral aerosol distribution in the lung. A contribution of API 
A B 
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degradation by the delivery devices and potential differences between the devices was not assessed 
though. 
The Respimat® Soft Mist Inhaler is approved for the pulmonary delivery of tiotropium bromide 
and a combination of ipratropium bromide and fenoterol both used for the treatment of asthma 
and COPD (Figure II-8 A). Energy for aerosol generation is provided mechanically by a loaded 
spring. Upon actuation, an aqueous formulation is forced through nozzles, forming two colliding 
jets that break up into a fine, slow aerosol mist. One puff aerosolizes 13µL solution with a 
viscosity of up to 1.6 mPa*s enabling the spraying of concentrated formulations for the delivery 
of high API doses in a single or few breathes. For example the spraying of 35 mg/mL insulin has 
been reported [47]. Respimat® impact on protein stability has been investigated for interferon 
omega (INF-ω) and manganese superoxide dismutase (MnSOD) [47]. MnSOD formulated at 3.3 
mg/mL in PBS was aerosolized and the mist collected in a trap. Remaining MnSOD activity was 
determined enzymatically and by an ELISA assay. According to ELISA, 78-89% of MnSOD 
activity remained while no activity loss was observed with the enzymatic xanthine / xanthine 
oxidase reaction. Interferon omega formulated in 50 mM sodium citrate and 150 mM NaCl at pH 
5.5 was aerosolized at either 5 mg/mL or 53 mg/mL. At the lower concentration 77-98% of the 
activity of a reference sample remained after aerosolization according to an ELISA assay or 
47-81% as determined by a cell based activity assay. Remaining activity was in a comparable 
range for the high INF-ω concentration with 60-100% and 61-98% according to ELISA and cell 
based assays respectively. The inhalable fractions were 61% for MnSOD and 67-70% for INF-ω 
as determined by an ACI. 
6 Formulation of Proteins for Nebulization 
Biopharmaceuticals are usually formulated with a range of excipients to avoid degradation and 
a loss of efficacy which they might face during any stage from production or processing over 
storage and shipment to application and delivery. Protein formulation is extensively covered in 
the literature with excellent reviews available [83, 197-199]. When it comes to formulations for 
pulmonary application a number of restrictions has to be considered. According to the Ph. Eur. 
the pH of inhaled drugs must be in a range of 3.5 to 8.0 [200] and should ideally be above pH 
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5.0 [201], which must be considered during selection of the buffering agent. Osmolality was well 
tolerated in a range of 150-549 mOsmol but isotonicity has been recommended for pulmonary 
formulations [201]. This limits the maximum concentration of osmotically active excipients (e.g. 
salts, sugars, polyols) often used in protein formulations. Another potentially limiting aspect 
found with many inhaler types is the impact of the formulation on the characteristics of the 
generated aerosol. It has been demonstrated that physicochemical properties like viscosity, 
surface tension or ionic strength can significantly affect important aerosol properties like the 
FPF, the total output or the output rate [185, 202-204]. Further complicating matters, the range 
of excipients currently approved for pulmonary delivery is very limited (FDA inactive ingredient 
database for approved drugs, [205]). Nevertheless a number of reviews deals with the topic of 
formulation for pulmonary drug delivery [12, 24, 206, 207]. 
Surfactants are most protective at interfaces [86] and thus are commonly incorporated in protein 
formulations for nebulization, as the air-liquid interface has been identified as the main site of 
protein degradation. Polysorbate 80 (PS80) and polysorbate 20 (PS20) (approved in Sanasthmax, 
Chiesi) are among the approved excipients and can be found in many biopharmaceutical 
formulations as they displace protein molecules from the air-liquid interface [208]. Niven et al. 
reported for PS80 and two other nonionic detergents (Zwittergent 3-08 and 3-16) that their 
applied concentration must lie above the respective critical micelle concentration in order to 
stabilize the protein during nebulization [134]. Accordingly for a range of proteins stabilization 
was reported for PS80 concentrations of 0.01% or above (G-CSF [134], LDH [135], rhConINF 
[165], t-Pa [209]). Reduced degradation of rhConINF has been reported after addition of 0.01% 
PS20 [165]. A comparable stabilizing potential was observed for the nonionic detergents PS80, 
poloxamer 188 and solutol H515 during aviscumine nebulization [210].  
Stabilization of various proteins including LDH [135], G-CSF [134], rhConINF [165], aviscumine 
[210] and urease [144] was also observed for formulation with polyethylene glycol (PEG) 
depending on PEG molecular weight. PEG 1000 and especially PEG 8000 were found to be more 
protective than PEG 400 at an equal concentration of 1% [134]. Addition of PEG results in 
preferential hydration of proteins by steric exclusion of the PEG molecules from native proteins 
[211, 212]. In order to explain the improved stabilization with larger PEG molecular weight, it 
has been suggested that PEG sterically hinders monomer to monomer interactions at the air-
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water interface thus preventing further aggregation [134]. Unlike nonionic detergents, PEGs have 
a distinct impact on viscosity, which can limit their use in nebulization. During US nebulization 
Niven et al. observed that both PS80 and PEG 8000 stabilized LDH activity at the beginning of 
nebulization but lost their stabilizing potency with ongoing operation and rising reservoir 
temperature [166]. When heating was prevented full LDH activity was maintained by the 
addition of PS80 or PEG 8000. 
  
Chapter II 
28 
7 References 
[1]  R. Siekmeier, G. Scheuch, Systemic Treatment by inhalation of Macromolecules - 
Principles, Problems and Examples, J Physiol Pharmacol, 59 (2008) 53-65. 
[2]  J.S. Patton, Mechanisms of macromolecule absorption by the lungs, Advanced Drug 
Delivery Reviews, 19 (1996) 3-36. 
[3]  J.S. Patton, P.R. Byron, Inhaling medicines: delivering drugs to the body through the 
lungs, Nat Rev Drug Discov, 6 (2007) 67-74. 
[4]  A. Tronde, B. Nordén, H. Marchner, A.-K. Wendel, H. Lennernäs, U.H. Bengtsson, 
Pulmonary absorption rate and bioavailability of drugs in vivo in rats: Structure
absorption relationships and physicochemical profiling of inhaled drugs, J Pharm Sci, 92 
(2003) 1216-1233. 
[5]  A.L. Adjei, P.K. Gupta, Inhalation Delivery of Therapeutic Peptides and Proteins, M. 
Dekker, New York, 1997. 
[6]  J.S. Patton, C.S. Fishburn, J.G. Weers, The Lungs as a Portal of Entry for Systemic 
Drug Delivery, Proceedings of the American Thoracic Society, 1 (2004) 338-344. 
[7]  J.G. Weers, J. Bell, H.K. Chan, D. Cipolla, C. Dunbar, A.J. Hickey, I.J. Smith, 
Pulmonary formulations: what remains to be done?, J Aerosol Med Pulm Drug Deliv, 23 
(2010) S5-23. 
[8]  L. Heinemann, The failure of exubera: are we beating a dead horse?, Journal of diabetes 
science and technology, 2 (2008) 518-529. 
[9]  R. Siekmeier, G. Scheuch, Inhaled insulin--does it become reality?, J Physiol Pharmacol, 
59 (2008) 81-113. 
[10]  D.E. Geller, The science of aerosol delivery in cystic fibrosis, Pediatric Pulmonology, 43 
(2008) S5-S17. 
[11]  A. Maillet, L. Guilleminault, E. Lemarié, S. Lerondel, N. Azzopardi, J. Montharu, N. 
Congy-Jolivet, P. Reverdiau, B. Legrain, C. Parent, D.-H. Douvin, J. Hureaux, Y. 
Courty, M. Monte, P. Diot, G. Paintaud, A. Pape, H. Watier, N. Heuzé-Vourc’h, The 
Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors, 
Pharmaceutical Research, 28 (2011) 2147-2156. 
[12]  G. Pilcer, K. Amighi, Formulation strategy and use of excipients in pulmonary drug 
delivery, International Journal of Pharmaceutics, 392 (2010) 1-19. 
[13]  Pulmozyme Worldwide Sales, Evaluate Ltd, Retrieved 2013-02-12 from 
http://www.evaluategroup.com/Universal/View.aspx?type=Search&query=pulmozyme. 
Introduction 
29 
[14]  N. Canavan, New Tools, Old Concerns in Inhalation Therapies, Pharmaceutical 
Formulation & Quality, (2012) 4-6. 
[15]  A. Maillet, N. Congy-Jolivet, S. Le Guellec, L. Vecellio, S. Hamard, Y. Courty, A. 
Courtois, F. Gauthier, P. Diot, G. Thibault, E. Lemarié, N. Heuzé-Vourc’h, 
Aerodynamical, Immunological and Pharmacological Properties of the Anticancer 
Antibody Cetuximab Following Nebulization, Pharmaceutical Research, 25 (2008) 1318-
1326. 
[16]  A.T. Iacono, B.A. Johnson, W.F. Grgurich, J.G. Youssef, T.E. Corcoran, D.A. Seiler, 
J.H. Dauber, G.C. Smaldone, A. Zeevi, S.A. Yousem, J.J. Fung, G.J. Burckart, K.R. 
McCurry, B.P. Griffith, A Randomized Trial of Inhaled Cyclosporine in Lung-Transplant 
Recipients, New England Journal of Medicine, 354 (2006) 141-150. 
[17]  M. Griese, P. Latzin, M. Kappler, K. Weckerle, T. Heinzlmaier, T. Bernhardt, D. Hartl, 
α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients, 
European Respiratory Journal, 29 (2007) 240-250. 
[18]  C. Vogelmeier, I. Kirlath, S. Warrington, N. Banik, E. Ulbrich, R.M. Du Bois, The 
intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal 
volunteers, American Journal of Respiratory and Critical Care Medicine, 155 (1997) 536-
541. 
[19]  M.P. Flament, P. Leterme, T. Burnouf, A. Gayot, Influence of formulation on jet 
nebulisation quality of α1 protease inhibitor, International Journal of Pharmaceutics, 
178 (1999) 101-109. 
[20]  M.P. Flament, P. Leterme, A. Gayot, Influence of the technological parameters of 
ultrasonic nebulisation on the nebulisation quality of α1 protease inhibitor (α1PI), 
International Journal of Pharmaceutics, 189 (1999) 197-204. 
[21]  A.B. Sabin, A. Arechiga, J. de Castro, et al., Successful immunization of children with 
and without maternal antibody by aerosolized measles vaccine: I. different results with 
undiluted human diploid cell and chick embryo fibroblast vaccines, JAMA, 249 (1983) 
2651-2662. 
[22]  G. Taylor, M. Gumbleton, Aerosols for Macromolecule Delivery: Design Challenges and 
Solutions, American Journal of Drug Delivery, 2 (2004) 143-155. 
[23]  S.-A. Cryan, Carrier-based strategies for targeting protein and peptide drugs to the lungs, 
The AAPS Journal, 7 (2005) E20-E41. 
[24]  F. Depreter, G. Pilcer, K. Amighi, Inhaled proteins: Challenges and perspectives, 
International Journal of Pharmaceutics, 447 (2013) 251-280. 
[25]  D. Cipolla, I. Gonda, S.J. Shire, Characterization of Aerosols of Human Recombinant 
Deoxyribonuclease I (rhDNase) Generated by Jet Nebulizers, Pharmaceutical Research, 
11 (1994) 491-498. 
Chapter II 
30 
[26]  D.C. Cipolla, A.R. Clark, H.K. Chan, I. Gonda, S.J. Shire, Assessment of Aerosol Delivery 
Systems for Recombinant Human Deoxyribonuclease, STP Pharma Sci., 4 (1994) 50-62. 
[27]  T. Scherer, D.E. Geller, L. Owyang, M. Tservistas, M. Keller, N. Boden, K.C. Kesser, 
S.J. Shire, A technical feasibility study of dornase alfa delivery with eflow® vibrating 
membrane nebulizers: Aerosol characteristics and physicochemical stability, J Pharm Sci, 
100 (2011) 98-109. 
[28]  M. Tservistas, F.-C. Lintz, M. Keller, Impact of the Nebulization principle on the 
biological activity of labile formulations containing liposomes, peptides and proteins, in: 
R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr (Eds.) Respiratory Drug 
Delivery IX, Palm Desert, CA, USA, 2004, pp. 613 - 616. 
[29]  E.M. Bakker, S. Volpi, E. Salonini, E.C. van der Wiel-Kooij, C.J.J.C.M. Sintnicolaas, 
W.C.J. Hop, B.M. Assael, P.J.F.M. Merkus, H.A.W.M. Tiddens, Improved treatment 
response to dornase alfa in cystic fibrosis patients using controlled inhalation, European 
Respiratory Journal, 38 (2011) 1328-1335. 
[30]  D. Geller, J. Thipphawong, B. Otulana, D. Caplan, D. Ericson, L. Milgram, J. Okikawa, 
J. Quan, C.M. Bowman, Bolus inhalation of rhDNase with the AERx system in subjects 
with cystic fibrosis, J. Aerosol Med.-Depos. Clear. Eff. Lung, 16 (2003) 175-182. 
[31]  D.E. Geller, K.C. Kesser, The I-neb Adaptive Aerosol Delivery System enhances delivery 
of alpha1-antitrypsin with controlled inhalation, J Aerosol Med Pulm Drug Deliv, 23 
(2010) S55-59. 
[32]  P. Brand, M. Schulte, M. Wencker, C.H. Herpich, G. Klein, K. Hanna, T. Meyer, Lung 
deposition of inhaled α1-proteinase inhibitor in cystic fibrosis and α1-antitrypsin 
deficiency, European Respiratory Journal, 34 (2009) 354-360. 
[33]  S. Pnina, S. Jan, M. Gerry, P. Eeva, S. Niels, R.C. Kenneth, H. Nick, M. William, R. 
Michale, V. Claus, G. Timm, B. Robert, A. Raja, K.E. Richard, A.S. Robert, Phase 
II/III, Double-Blind, Randomized, Placebo-Controlled, International Study Evaluating 
The Safety And Efficacy Of Inhaled, Human, Alpha-1 Antitrypsin (AAT) In Alpha-1 
Antitrypsin Deficient Patients (AATD), in:  D38. UPDATE IN ALPHA ONE 
DEFICIENCY, American Thoracic Society, 2014, pp. A5790-A5790. 
[34]  I. Fängmark, J.C. Carpin, Protein nebulization, Journal of Aerosol Science, 27, 
Supplement 1 (1996) S231-S232. 
[35]  S. Schüle (2005): Stabilization of Antibodies in Spray-dried Powders for Inhalation. PhD 
thesis, Ludwig Maximilian University Munich: Faculty of Chemistry and Pharmacy. 
[36]  S. Schüle, T. Schulz-Fademrecht, P. Garidel, K. Bechtold-Peters, W. Frieß, Stabilization 
of IgG1 in spray-dried powders for inhalation, European Journal of Pharmaceutics and 
Biopharmaceutics, 69 (2008) 793-807. 
Introduction 
31 
[37]  R. Fuhrherr (2005): Spray-dried antibody powders for pulmonary application. PhD thesis, 
Ludwig Maximilian University Munich: Faculty of Chemistry and Pharmacy. 
[38]  A. Agrawal, E.C. Murphy III, J. Park, K.B. Adler, I. Parikh, Aerosolized BIO-11006, a 
novel MARCKS-related peptide, improves airway obstruction in a mouse model of mucus 
hypersecretion, Journal of Epithelial Biology and Pharmacology, 4 (2011) 1-6. 
[39]  S. Wenzel, D. Wilbraham, R. Fuller, E.B. Getz, M. Longphre, Effect of an interleukin-4 
variant on late phase asthmatic response to allergen challenge in asthmatic patients: 
results of two phase 2a studies, The Lancet, 370 (2007) 1422-1431. 
[40]  S. Sangwan, J.M. Agosti, L.A. Bauer, B.A. Otulana, R.J. Morishige, D.C. Cipolla, J.D. 
Blanchard, G.C. Smaldone, Aerosolized protein delivery in asthma: gamma camera 
analysis of regional deposition and perfusion, Journal of aerosol medicine : the official 
journal of the International Society for Aerosols in Medicine, 14 (2001) 185-195. 
[41]  A. Gibbons, N.G. McElvaney, C.C. Taggart, S.-A. Cryan, Delivery of rSLPI in a 
liposomal carrier for inhalation provides protection against cathepsin L degradation, 
Journal of Microencapsulation, 26 (2009) 513-522. 
[42]  A. Gibbons, N. McElvaney, S.-A. Cryan, A Dry Powder Formulation of Liposome-
Encapsulated Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) for 
Inhalation: Preparation and Characterisation, AAPS PharmSciTech, 11 (2010) 1411-
1421. 
[43]  V. Kinnula, K. Mattson, K. Cantell, Pharmacokinetics and toxicity of inhaled human 
interferon-alpha in patients with lung cancer, Journal of interferon research, 9 (1989) 419-
423. 
[44]  S. Giosue, M. Casarini, F. Ameglio, P. Zangrilli, M. Palla, A.M. Altieri, A. Bisetti, 
Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary 
tuberculosis, European cytokine network, 11 (2000) 99-104. 
[45]  G. Balwani, B. Boyd, J. Whatley, J. Thipphawong, R. Morishige, J. Okikawa, B. 
Otulana, E. Tamches, T. Buclin, J. Biollaz, Evaluation of the AERx system for the 
pulmonary delivery of recombinant human interferon alfa-2b to healthy subjects, in:  29th 
Annual Meeting of the Controlled Release Society, Seoul, Korea, 2002. 
[46]  K.T. Diaz, S. Skaria, K. Harris, M. Solomita, S. Lau, K. Bauer, G.C. Smaldone, R. 
Condos, Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary 
fibrosis, J Aerosol Med Pulm Drug Deliv, 25 (2012) 79-87. 
[47]  H. Lamche, C.J.M. Meade, B. Zierenberg, R.C. Reimholz, Process for nebulizing aqueous 
compositions containing highly concentrated insulin, U.S. Patent US20030064032 A1, 
issued 6. Nov. 2002. 
[48]  O. Merimsky, E. Gez, R. Weitzen, H. Nehushtan, R. Rubinov, H. Hayat, T. Peretz, M. 
Ben-Shahar, H. Biran, R. Katsenelson, V. Mermershtein, D. Loven, N. Karminsky, A. 
Chapter II 
32 
Neumann, D. Matcejevsky, M. Inbar, Targeting pulmonary metastases of renal cell 
carcinoma by inhalation of interleukin-2, Annals of Oncology, 15 (2004) 610-612. 
[49]  E. Esteban-González, J. Carballido, V. Navas, Z. Torregrosa, A. Muñoz, M. Álvarez de 
Mon, Retrospective review in patients with pulmonary metastases of renal cell carcinoma 
receiving inhaled recombinant interleukin-2, Anti-Cancer Drugs, 18 (2007) 291-296. 
[50]  J.V. Fahy, D.W. Cockcroft, L.-P. Boulet, H.H. Wong, F. Deschesnes, E.E. Davis, J. 
Ruppel, J.Q. Su, D.C. Adelman, Effect of Aerosolized Anti-IgE (E25) on Airway 
Responses to Inhaled Allergen in Asthmatic Subjects, Am. J. Respir. Crit. Care Med., 
160 (1999) 1023-1027. 
[51]  J. Andya, Y.-F. Maa, H. Costantino, P.-A. Nguyen, N. Dasovich, T. Sweeney, C. Hsu, S. 
Shire, The Effect of Formulation Excipients on Protein Stability and Aerosol Performance 
of Spray-Dried Powders of a Recombinant Humanized Anti-IgE Monoclonal Antibody1, 
Pharmaceutical Research, 16 (1999) 350-358. 
[52]  V.R. Muzykantov, Delivery of antioxidant enzyme proteins to the lung, Antioxidants & 
redox signaling, 3 (2001) 39-62. 
[53]  A. Wagner, K. Vorauer-Uhl, H. Katinger, Nebulization of Liposomal rh-Cu/Zn SOD with 
a Novel Vibrating Membrane Nebulizer, Journal of Liposome Research, 16 (2006) 113-
125. 
[54]  L.J. Deftos, J.J. Nolan, B.L. Seely, P.L. Clopton, G.J. Cote, C.L. Whitham, L.J. Florek, 
T.A. Christensen, M.R. Hill, Intrapulmonary Drug Delivery of Salmon Calcitonin, Calcif 
Tissue Int, 61 (1997) 345-347. 
[55]  J.S. Patton, Pulmonary delivery of drugs for bone disorders, Advanced Drug Delivery 
Reviews, 42 (2000) 239-248. 
[56]  E.C. Walvoord, A. de la Peña, S. Park, B. Silverman, L. Cuttler, S.R. Rose, G. Cutler, 
S. Drop, J.J. Chipman, Inhaled Growth Hormone (GH) Compared with Subcutaneous 
GH in Children with GH Deficiency: Pharmacokinetics, Pharmacodynamics, and Safety, 
Journal of Clinical Endocrinology & Metabolism, 94 (2009) 2052-2059. 
[57]  S. White, D.B. Bennett, S. Cheu, P.W. Conley, D.B. Guzek, S. Gray, J. Howard, R. 
Malcolmson, J.M. Parker, P. Roberts, N. Sadrzadeh, J.D. Schumacher, S. Seshadri, G.W. 
Sluggett, C.L. Stevenson, N.J. Harper, EXUBERA: pharmaceutical development of a 
novel product for pulmonary delivery of insulin, Diabetes Technol Ther, 7 (2005) 896-
906. 
[58]  A. Rossiter, C.P. Howard, N. Amin, D.J. Costello, A.H. Boss, Technosphere® Insulin: 
Safety in Type 2 Diabetes Mellitus, in: A.D. Association (Ed.) ADA Scientific Sessions, 
American Diabetes Association, Orlando, FL, USA, 2010, pp. 1. 
Introduction 
33 
[59]  O. Germershaus, I. Schultz, T. Lühmann, M. Beck-Broichsitter, P. Högger, L. Meinel, 
Insulin-like growth factor-I aerosol formulations for pulmonary delivery, European 
Journal of Pharmaceutics and Biopharmaceutics, 85 (2013) 61-68. 
[60]  K.C. Lee, S.Y. Chae, T.H. Kim, S. Lee, E.S. Lee, Y.S. Youn, Intrapulmonary potential 
of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent, 
Regulatory Peptides, 152 (2009) 101-107. 
[61]  R. Niven, K.L. Whitcomb, L. Shaner, A. Ip, O. Kinstler, The Pulmonary Absorption of 
Aerosolized and Intratracheally Instilled rhG-CSF and monoPEGylated rhG-CSF, 
Pharmaceutical Research, 12 (1995) 1343-1349. 
[62]  M. Luisetti, P. Kroneberg, T. Suzuki, Z. Kadija, B. Muellinger, I. Campo, J. Gleske, G. 
Rodi, W.C. Zimlich, F. Mariani, F. Ferrari, M. Frey, B.C. Trapnell, Physical properties, 
lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a 
highly efficient nebulizer, Pulmonary Pharmacology & Therapeutics, 24 (2011) 123-127. 
[63]  R.D. Rao, P.M. Anderson, C.A.S. Arndt, P.J. Wettstein, S.N. Markovic, Aerosolized 
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Therapy in Metastatic 
Cancer, American Journal of Clinical Oncology, 26 (2003) 493-498. 
[64]  R. Tazawa, B.C. Trapnell, Y. Inoue, T. Arai, T. Takada, Y. Nasuhara, N. Hizawa, Y. 
Kasahara, K. Tatsumi, M. Hojo, H. Ishii, M. Yokoba, N. Tanaka, E. Yamaguchi, R. Eda, 
Y. Tsuchihashi, K. Morimoto, M. Akira, M. Terada, J. Otsuka, M. Ebina, C. Kaneko, T. 
Nukiwa, J.P. Krischer, K. Akazawa, K. Nakata, Inhaled granulocyte/macrophage-colony 
stimulating factor as therapy for pulmonary alveolar proteinosis, Am J Respir Crit Care 
Med, 181 (2010) 1345-1354. 
[65]  S.N. Markovic, V.J. Suman, W.K. Nevala, L. Geeraerts, E.T. Creagan, L.A. Erickson, 
K.M. Rowland, Jr., R.F. Morton, W.L. Horvath, M.R. Pittelkow, A dose-escalation study 
of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study, 
Am J Clin Oncol, 31 (2008) 573-579. 
[66]  M.E. Wylam, R. Ten, U.B.S. Prakash, H.F. Nadrous, M.L. Clawson, P.M. Anderson, 
Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar 
proteinosis, European Respiratory Journal, 27 (2006) 585-593. 
[67]  A.J. Bitonti, J.A. Dumont, S.C. Low, R.T. Peters, K.E. Kropp, V.J. Palombella, J.M. 
Stattel, Y. Lu, C.A. Tan, J.J. Song, A.M. Garcia, N.E. Simister, G.M. Spiekermann, W.I. 
Lencer, R.S. Blumberg, Pulmonary delivery of an erythropoietin Fc fusion protein in non-
human primates through an immunoglobulin transport pathway, Proc Natl Acad Sci U 
S A, 101 (2004) 9763-9768. 
[68]  J.A. Dumont, A.J. Bitonti, D. Clark, S. Evans, M. Pickford, S.P. Newman, Delivery of 
an Erythropoietin-Fc Fusion Protein by Inhalation in Humans through an 
Immunoglobulin Transport Pathway, Journal of aerosol medicine : the official journal of 
the International Society for Aerosols in Medicine, 18 (2005) 294-303. 
Chapter II 
34 
[69]  A.J. Bitonti, J.A. Dumont, Pulmonary administration of therapeutic proteins using an 
immunoglobulin transport pathway, Advanced Drug Delivery Reviews, 58 (2006) 1106-
1118. 
[70]  S. Vallee, S. Rakhe, T. Reidy, S. Walker, Q. Lu, P. Sakorafas, S. Low, A. Bitonti, 
Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates 
using an immunoglobulin transport pathway, Journal of interferon & cytokine research : 
the official journal of the International Society for Interferon and Cytokine Research, 32 
(2012) 178-184. 
[71]  S.C. Low, S.L. Nunes, A.J. Bitonti, J.A. Dumont, Oral and pulmonary delivery of FSH
Fc fusion proteins via neonatal Fc receptor-mediated transcytosis, Human Reproduction, 
20 (2005) 1805-1813. 
[72]  K.C. Stone, R.R. Mercer, P. Gehr, B. Stockstill, J.D. Crapo, Allometric Relationships of 
Cell Numbers and Size in the Mammalian Lung, American Journal of Respiratory Cell 
and Molecular Biology, 6 (1992) 235-243. 
[73]  C. Lombry, D.A. Edwards, V. Preat, R. Vanbever, Alveolar macrophages are a primary 
barrier to pulmonary absorption of macromolecules, Am J Physiol Lung Cell Mol Physiol, 
286 (2004) L1002-1008. 
[74]  T. Martonen, I. Katz, Deposition Patterns of Aerosolized Drugs Within Human Lungs: 
Effects of Ventilatory Parameters, Pharmaceutical Research, 10 (1993) 871-878. 
[75]  G. Scheuch, M.J. Kohlhaeufl, P. Brand, R. Siekmeier, Clinical perspectives on pulmonary 
systemic and macromolecular delivery, Advanced Drug Delivery Reviews, 58 (2006) 996-
1008. 
[76]  K. Bechtold-Peters, H. Luessen, Pulmonary Drug Delivery: Basics, Applications and 
Opportunities for Small Molecules and Biopharmaceutics, ECV Editio Cantor Verlag, 
Aulendorf, 2007. 
[77]  A.J. Hickey, T.B. Martonen, Y. Yang, Theoretical relationship of lung deposition to the 
fine particle fraction of inhalation aerosols, Pharmaceutica Acta Helvetiae, 71 (1996) 185-
190. 
[78]  T. Martonen, I. Katz, K. Fults, A. Hickey, Use of Analytically Defined Estimates of 
Aerosol Respirable Fraction to Predict Lung Deposition Patterns, Pharmaceutical 
Research, 9 (1992) 1634-1639. 
[79]  G. Scheuch, W. Stahlhofen, Deposition and Dispersion of Aerosols in the Airways of the 
Human Respiratory Tract: The Effect of Particle Size, Experimental Lung Research, 18 
(1992) 343-358. 
[80]  R. Liste, ROTE LISTE® 2013 Buchausgabe - Einzelausgabe: Arzneimittelverzeichnis für 
Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte), Rote 
Liste Service GmbH, Frankfurt/Main, 2013. 
Introduction 
35 
[81]  R.K. Wolff, R.W. Niven, Generation of aerosolized drugs, Journal of aerosol medicine : 
the official journal of the International Society for Aerosols in Medicine, 7 (1994) 89-106. 
[82]  N.R. Labiris, M.B. Dolovich, Pulmonary drug delivery. Part II: The role of inhalant 
delivery devices and drug formulations in therapeutic effectiveness of aerosolized 
medications, British Journal of Clinical Pharmacology, 56 (2003) 600-612. 
[83]  W. Wang, Instability, stabilization, and formulation of liquid protein pharmaceuticals, 
International Journal of Pharmaceutics, 185 (1999) 129-188. 
[84]  W. Wang, Protein aggregation and its inhibition in biopharmaceutics, International 
Journal of Pharmaceutics, 289 (2005) 1-30. 
[85]  H.-C. Mahler, W. Friess, U. Grauschopf, S. Kiese, Protein aggregation: Pathways, 
induction factors and analysis, J Pharm Sci, 98 (2009) 2909-2934. 
[86]  M. Manning, D. Chou, B. Murphy, R. Payne, D. Katayama, Stability of Protein 
Pharmaceuticals: An Update, Pharmaceutical Research, 27 (2010) 544-575. 
[87]  J.S. Philo, T. Arakawa, Mechanisms of Protein Aggregation, Current Pharmaceutical 
Biotechnology, 10 (2009) 348-351. 
[88]  W. Wang, S. Nema, D. Teagarden, Protein aggregation Pathways and influencing 
factors, International Journal of Pharmaceutics, 390 (2010) 89-99. 
[89]  H.-Y. Li, P.C. Seville, Novel pMDI formulations for pulmonary delivery of proteins, 
International Journal of Pharmaceutics, 385 (2010) 73-78. 
[90]  R.O. Williams Iii, J. Liu, Formulation of a protein with propellant HFA 134a for aerosol 
delivery, European Journal of Pharmaceutical Sciences, 7 (1999) 137-144. 
[91]  Y. Tan, Z. Yang, X. Peng, F. Xin, Y. Xu, M. Feng, C. Zhao, H. Hu, C. Wu, A novel 
bottom-up process to produce nanoparticles containing protein and peptide for suspension 
in hydrofluoroalkane propellants, International Journal of Pharmaceutics, 413 (2011) 167-
173. 
[92]  Y. Tan, Z. Yang, X. Pan, M. Chen, M. Feng, L. Wang, H. Liu, Z. Shan, C. Wu, Stability 
and aerosolization of pressurized metered dose inhalers containing thymopentin 
nanoparticles produced using a bottom-up process, International Journal of 
Pharmaceutics, 427 (2012) 385-392. 
[93]  R. Pauwels, S. Newman, L. Borgstrom, Airway deposition and airway effects of 
antiasthma drugs delivered from metered-dose inhalers, European Respiratory Journal, 
10 (1997) 2127-2138. 
[94]  A.R. Clark, Medical Aerosol Inhalers: Past, Present, and Future, Aerosol Science and 
Technology, 22 (1995) 374-391. 
Chapter II 
36 
[95]  P.J. Thompson, Drug Delivery to the Small Airways, American Journal of Respiratory 
and Critical Care Medicine, 157 (1998) S199-S202. 
[96]  O. Aswania, S. Ritson, S.M. Iqbal, J. Bhatt, A.S. Rigby, M.L. Everard, Intra-subject 
variability in lung dose in healthy volunteers using five conventional portable inhalers, 
Journal of aerosol medicine : the official journal of the International Society for Aerosols 
in Medicine, 17 (2004) 231-238. 
[97]  L. Borgström, T. Bengtsson, E. Derom, R. Pauwels, Variability in lung deposition of 
inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder 
inhaler, Turbuhaler®, International Journal of Pharmaceutics, 193 (2000) 227-230. 
[98]  M. Molimard, C. Raherison, S. Lignot, F. Depont, A. Abouelfath, N. Moore, Assessment 
of handling of inhaler devices in real life: an observational study in 3811 patients in 
primary care, Journal of aerosol medicine : the official journal of the International Society 
for Aerosols in Medicine, 16 (2003) 249-254. 
[99]  F. Lavorini, A. Magnan, J. Christophe Dubus, T. Voshaar, L. Corbetta, M. Broeders, R. 
Dekhuijzen, J. Sanchis, J.L. Viejo, P. Barnes, C. Corrigan, M. Levy, G.K. Crompton, 
Effect of incorrect use of dry powder inhalers on management of patients with asthma 
and COPD, Respiratory medicine, 102 (2008) 593-604. 
[100]  I.J. Smith, M. Parry-Billings, The inhalers of the future? A review of dry powder devices 
on the market today, Pulmonary Pharmacology & Therapeutics, 16 (2003) 79-95. 
[101]  S.A. Shoyele, S. Cawthorne, Particle engineering techniques for inhaled 
biopharmaceuticals, Advanced Drug Delivery Reviews, 58 (2006) 1009-1029. 
[102]  J.G. Weers, T.E. Tarara, A.R. Clark, Design of fine particles for pulmonary drug delivery, 
Expert Opinion on Drug Delivery, 4 (2007) 297-313. 
[103]  M. Irngartinger, V. Camuglia, M. Damm, J. Goede, H.W. Frijlink, Pulmonary delivery 
of therapeutic peptides via dry powder inhalation: effects of micronisation and 
manufacturing, European Journal of Pharmaceutics and Biopharmaceutics, 58 (2004) 7-
14. 
[104]  D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, 
D. Deaver, N. Lotan, R. Langer, Large Porous Particles for Pulmonary Drug Delivery, 
Science, 276 (1997) 1868-1872. 
[105]  D.E. Geller, J. Weers, S. Heuerding, Development of an inhaled dry-powder formulation 
of tobramycin using PulmoSphere technology, J Aerosol Med Pulm Drug Deliv, 24 (2011) 
175-182. 
[106]  V. Codrons, F. Vanderbist, B. Ucakar, V. Préat, R. Vanbever, Impact of formulation and 
methods of pulmonary delivery on absorption of parathyroid hormone (1?34) from rat 
lungs Journal of Pharmaceutical Sciences Volume 93, Issue 5, J Pharm Sci, 93 (2004) 
1241-1252. 
Introduction 
37 
[107]  C. Bosquillon, V. Préat, R. Vanbever, Pulmonary delivery of growth hormone using dry 
powders and visualization of its local fate in rats, Journal of Controlled Release, 96 (2004) 
233-244. 
[108]  S.S. Steiner, R. Feldstein, H. Lian, C.A. Rhodes, G.S. Shen, Method for drug delivery to 
the pulmonary system, issued 03/12/2013. 
[109]  M.T. Marino, D. Costello, R. Baughman, A. Boss, J. Cassidy, C. Damico, S. van Marle, 
A. van Vliet, P.C. Richardson, Pharmacokinetics and Pharmacodynamics of Inhaled 
GLP-1 (MKC253): Proof-of-Concept Studies in Healthy Normal Volunteers and in 
Patients With Type 2 Diabetes, Clin Pharmacol Ther, 88 (2010) 243-250. 
[110]  A. Bot, T. Tarara, D. Smith, S. Bot, C. Woods, J. Weers, Novel Lipid-Based Hollow-
Porous Microparticles as a Platform for Immunoglobulin Delivery to the Respiratory 
Tract, Pharmaceutical Research, 17 (2000) 275-283. 
[111]  L. Dellamary, D.J. Smith, A. Bloom, S. Bot, G.-R. Guo, H. Deshmuk, M. Costello, A. 
Bot, Rational design of solid aerosols for immunoglobulin delivery by modulation of 
aerodynamic and release characteristics, Journal of Controlled Release, 95 (2004) 489-
500. 
[112]  A. Hawe, M. Wiggenhorn, M. van de Weert, J.H.O. Garbe, H.-C. Mahler, W. Jiskoot, 
Forced degradation of therapeutic proteins, J Pharm Sci, 101 (2012) 895-913. 
[113]  A. Eppler, M. Weigandt, A. Hanefeld, H. Bunjes, Relevant shaking stress conditions for 
antibody preformulation development, European Journal of Pharmaceutics and 
Biopharmaceutics, 74 (2010) 139-147. 
[114]  V. Sluzky, A.M. Klibanov, R. Langer, Mechanism of insulin aggregation and stabilization 
in agitated aqueous solutions, Biotechnology and Bioengineering, 40 (1992) 895-903. 
[115]  Sylvia Kiese, Astrid Papppenberger, Wolfgang Friess, Hanns-Christian Mahler, Shaken, 
not stirred: Mechanical stress testing of an IgG1 antibody, J Pharm Sci, 97 (2008) 4347-
4366. 
[116]  H.-C. Mahler, R. Müller, W. Frie, A. Delille, S. Matheus, Induction and analysis of 
aggregates in a liquid IgG1-antibody formulation, European Journal of Pharmaceutics 
and Biopharmaceutics, 59 (2005) 407-417. 
[117]  L. Krielgaard, L.S. Jones, T.W. Randolph, S. Frokjaer, J.M. Flink, M.C. Manning, J.F. 
Carpenter, Effect of tween 20 on freeze-thawing- and agitation-induced aggregation of 
recombinant human factor XIII, J Pharm Sci, 87 (1998) 1593-1603. 
[118]  M. Katakam, L.N. Bell, A.K. Banga, Effect of surfactants on the physical stability of 
recombinant human growth hormone, J Pharm Sci, 84 (1995) 713-716. 
[119]  Y.-F. Maa, C.C. Hsu, Protein denaturation by combined effect of shear and air-liquid 
interface, Biotechnology and Bioengineering, 54 (1997) 503-512. 
Chapter II 
38 
[120]  M. Calamai, N. Taddei, M. Stefani, G. Ramponi, F. Chiti, Relative Influence of 
Hydrophobicity and Net Charge in the Aggregation of Two Homologous Proteins, 
Biochemistry, 42 (2003) 15078-15083. 
[121]  E. Querol, J.A. Perez-Pons, A. Mozo-Villarias, Analysis of protein conformational 
characteristics related to thermostability, Protein Engineering, 9 (1996) 265-271. 
[122]  T.W. Randolph, L.S. Jones, Surfactant-Protein Interactions, in: J.F. Carpenter, M.C. 
Manning (Eds.) Rational Design of Stable Protein Formulations, Springer US, New York, 
2002, pp. 159-175. 
[123]  S. Magdassi, Surface Activity of Proteins: Chemical and Physicochemical Modifications, 
Taylor & Francis, New York, 1996. 
[124]  V.A. Voelz, M. Jäger, S. Yao, Y. Chen, L. Zhu, S.A. Waldauer, G.R. Bowman, M. 
Friedrichs, O. Bakajin, L.J. Lapidus, S. Weiss, V.S. Pande, Slow Unfolded-State 
Structuring in Acyl-CoA Binding Protein Folding Revealed by Simulation and 
Experiment, Journal of the American Chemical Society, 134 (2012) 12565-12577. 
[125]  Y.F. Yano, T. Uruga, H. Tanida, H. Toyokawa, Y. Terada, M. Takagaki, H. Yamada, 
Driving Force Behind Adsorption-Induced Protein Unfolding: A Time-Resolved X-ray 
Reflectivity Study on Lysozyme Adsorbed at an Air/Water Interface, Langmuir, 25 
(2008) 32-35. 
[126]  A.K. Hüsecken, F. Evers, C. Czeslik, M. Tolan, Effect of Urea and Glycerol on the 
Adsorption of Ribonuclease A at the Air−Water Interface, Langmuir, 26 (2010) 13429-
13435. 
[127]  M.D. Lad, F. Birembaut, J.M. Matthew, R.A. Frazier, R.J. Green, The adsorbed 
conformation of globular proteins at the air/water interface, Physical Chemistry 
Chemical Physics, 8 (2006) 2179-2186. 
[128]  R.J. Green, I. Hopkinson, R.A.L. Jones, Unfolding and Intermolecular Association in 
Globular Proteins Adsorbed at Interfaces, Langmuir, 15 (1999) 5102-5110. 
[129]  A. Tronin, T. Dubrovsky, S. Dubrovskaya, G. Radicchi, C. Nicolini, Role of Protein 
Unfolding in Monolayer Formation on Air−Water Interface, Langmuir, 12 (1996) 3272-
3275. 
[130]  A. Singh, O. Konovalov, J. Novak, A. Vorobiev, The sequential growth mechanism of a 
protein monolayer at the air-water interface, Soft Matter, 6 (2010) 3826-3831. 
[131]  Y.F. Yano, E. Arakawa, W. Voegeli, T. Matsushita, Real-time investigation of protein 
unfolding at an air-water interface at the 1 s time scale, Journal of Synchrotron Radiation, 
20 (2013) 980-983. 
Introduction 
39 
[132]  A.H. Martin, M.B.J. Meinders, M.A. Bos, M.A. Cohen Stuart, T. van Vliet, 
Conformational Aspects of Proteins at the Air/Water Interface Studied by Infrared 
Reflection−Absorption Spectroscopy, Langmuir, 19 (2003) 2922-2928. 
[133]  B.R. Simler, G. Hui, J.E. Dahl, B. Perez-Ramirez, Mechanistic complexity of subvisible 
particle formation: Links to protein aggregation are highly specific, J Pharm Sci, 101 
(2012) 4140-4154. 
[134]  R.W. Niven, S.J. Prestrelski, M.J. Treuheit, A.Y. Ip, T. Arakawa, Protein nebulization 
II. Stabilization of G-CSF to air-jet nebulization and the role of protectants, International 
Journal of Pharmaceutics, 127 (1996) 191-201. 
[135]  R.W. Niven, A.Y. Ip, S.D. Mittelman, C. Farrar, T. Arakawa, S.J. Prestrelski, Protein 
nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte-colony 
stimulating factor to air-jet nebulization, International Journal of Pharmaceutics, 109 
(1994) 17-26. 
[136]  R.W. Niven, Delivery of Biotherapeutics by Inhalation Aerosol, Critical Reviews™ in 
Therapeutic Drug Carrier Systems, 12 (1995) 151-231. 
[137]  R. Uchenna Agu, M. Ikechukwu Ugwoke, M. Armand, R. Kinget, N. Verbeke, The lung 
as a route for systemic delivery of therapeutic proteins and peptides, Respiratory 
Research, 2 (2001) 198-209. 
[138]  D.T. Loffert, D. Ikle, H.S. Nelson, A comparison of commercial jet nebulizers, CHEST 
Journal, 106 (1994) 1788-1792. 
[139]  R.A. Lewis, J.S. Fleming, Fractional deposition from a jet nebulizer: How it differs from 
a metered dose inhaler, British Journal of Diseases of the Chest, 79 (1985) 361-367. 
[140]  A.L. Coates, M. Green, K. Leung, J. Chan, N. Ribeiro, F. Ratjen, M. Charron, A 
comparison of amount and speed of deposition between the PARI LC STAR(R) jet 
nebulizer and an investigational eFlow(R) nebulizer, J Aerosol Med Pulm Drug Deliv, 24 
(2011) 157-163. 
[141]  B.M. Zainudin, M. Biddiscombe, S.E. Tolfree, M. Short, S.G. Spiro, Comparison of 
bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised 
metered dose inhaler, as a dry powder, and as a nebulised solution, Thorax, 45 (1990) 
469-473. 
[142]  J.H. Wildhaber, N.D. Dore, J.M. Wilson, S.G. Devadason, P.N. LeSouëf, Inhalation 
therapy in asthma: Nebulizer or pressurized metered-dose inhaler with holding chamber? 
In vivo comparison of lung deposition in children, The Journal of Pediatrics, 135 (1999) 
28-33. 
[143]  P. Brand, S. Häußermann, B. Müllinger, A. Fischer, B. Wachall, J. Stegemann, Reduction 
of drug-dose and therapy-costs in the inhalation therapy with high dose tobramycin, 
Chapter II 
40 
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 5 (2006) 
S40. 
[144]  I. Fängmark, J.C. Carpin, Stability of urease during aerosolization: The effect of operating 
conditions, Journal of Aerosol Science, 29 (1998) 279-288. 
[145]  H. Steckel, F. Eskandar, K. Witthohn, Effect of Excipients on the Stability and Aerosol 
Performance of Nebulized Aviscumine, Journal of Aerosol Medicine, 16 (2003) 417-432. 
[146]  P.R. Phipps, I. Gonda, Evaporation of aqueous aerosols produced by jet nebulizers: effects 
on particle size and concentration of solution in the droplets, Journal of aerosol medicine 
: the official journal of the International Society for Aerosols in Medicine, 7 (1994) 239-
258. 
[147]  H. Steckel, F. Eskandar, Factors affecting aerosol performance during nebulization with 
jet and ultrasonic nebulizers, European Journal of Pharmaceutical Sciences, 19 (2003) 
443-456. 
[148]  M. Beck-Broichsitter, P. Kleimann, T. Schmehl, T. Betz, U. Bakowsky, T. Kissel, W. 
Seeger, Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on 
the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers, European Journal 
of Pharmaceutics and Biopharmaceutics, 82 (2012) 272-280. 
[149]  J.S. Patton, R.M. Platz, (D) Routes of delivery: Case studies: (2) Pulmonary delivery of 
peptides and proteins for systemic action, Advanced Drug Delivery Reviews, 8 (1991) 
179-196. 
[150]  R.C. Hubbard, N.G. McElvaney, S.E. Sellers, J.T. Healy, D.B. Czerski, R.G. Crystal, 
Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower 
respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin 
deficiency, The Journal of clinical investigation, 84 (1989) 1349-1354. 
[151]  R.C. Hubbard, M.A. Casolaro, M. Mitchell, S.E. Sellers, F. Arabia, M.A. Matthay, R.G. 
Crystal, Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the 
epithelial surface of the lower respiratory tract to administer proteins of therapeutic 
importance, Proceedings of the National Academy of Sciences, 86 (1989) 680-684. 
[152]  E. Huland, H. Heinzer, H. Huland, R. Yung, Overview of interleukin-2 inhalation therapy, 
The cancer journal from Scientific American, 6 Suppl 1 (2000) S104-112. 
[153]  T.S. Hallstrand, H.D. Ochs, Q. Zhu, W.C. Liles, Inhaled IFN-γ for persistent 
nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency, 
European Respiratory Journal, 24 (2004) 367-370. 
[154]  R.B. Moss, N. Mayer-Hamblett, J. Wagener, C. Daines, K. Hale, R. Ahrens, R.L. Gibson, 
P. Anderson, G. Retsch-Bogart, S.Z. Nasr, I. Noth, D. Waltz, P. Zeitlin, B. Ramsey, K. 
Starko, Randomized, double-blind, placebo-controlled, dose-escalating study of 
Introduction 
41 
aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung 
disease, Pediatric pulmonology, 39 (2005) 209-218. 
[155]  K.M.G. Taylor, O.N.M. McCallion, Ultrasonic nebulisers for pulmonary drug delivery, 
International Journal of Pharmaceutics, 153 (1997) 93-104. 
[156]  T. Gessler, T. Schmehl, M.M. Hoeper, F. Rose, H.A. Ghofrani, H. Olschewski, F. 
Grimminger, W. Seeger, Ultrasonic versus jet nebulization of iloprost in severe pulmonary 
hypertension, European Respiratory Journal, 17 (2001) 14-19. 
[157]  M.B. Dolovich, R. Dhand, Aerosol drug delivery: developments in device design and 
clinical use, The Lancet, 377 (2011) 1032-1045. 
[158]  B. Avvaru, M.N. Patil, P.R. Gogate, A.B. Pandit, Ultrasonic atomization: Effect of liquid 
phase properties, Ultrasonics, 44 (2006) 146-158. 
[159]  B. Howard (2010): High speed photography of ultrasonic atomization. Master thesis, 
Brown University: School of Engineering. 
[160]  B. Howard, Ultrasonic Atomization, Brown University, Retrieved 11/18/2013 from 
http://ultrasoundatomization.com/15.html. 
[161]  G. Cewers, Ultrasonic nebulizer, U.S. Patent US6357671 B1, issued 03/19/2002. 
[162]  L. Huamao, L. Yuhua, L. Zhouhua, The heating phenomenon produced by an ultrasonic 
fountain, Ultrasonics Sonochemistry, 4 (1997) 217-218. 
[163]  J.A. Giarratano, J. Carpenter, C.S. Lengsfeld, Protein Aggregation during Ultrasonic 
Nebulization, in: I. Americas (Ed.) 24rd Annual Conference on Liquid Atomization and 
Spray Systems, ILASS Americas, San Antonio, Texas, USA, 2012. 
[164]  H.I. Elsner, E.B. Lindblad, Ultrasonic degradation of DNA, DNA (Mary Ann Liebert, 
Inc.), 8 (1989) 697-701. 
[165]  A.Y. Ip, T. Arakawa, H. Silvers, C.M. Ransone, R.W. Niven, Stability of recombinant 
consensus interferon to air-jet and ultrasonic nebulization, J Pharm Sci, 84 (1995) 1210-
1214. 
[166]  R.W. Niven, A.Y. Ip, S. Mittelman, S.J. Prestrelski, T. Arakawa, Some Factors 
Associated with the Ultrasonic Nebulization of Proteins, Pharmaceutical Research, 12 
(1995) 53-59. 
[167]  G.A. Ferron, K.F. Kerrebijn, J. Weber, Properties of aerosols produced with three 
nebulizers, The American review of respiratory disease, 114 (1976) 899-908. 
[168]  S.P. Newman, P.G. Pellow, S.W. Clarke, In vitro comparison of devilbiss jet and 
ultrasonic nebulizers, CHEST Journal, 92 (1987) 991-994. 
Chapter II 
42 
[169]  M. Zeles-Hahn, T.J. Anchordoquy, C.S. Lengsfeld, Observations on the impact of 
aerosolization on macromolecular therapeutics, in:  European Conference on Liquid 
Atomization and Spray Systems, Como Lake, Italy, 2008, pp. 8-3. 
[170]  Z.M. Corden, C.M. Bosley, P.J. Rees, G.M. Cochrane, Home Nebulized Therapy for 
Patients with COPD Patient Compliance With Treatment and Its Relation to Quality 
of Life, CHEST Journal, 112 (1997) 1278-1282. 
[171]  L. Khatri, K.M.G. Taylor, D.Q.M. Craig, K. Palin, An assessment of jet and ultrasonic 
nebulisers for the delivery of lactate dehydrogenase solutions, International Journal of 
Pharmaceutics, 227 (2001) 121-131. 
[172]  A.M. Munster, E. Bendstrup, J.I. Jensen, J. Gram, Jet and ultrasonic nebulization of 
single chain urokinase plasminogen activator (scu-PA), Journal of aerosol medicine : the 
official journal of the International Society for Aerosols in Medicine, 13 (2000) 325-333. 
[173]  T. Kosugi, S. Saitoh, N. Tamaki, K. Hanashiro, K. Nakahodo, M. Nakamura, Inhalation 
of platelet-activating factor increases respiratory resistance in rats: Determination by 
means of an astograph under nonanesthetized conditions, The Laryngoscope, 103 (1993) 
428-430. 
[174]  E.G. Langenback, J.M. Davis, C. Robbins, N. Sahgal, R.J. Perry, S.R. Simon, Improved 
pulmonary distribution of recombinant human Cu/Zn superoxide dismutase, using a 
modified ultrasonic nebulizer, Pediatric Pulmonology, 27 (1999) 124-129. 
[175]  J.C. Waldrep, R. Dhand, Advanced Nebulizer Designs Employing Vibrating 
Mesh/Aperture Plate Technologies for Aerosol Generation, Current Drug Delivery, 5 
(2008) 114-119. 
[176]  A.B. Watts, J.T. McConville, R.O. Williams, Current therapies and technological 
advances in aqueous aerosol drug delivery, Drug Development and Industrial Pharmacy, 
34 (2008) 913-922. 
[177]  L. Vecellio, The mesh nebuliser: a recent technical innovation for aerosol delivery, 
Breathe, 2 (2006) 252-260. 
[178]  H.W. Frijlink, A.H. de Boer, Trends in the technology-driven development of new 
inhalation devices, Drug Discovery Today: Technologies, 2 (2005) 47-57. 
[179]  J.S. Lass, A. Sant, M. Knoch, New advances in aerosolised drug delivery: vibrating 
membrane nebuliser technology, Expert Opinion on Drug Delivery, 3 (2006) 693-702. 
[180]  Y. Saeki Adachi, T. Itazawa, M. Nakabayashi, T. Fuchizawa, Y. Okabe, Y. Ito, Y. 
Adachi, G. Murakami, T. Miyawaki, Safety and usefulness of a novel eMotion electric 
mesh nebulizer in children with asthma, Allergology international : official journal of the 
Japanese Society of Allergology, 55 (2006) 167-171. 
Introduction 
43 
[181]  L. Pitance, L. Vecellio, T. Leal, G. Reychler, H. Reychler, G. Liistro, Delivery efficacy of 
a vibrating mesh nebulizer and a jet nebulizer under different configurations, J Aerosol 
Med Pulm Drug Deliv, 23 (2010) 389-396. 
[182]  A.L. Coates, M. Green, K. Leung, J. Chan, N. Ribeiro, E. Louca, F. Ratjen, M. Charron, 
M. Tservistas, M. Keller, Rapid pulmonary delivery of inhaled tobramycin for 
Pseudomonas infection in cystic fibrosis: A pilot project, Pediatric Pulmonology, 43 
(2008) 753-759. 
[183]  A.L. Coates, M. Green, K. Leung, E. Louca, M. Tservistas, J. Chan, N. Ribeiro, M. 
Charron, The challenges of quantitative measurement of lung deposition using 99mTc-
DTPA from delivery systems with very different delivery times, Journal of aerosol 
medicine : the official journal of the International Society for Aerosols in Medicine, 20 
(2007) 320-330. 
[184]  K.G. Schuepp, S. Devadson, C. Roller, J.H. Wildhaber, A complementary combination 
of delivery device and drug formulation for inhalation therapy in preschool children, Swiss 
medical weekly, 134 (2004) 198-200. 
[185]  T. Ghazanfari, A.M.A. Elhissi, Z. Ding, K.M.G. Taylor, The influence of fluid 
physicochemical properties on vibrating-mesh nebulization, International Journal of 
Pharmaceutics, 339 (2007) 103-111. 
[186]  R. Dhand, New Frontiers in Aerosol Delivery during mechanical Ventilation, Respiratory 
Care, 49 (2004) 666-677. 
[187]  M. Knoch, M. Keller, The customised electronic nebuliser: a new category of liquid aerosol 
drug delivery systems, Expert Opinion on Drug Delivery, 2 (2005) 377-390. 
[188]  R. Stangl, S. Seemann, M. Knoch, Customizing an Electronic Nebulizer in:  ISAM 15th, 
Perth, Australia, 2005. 
[189]  K. Schmid (2011): Spray drying of protein precipitates and Evaluation of the Nano Spray 
Dryer B-90. PhD thesis, Ludwig Maximilian University Munich: Faculty of Chemistry 
and Pharmacy. 
[190]  K. Nikander, I. Prince, S. Coughlin, S. Warren, G. Taylor, Mode of breathing-tidal or 
slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung 
deposition of (99m)Tc-DTPA, J Aerosol Med Pulm Drug Deliv, 23 (2010) S37-43. 
[191]  M. Keller, M. Tservistas, E. Bitterle, S. Bauer, Aerosol Characterization of Alpha-1 
Antitrypsin After Nebulization with the eFlow(R): A Novel Vibrating Perforated 
Membrane Nebulizer, in: R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr (Eds.) 
Respiratory Drug Delivery X, Boca Raton, FL, USA, 2006, pp. 733-736. 
[192]  A. Poncin, M. Tservistas, C. Zankl, T. Gerlza, A. Luithlen, R. Egle, R. Doornbos, M. 
Knoch, A. Kungl, a novel formulation of an il-8 decoy chemokine, pa401, with potential 
application for the treatment of copd can be nebulized by eflow (r) technology, in:  
Chapter II 
44 
Journal Of Aerosol Medicine And Pulmonary Drug Delivery, Mary Ann Liebert, Inc 140 
Huguenot Street, 3rd Fl, New Rochelle, Ny 10801 USA, 2013, pp. A248-A249. 
[193]  J. Tepper, A. Tomkinson, Methods for treating asthma in human and non human 
primates using IL-4 mutant compositions, U.S. Patent 7947648, issued 05/24/2011. 
[194]  R. Dalby, M. Spallek, T. Voshaar, A review of the development of Respimat® Soft Mist™ 
Inhaler, International Journal of Pharmaceutics, 283 (2004) 1-9. 
[195]  S.J. Farr, A. McElduff, L.E. Mather, J. Okikawa, M.E. Ward, I. Gonda, V. Licko, R.M. 
Rubsamen, Pulmonary insulin administration using the AERx system: physiological and 
physicochemical factors influencing insulin effectiveness in healthy fasting subjects, 
Diabetes Technol Ther, 2 (2000) 185-197. 
[196]  J. Thipphawong, B. Otulana, P. Clauson, J. Okikawa, S.J. Farr, Pulmonary insulin 
administration using the AERx insulin diabetes system, Diabetes Technol Ther, 4 (2002) 
499-504. 
[197]  T.J. Kamerzell, R. Esfandiary, S.B. Joshi, C.R. Middaugh, D.B. Volkin, Protein
excipient interactions: Mechanisms and biophysical characterization applied to protein 
formulation development, Advanced Drug Delivery Reviews, 63 (2011) 1118-1159. 
[198]  S. Frokjaer, D.E. Otzen, Protein drug stability: a formulation challenge, Nat Rev Drug 
Discov, 4 (2005) 298-306. 
[199]  S.P. Sellers, Y.-F. Maa, Principles of Biopharmaceutical Protein Formulation: An 
Overview, in: C.M. Smales, D.C. James (Eds.) Therapeutic Proteins, Humana Press Inc., 
Totowa, NJ, 2005, pp. 243-263. 
[200]  Ph.EUR., Preparations for Inhalation, in: B. European Directorate for the quality of 
Medicine (EDQM), Belgium (Ed.) 0671, European Directorate for the quality of Medicine 
(EDQM), Ph.Eur., 2008, pp. 1048-1053. 
[201]  R. Beasley, P. Rafferty, S.T. Holgate, Adverse reactions to the non-drug constituents of 
nebuliser solutions, British Journal of Clinical Pharmacology, 25 (1988) 283-288. 
[202]  O.N.M. Mc Callion, K.M.G. Taylor, M. Thomas, A.J. Taylor, The influence of surface 
tension on aerosols produced by medical nebulisers, International Journal of 
Pharmaceutics, 129 (1996) 123-136. 
[203]  O.M. McCallion, K.G. Taylor, M. Thomas, A. Taylor, Nebulization of Fluids of Different 
Physicochemical Properties with Air-Jet and Ultrasonic Nebulizers, Pharmaceutical 
Research, 12 (1995) 1682-1688. 
[204]  O.N.M. Mccallion, K.M.G. Taylor, M. Thomas, A.J. Taylor, Ultrasonic Nebulisation of 
Fluids with Different Viscosities and Surface Tensions, Journal of Aerosol Medicine, 8 
(1995) 281-284. 
Introduction 
45 
[205]  FDA, Inactive Ingredient Database for Approved Drug Products, FDA, Center for Drug 
Evaluation and Research, Office of Generic Drugs, Silver Spring, MD, USA. Retrieved 
09/03/2013 from http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. 
[206]  S.A. Shoyele, A. Slowey, Prospects of formulating proteins/peptides as aerosols for 
pulmonary drug delivery, International Journal of Pharmaceutics, 314 (2006) 1-8. 
[207]  L. Garcia-Contreras, H.D.C. Smyth, Liquid-Spray or Dry-Powder Systems for Inhaled 
Delivery of Peptide and Proteins?, American Journal of Drug Delivery, 3 (2005) 29-45. 
[208]  T. Serno, E. Hartl, A. Besheer, R. Miller, G. Winter, The role of polysorbate 80 and 
HPbetaCD at the air-water interface of IgG solutions, Pharm Res, 30 (2013) 117-130. 
[209]  J. Dunn, R. Nayar, J. Campos, B. Hybertson, Y. Zhou, M. Manning, J. Repine, K. 
Stringer, Feasibility of Tissue Plasminogen Activator Formulated for Pulmonary 
Delivery, Pharmaceutical Research, 22 (2005) 1700-1707. 
[210]  H. Steckel, F. Eskandar, K. Witthohn, The effect of formulation variables on the stability 
of nebulized aviscumine, International Journal of Pharmaceutics, 257 (2003) 181-194. 
[211]  R. Bhat, S.N. Timasheff, Steric exclusion is the principal source of the preferential 
hydration of proteins in the presence of polyethylene glycols, Protein Science, 1 (1992) 
1133-1143. 
[212]  T. Arakawa, S.N. Timasheff, Mechanism of polyethylene glycol interaction with proteins, 
Biochemistry, 24 (1985) 6756-6762. 
 

Materials and Methods 
47 
Chapter III Materials and Methods 
1 Materials 
1.1 Proteins 
1.1.1 SM101 
SM101 was provided by SuppreMol GmbH (Martinsried, Germany). SM101 is the soluble Fc 
gamma receptor IIB (sFcγRIIB) produced by expression of the extracellular domain of human 
FcγRIIB in E. coli. The molecule is unglycosylated and has a molecular weight of approximately 
20 kDa. The crystal structure was revealed by Sondermann et al. [1, 2]. SM101 belongs to the 
immunoglobulin superfamily and exhibits mainly beta-sandwich tertiary structure (Figure III-1). 
 
Figure III-1: Stereoscopic view of the crystal structure of human Fc gamma receptor IIb ectodomain (cd32). 
Secondary structure elements are color coded: beta strand (yellow), 3/10 helix (violet) and random coil (grey). 
Receptors of the Fc region of immunoglobulins mediate the effects of antibodies and immune 
complexes (IC) and thereby link the humoral and the cellular immune system [3]. FcRs binding 
IgG antibodies are labeled FcγR. Different FcγR subclasses occur endogenously in humans as 
type I transmembrane proteins or in a soluble form of which FcγRIIB is the only inhibitory 
receptor. FcγR are expressed on most immune cells, except T-cells and are involved in the 
activation and regulation of immune responses. FcγRIIB is involved in down regulation and 
control of antibody or IC mediated phagocytosis, antigen presentation, antibody dependent 
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cellular cytotoxicity (ADCC) and release of pro-inflammatory cytokines. Additionally FcγRIIB 
downregulate B-cell activity and thereby reduce antibody production. The absence or insufficient 
ratio of inhibitory FcγRIIB was related to autoimmune diseases like arthritis and systemic lupus 
erythematosus (SLE) in mice and in humans.  
SM101 competes with FcR bearing immune cells for autoantigen/autoantibody complexes and 
thus prevents autoantibody production by plasma-cells and the triggering of the inflammatory 
cascade. This suggests the efficacy of SM101 for the treatment of various autoimmune diseases. 
Clinical studies evaluating the potential of intravenously administered SM101 for the treatment 
of primary immune thrombocytopenia (ITP) and SLE are currently in phases IIb and IIa 
respectively [4] and “excellent safety and long lasting pharmacodynamic effects” have been 
shown. Local pulmonary delivery of SM101 would enable the treatment of immune related 
diseases or symptoms occurring in the lungs. Possible conditions include farmer’s lung, SLE 
alveolitis or COPD. 
Since SM101 is homologous to the endogenously occurring sFcγRIII, a rise of anti-drug antibodies 
(ADA) might have serious consequence involving depletion of the natural counterpart [5-7] with 
serious impact on the immune system. Notably no ADA against SM101 were found in patients 
repeatedly receiving SM101 infusions [8]. 
Bulk drug substance was supplied in 5.3 mM NaH2PO4, 1.96 mM KH2PO4 and 150 mM NaCl, 
pH 6.5 at a SM101 concentration of 8.2 mg/mL. Each batch of API material was reformulated 
and the phosphate buffer was quantitatively exchanged via cation-exchange chromatography 
(CEX) on an ÄKTA Explorer 100 (GE Healthcare). CEX buffer exchange yielded SM101 in 
histidine buffered saline (HBS) of 20 mM histidine and 216-264 mM sodium chloride at pH 6.5 
with SM101 concentrations ranging from 7.2-14.1 mg/mL. Sodium chloride content was 
calculated from the conductivity, normalized to the values of the loading and elution buffer 
employed. SM101 concentration in the eluate was determined via UV/Vis spectroscopy at 280nm 
with an extinction coefficient of 1.51625 g/L*cm used for calculation. Aliquots of reformulated 
SM101 stock were stored at -80°C until used. 
SM101 formulations were made up from concentrated excipient stock solutions and aliquoted 
SM101 stock and then filtered through 0.2 µm PVDF syringe filters (Acrodisc® LC 25mm Syringe 
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Filter, PALL Life Science, Dreieich, Germany), whereas surfactant stock was added afterwards. 
Surfactant stock was filtered separately whereby the first syringe volume was discarded for filter 
saturation. SM101 was used in several formulations and concentrations throughout different 
stages of this thesis as indicated in Table III-1. Sodium chloride content was adjusted to either 
75 or 150 mM and the SM101 concentration was set to the desired value in a range of 0.25 to 
20.0 mg/mL.  
To obtain SM101 concentrations of 10 mg/mL or above SM101 stock was concentrated by 
ultracentrifugation with Vivaspin 15 units with a molecular weight cut-off (MWCO) of 5kDa 
(Sartorius Stedim Biotech GmbH, Goettingen, Germany) in a swing bucket centrifuge at 4000 g 
and 4°C (Sigma 4K15, Osterode am Harz, Germany). Concentrator membranes were flushed with 
a unit volume of placebo buffer prior to use. Recovered SM101 was syringe filtered (Puradisc™ 
PVDF, Whatman, Whatman International, Kent, UK), SM101 concentration determined via 
UV/Vis spectroscopy and adjusted to a desired value with a respective buffer solution. To reduce 
sodium chloride content of formulation candidate C to 0 mM, the buffer was exchanged by 
repeated dilution and ultrafiltration of the SM101 stock solution. 
At a later stage of the project, SuppreMol GmbH had established a new manufacturing process 
that yielded SM101 drug substance formulated directly in the newly developed (Chapter V) 
parenteral formulation (Table III-1: parenteral formulation / candidate B). Using this as a 
starting material, the aerosol formulation (Table III-1) used in the in vivo studies (Chapter VI) 
was generated by 1:1 dilution with an excipient stock solution containing 20 mM histidine, 0 mM 
NaCl, pH 6.5, 3.33% sucrose and 1.67% mannitol. This was done under aseptic conditions, under 
a laminar airflow and the final formulation was sterile filtered into pyrogen-free and sterile falcon 
tubes. 
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naturally occurring in the cytoplasm of virtually all living beings, where it catalyzes the reduction 
of pyruvate to lactate under concomitant regeneration of the reduced β-NADH/H+ to β-NAD+ 
during anaerobic glycolysis (lactic acid fermentation). Another motivation for LDH application 
throughout this thesis was its readily available activity assay, which is based on the 
spectrophotometric monitoring of this enzymatic reaction. LDH is a tetrameric protein made up 
of two different sub-units  the M- and the H-type. All five possible isoforms are distributed in 
an organ specific manner in the human body. Serum levels of LDH isozymes are therefore used 
to diagnose damage of particular organs or tissue.  
According to the structural classification of proteins (SCOP), LDH belongs to the alpha and beta 
proteins class. Rabbit muscle lactic dehydrogenase (LDH) with a total molecular weight of 140 
kDa was purchased from Sigma Aldrich (LDH, Cat. # L2500, Sigma-Aldrich Chemie GmbH, 
Munich, Germany). Prior to use, LDH was dialyzed against an excess of 20 mM potassium 
phosphate buffer, pH 7.4 with 12-30 mL Slide-a-Lyzer® casettes (Thermo Fisher Scientific, 
Rockford, Il, USA) of 30 kDa MWCO. Dialysis buffer was exchanged twice before overnight 
dialysis. LDH solution was filtered through 0.2 µm PVDF syringe filters (Puradisc PVDF, 
Whatman, Whatman International, Kent, UK) after removal from the dialysis cassette. LDH 
concentration was determined spectrophotometrically at 280nm with an extinction coefficient 
ε = 1.49 mL*mg-1*cm-1. During surrogate screening studies (Chapter V), formulations containing 
one additional excipient were made from excipient stock solutions and LDH stock of 1.0 mg/mL. 
LDH was used in a final concentration of 0.2 mg/mL throughout all experiments. 
1.1.3 Granulocyte-colony stimulating factor (G-CSF) 
Recombinant human granulocyte-colony stimulating factor (G-CSF) material from two sources 
was used throughout this thesis. Studies evaluating the feasibility of systemic pulmonary delivery 
of G-CSF revealed its sensitivity to nebulization [15, 16]. Therefore, G-CSF was chosen as a 
second model protein. Its surface activity and its distinct pH sensitive stability made it the ideal 
model protein for the investigation about the impact of proteins on nebulizer performance 
(Chapter IV) and for the surrogate screening method (Chapter V).  
Physiologically, it is a cytokine involved in hematopoiesis, controlling the production, 
differentiation and function of neutrophil and basophile granulocytes from bone marrow. 
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Recombinant human G-CSF is used to treat febrile neutropenia, prevent neutropenia after 
chemotherapy and to increase the count of hematopoietic stem cells (HSC) before HSC donation. 
Besides the original Neupogen® (Amgen GmbH, Thousand Oaks, CA, USA), several biosimilars 
are marketed. G-CSF has a molecular weight of 19.6 kDa and belongs to the all alpha proteins 
class (SCOP) with a four-helix bundle tertiary structure. 
G-CSF was provided at 4.04 mg/mL G-CSF in 10 mM acetate buffer, 0.005% PS20 at pH 4.0. 
It was excessively dialyzed to a 100mM acetate buffer pH 3.5 to eliminate PS20 content following 
the dialysis procedure described above. Dialyzed G-CSF was filtered through 0.2 µm PVDF 
syringe filters (Puradisc PVDF, Whatman, Whatman International, Kent, UK) and adjusted to 
a concentration of 0.3 or 3.0 mg/mL. Sodium hydroxide was added to adjust pH to 4.0, 4.5 or 
5.0. The experiments described in chapter IV were conducted with this material. Surrogate 
screening experiments reported in chapter V were carried out with 1.0 mg/mL G-CSF in 20 mM 
potassium hydrogen phosphate buffer at pH 4.4. Formulations with one additional excipient were 
made from stock solutions. G-CSF starting material for this experiment was provided at 4 mg/mL 
G-CSF in 20 mM KHPO4 pH 4.0. At pH 4.4, G-CSF remained sufficiently storage stable but was 
very sensitive to nebulization and interfacial stress.  
1.1.4 Monoclonal immunoglobulin G (IgG) 
The monoclonal antibody of the IgG 1 class was a gift from Roche Diagnostics GmbH (Penzberg, 
Germany). Degradation of this IgG has been described after vortexing [17] and freeze/thawing 
[18] which indicates its sensitivity towards interfacial stress. It was therefore selected as a more 
thermostable model protein for nebulization at high protein concentrations (Chapter IV). 
IgG starting material was formulated in 10 mM potassium phosphate buffer at pH 6.9. 15 mg/mL 
IgG were used to investigate the impact of aerosol cloud collection and nebulization on protein 
stability. IgG formulations at 15 mg/mL or 40 mg/mL IgG served as models to investigate the 
impact of protein induced viscosity increase on nebulizer performance. In the case of 40 mg/mL, 
IgG was concentrated by ultrafiltration (Vivaspin 20, 30.000 kDa MWCO, Sartorius Stedim, 
Göttingen, Germany). All IgG formulations were syringe filtered through 0.2 µm PVDF filters 
(Puradisc PVDF, Whatman, Whatman International, Kent, UK). 
Materials and Methods 
53 
1.1.5 Anti-chicken egg albumin antibody (Anti-OVA IgG) 
Polyclonal anti-chicken egg albumin antibody (anti-OVA IgG) was used to initiate an immediate 
immune response to OVA antigen in the passive pulmonary Arthus reaction model in mice as 
described by Skokowa [19] (Chapter VI). Polyclonal anti-OVA IgG in whole serum was bought 
from Sigma Aldrich (Munich, Germany, Cat. # C5634). The serum contained a total protein 
fraction of 70.8 mg/mL mainly made up of albumin and immunoglobulins, while the specific anti-
OVA IgG concentration was 4.2 mg/mL. The formulation was used undiluted during in vitro 
stability/activity assessment and for in vivo studies. 
1.1.6 Ovalbumin (OVA, chicken egg albumin) 
Endotoxin free OVA (lot # 11785, Hyglos GmbH, Bernried am Starnberger See, Germany) was 
used as an antigen in the Arthus reaction model in mice (Chapter VI). OVA was purchased as a 
lyophilized powder and a stock solution of 19.3 mg/mL OVA in 20 mM histidine, 150 mM NaCl, 
2% sucrose, 1% mannitol, 0.005% polysorbate 20 was prepared. Prior to instillation, OVA 
concentration was diluted to 0.8 mg/mL with respective placebo buffer. For preliminary stability 
testing, OVA grade 5 was bought from Sigma Aldrich (Steinheim, Germany). Formulations of 
4.0-10.0 mg/mL OVA in PBS or 10 mM or 100 mM sodium phosphate buffer at pH 7.0, 7.4 or 
8.0 were subjected to in vitro stability determination after nebulization. 
OVA is the main protein component in chicken egg white. OVA belongs to the serpin superfamily 
and has a molecular weight of 43-45 kDa. It is commonly used as a model antigen to induce 
immune reactions in animal models. Available commercial OVA material is often contaminated 
with endotoxic LPS which interferes with the inflammatory response.  
1.2 Excipients 
Table III-2 lists all excipients used in formulations throughout this thesis. Excipients used for 
purposes other than formulation are summarized in Table III-3. 
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2 Methods 
2.1 Nebulization  
Throughout this thesis, various vibrating mesh (VM) and a jet nebulizer have been employed. 
The nebulization conditions applied are mentioned below and referred to the respective chapter 
and section. 
2.1.1 Nebulizer performance 
Three different VM nebulizers  a PARI eFlow® (PARI GmbH, Starnberg, Germany, Cat. # 
678G200), an Aeroneb® Go (Aerogen, Galway, Ireland) and a MicroAIR U22 (OMRON 
Healthcare Europe, Hoofddorp, Netherlands)  were charged with 1 mL solution and operated 
until complete nebulization. Nebulized solutions contained physiologic saline with or without the 
addition of sucrose or PS20 to manipulate viscosity or surface tension respectively. Furthermore, 
the impact of proteins and excipients on VM nebulizer performance was examined with a PARI 
eFlow® loaded with 4 mL solution, which were completely nebulized. The same conditions were 
applied for the evaluation of protein aggregation on VM nebulizer performance. 
2.1.2 Aerosol collection method evaluation  
Aerosol collection procedures were evaluated for aerosols of either 3 mg/mL SM101 or 15 mg/mL 
IgG1 generated with a PARI® eFlow loaded with 4mL solution. 
2.1.3 Nebulizer heat up  
A PARI eFlow® was charged with either 1, 2, 3 or 4 mL saline and completely nebulized to 
assess the impact of initial load (IL) on reservoir temperature progression during nebulization.  
2.1.4 Normal and passively cooled nebulization  
A PARI eFlow® was used to compare different nebulization procedures regarding their effect on 
the temperature in the medication reservoir (TRES). The impact on aerosol characteristics was 
assessed by physiologic saline nebulization. Resulting protein degradation was studied for three 
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different proteins including LDH, IgG and SM101. For all nebulization procedures, 3 mL solution 
were nebulized. Further details of the nebulization procedures were as follows: 
Normal 
During ‘Normal’ nebulization the PARI eFlow® was charged with 3 mL solution at room 
temperature and then nebulized completely. 
Pre-cooled (PC) 
Nebulizer solution was ‘pre-cooled’ (PC) in a refrigerator and 3mL of pre-cooled solution were 
charged into the reservoir and nebulized completely without prior equilibration to room 
temperature. 
Overloaded (OL) 
Another approach included loading the medication reservoir with 4 mL solution of which only 3 
mL were nebulized. Overloading was performed either with solutions equilibrated to room 
temperature (OL) or in combination with pre-cooled solution (PC-OL). Nebulization time was 
used to determine the moment when 3mL solution had been nebulized and operation had to be 
terminated. 
Intermittent (IM) 
Intermittent nebulization (IM) was achieved manually with a frequency of 5s nebulization 
followed by 5s pausing. 3mL solution equilibrated to room temperature was completely nebulized. 
2.1.5 Nebulization of the parenteral SM101 formulation  
A PARI eFlow® was overloaded with 2.2 mL pre-cooled parenteral formulation containing 20 
mg/mL SM101. 1.2 mL were nebulized and collected in 2 mL PP tubes as described in section 
2.5. The nebulized-collected and the residual fraction were analyzed for SM101 stability and 
activity.  
2.1.6 Surrogate method development  
During surrogate screening method development and parameter tuning for the proteins LDH and 
G-CSF, reference nebulization was performed with a PARI eFlow®. For SM101 and LDH 
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reservoir overloading as described above (section 2.1.4) was applied and a total of 4 mL solution 
was charged into the medication reservoir. For G-CSF the loaded 4mL were completely nebulized. 
All protein aerosols were collected in either 2 mL or 0.65 mL PP caps as described in section 2.5. 
2.1.7 Aerosol formulation candidate nebulization  
The candidates for the SM101 aerosol formulation were nebulized with an AKITA2 vibrating 
mesh nebulizer and an AKITA jet (both Activaero GmbH, Gemünden, Germany) nebulizer. Both 
devices were operated in an intermittent mode consisting of a 5 s inhalation and 5 s exhalation 
phase. Aerosol was only generated during the first 4 s of the inhalation phase. AKITA2 
nebulization conditions followed the PC-OL procedure mentioned above (section 2.1.4). The 
formulations were pre-cooled to 10-15°C. And 2.0-2.5 mL of the 4.0 mL charge were nebulized 
and collected in 2 mL PP tubes and pooled prior analysis. 
Nebulization conditions for the AKITA jet were designed to generate a comparable amount of 
aerosol as the AKITA2. Aiming for approximately 2 mL to remain inside the medication reservoir 
for subsequent analysis of SM101 activity and stability, 5 mL were loaded in the reservoir and 
the device was operated for 20 minutes.  
2.1.8 Pneumatic and manual in vitro MicroSprayer® use  
A MicroSprayer® Aerosolizer  Model IA-1C-M with a FMJ-250 High Pressure Syringe (both 
Penn-Century. Inc., Wyndmoor, PA, USA) was used to generate aerosols from 100-250µL 
solutions, previously filtered through 0.2 µm syringe filters (Puradisc PVDF, Whatman, 
Whatman International, Kent, UK). After spraying of protein formulations, the MicroSprayer® 
was cleaned with filtered 1% SDS solution. Actuation of the MicroSprayer® was either done 
manually or with a pneumatic actuator device operated with pressurized air, set to a defined 
pressure in a range of 2.0-8.0 bar. The pneumatic actuator was developed by Otmar Schmid and 
his group (CPC, Neuherberg, Germany). 
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2.1.9 In vitro stability to small volume vibrating mesh nebulization  
Prior to selection of the nebulizer employed for vented intubated inhalation in in vivo studies, 
three prospect vibrating mesh nebulizers were compared regarding aerosol characteristics and 
operating temperature. Therefore, a PARI eFlow®, an Aeroneb® Pro and an Aeroneb® Solo were 
loaded with 1 mL placebo aerosol formulation and operated until dryness. 
The stability of SM101 and anti-OVA IgG after complete nebulization in small volume samples 
was investigated with an Aeroneb® Pro. Therefore, 100 µL 10 mg/mL SM101 in HBS or in the 
aerosol formulation was nebulized. The solution was dispensed directly onto the mesh of the 
nebulizer. Five aliquots were pooled into one sample for stability analysis. For anti-OVA IgG, 
400 µL samples were completely nebulized. 
2.2 Temperature measurement during nebulization 
Nebulizer reservoir temperature was recorded with a Data Logger (OMEGA HH147U, Newport 
Electronics GmbH, Deckenpfronn, Germany). A thin wire thermocouple was placed at the bottom 
of the reservoir in proximity to the membrane while not touching it, to measure reservoir 
temperature during the entire nebulization. The heating rate was calculated as the slope of the 
linear regression of the TRES curve. The temperature of the vibrating membrane itself was 
approximated by temperature measurements on the metal substrate holding both the membrane 
and the vibrating piezo element [20]. A wire thermocouple was connected to the metal substrate 
with thermal adhesive (Conrad Electronic SE, Hirschau, Germany), so that neither piezo nor 
membrane operation were impaired (Figure III-2). 
 
Figure III-2: Thermo couple attached to PARI eFlow® aerosol head. 
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2.4.1 Output rate 
The output rate (OR) of a nebulizer was determined gravimetrically as evaporation was negligible 
[21]. Therefore, nebulizer weight was determined before and after nebulization and the 
nebulization time was recorded. OR was calculated according to Equation III-1. 
Equation III-1  
 
2.4.2 Time resolved output rate 
Time resolved output rate data was generated by operating a PARI eFlow® placed on an 
analytical balance (Mettler-Toledo GmbH, Gießen, Germany). The weight loss upon nebulization 
was recorded on a computer and plotted over nebulization time. The weight was also monitored 
before and after nebulization to assure a balanced setup. The output rate at any time point was 
calculated as the first derivative of the mass loss over time curve. ORIGIN v8.0 was used to 
generate the first derivative in a three step process. Initially the raw data was smoothed with a 
5 point Savitzky-Golay filter. The first derivative was calculated and the data set smoothed with 
a percentile filter set to 50% percentile and a 25 point window. 
2.4.3 Aerosol droplet size distribution 
Aerosol droplet size distribution was determined via laser diffraction on a MasterSizer X (Malvern 
Instruments GmbH, Herrenberg, Germany) equipped with a 300 mm lens. Nebulizers were placed 
such that the aerosol passed the lens at a distance of 4 cm before being cleared by a vacuum 
suction system. Measurements were performed continuously every 3 seconds during the entire 
duration of nebulization. Results are either presented time-resolved by plotting the single values 
over nebulization time or as a mean value calculated from all single values of the entire duration 
of nebulization. 
Aerosol size distribution was characterized as the volume median diameter (d[v,50] or VMD) and 
the geometric standard deviation (GSD). The respirable fraction (RF, also: fine particle fraction 
(FPF)) was calculated as the fraction of nebulized volume within 1.0-5.0 µm sized droplets. 
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For the MicroSprayer®, a modified setup was used since the atomization process lasted only few 
seconds not minutes as during nebulization. Time resolved data of up to 100 measurements were 
recorded in the internal buffer of the MasterSizer for each atomization. The duration of a single 
measurement was adjusted such that the entire atomization process was recorded in no more 
than 100 measurements. Therefore, the number of sweeps (1 sweep = 2 µs) was set in a range of 
1-50 depending on the spray duration (sprayed volume and the applied actuation pressure). 
2.4.4 Calculation of derived aerosol characteristics 
Additional aerosol parameters derived from OR, RF and remaining protein activity were 
calculated as follows. 
The inhalable aerosol rate (IAR) was calculated from OR and RF: 
Equation III-2 
 
The fraction of protein aerosols which is both respirable and biologically active is indicated by 
the active respirable fraction (aRF), i.e. the product of RF and remaining protein activity: 
Equation III-3 
 
Finally, the rate at which active and respirable aerosol is generated can be calculated as the 
product of OR, RF and remaining activity  the active inhalable aerosol rate (aIAR). 
Equation III-4 
 
2.5 Aerosol Cloud Collection 
In order to analyze protein stability after nebulization, generated aerosol clouds had to be re-
collected. By default, re-collection of aerosols from VM nebulizers and the MicroSprayer® was 
achieved by condensation in 2 mL polypropylene (PP) caps (VWR International, Darmstadt, 
Germany), which were placed directly in front of the vibrating mesh or the MicroSprayer® tip. 
No more than 1 mL condensate was collected per cap to ensure enough space for aerosol droplet 
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formation. Larger aerosol quantities were collected in multiple caps and the fractions 
subsequently pooled prior to analysis. The amount of aerosol collected was determined by 
weighing the caps. In chapter IV.4, smaller fractions of 300-600 µL condensate were collected and 
not pooled but analyzed fraction-wise in order to monitor protein degradation over nebulization 
time. 
Additional collection procedures for VM nebulizers were evaluated in chapter IV.3 regarding the 
impact on protein degradation and collection efficiency (Figure III-4). Collection efficiency was 
defined as the fraction of the initial reservoir charge recovered by the collection procedure and 
determined gravimetrically. If the collection procedure included dilution, solvent evaporation or 
washing steps (TSI and RC collection method), collection efficiency was calculated from the 
recovery of an inert marker. The use of SM101 itself was not feasible since SM101 concentration 
may also be altered by degradation. Instead, 1 µg/mL 5/6-carboxyfluorescein (CF) was added to 
the formulation to retrace the extent of dilution and solvent evaporation. The factor f(CF) was 
calculated as the CF amount recovered after sample collection divided by the initial CF amount 
and used to correct results of stability indicating assays for sample dilution or solvent 
evaporation. 
Equation III-5 
 
2.5.1 Fluorescence (CF) 
CF fluorescence was determined in a 96 well plate on a FLUOstar Omega (BMG LABTECH 
GmbH, Offenburg, Germany). The excitation filter was set to 485nm and emission was recorded 
at 520 nm. Calibration was performed with CF standards at 0.078, 0.156, 0.312, 0.625, 1.25 and 
2.50 µg/mL.  
2.5.2 Collection procedures 
Collection in test tubes of different size 
PP caps of 2 mL, 4 mL and 15 mL and 4 mL glass cuvettes (Nephla turbidity tube, Hach Lange, 
Düsseldorf, Germany) were used to collect aerosol clouds by placing the collectors directly in 
front of the vibrating mesh. 
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Collection inside the aerosol chamber 
The aerosol chamber of a PARI eFlow® was used to collect its aerosol by simply exchanging the 
mouthpiece with a tightly sealing cap [22], so that the emitted aerosol condensed inside the 
aerosol chamber. Aerosol chambers of 27.4 mL (small) or 48 mL (large) were compared [23]. 
Collection in a twin-stage impinger (TSI)  
A twin-stage glass impinger (TSI) was used for aerosol collection [11, 13, 24]. Air-flow through 
the impinger was set to 30 L/min. Depending on droplet size, the aerosol deposits in the placebo 
buffer filled first or second stage of the collector. The stages were filled with 7 mL or 30 mL 
placebo buffer respectively. 
Collection in a reflux condenser (RC) 
Inspired by the methods proposed by Ip et al. [25] and Steckel et al. [26], aerosol was collected 
in a modified reflux condenser. Aerosol was drawn through a water cooled RC by a vacuum at a 
flow rate of 15 L/min and condensed on the walls of the internal coil. Condensed liquid collected 
in a PP tube below the RC. After nebulization, the internal coil was flushed with 3 mL of placebo 
buffer and the washing fraction was collected separately. 
Collection negative controls 
In order to discriminate nebulizer induced protein degradation from collection artifacts, both 
nebulized and non-nebulized protein formulation were collected by the same methods and protein 
stability compared. For test tube and aerosol chamber collection protein solution was pipetted 
repeatedly along test tube walls for five minutes, to simulate surface related stress without 
nebulization. Additionally, the data for the different sized tubes were compared to evaluate the 
impact of collector surface on protein degradation. TSI induced protein degradation was 
controlled by the addition of 4 mL protein solution directly into the 30 mL placebo buffer of the 
second stage and applying an air-flow of 30 L/min for 5 minutes. Non-nebulized protein solution 
was drawn through the reflux condenser at an air-flow of 15 L/min. Approximately 0.5 mL 
protein solution were added to the RC per minute for a total of five minutes. The solution was 
collected in a PP tube and a 3mL wash fraction was collected separately. 
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Figure III-4: Pictures of the evaluated aerosol collection methods, including collection in a reflux condenser (top 
left), in a buffer filled twin-stage impinger (bottom right), inside the aerosol chamber of the nebulizer (top right) 
or in test tubes (bottom left). 
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2.6 Formulation Development 
2.6.1 Parenteral formulation development 
1 mL of each SM101 formulation candidate was filled into 2R glass vials (FIOLAX 35.0 x 16.00 
x 1.00 mm, klar HGB1/ISO719, Zscheile & Klinger, Hamburg, Germany) under a laminar air-
flow and sealed with rubber stoppers (Ø=13mm, Chlorobutyl Typ11044/VII/703, Zscheile & 
Klinger, Hamburg, Germany) and an aluminum cap (Ø=13mm, Zscheile & Klinger, Hamburg, 
Germany).  
Freeze/thaw (-20°C/+25°C) 
Freeze/thaw stability was determined after 0, 1, 2, 4 and 6 cycles. Therefore, 2R vials were placed 
into a freezer at -20°C for at least 2h. Frozen samples were thawed under gentle agitation 
(150rpm) at room temperature. Respective placebo controls were handled accordingly, while non-
frozen reference samples were stored at 2-8°C until analyzed. 
Accelerated storage stability at 25°C and 40°C 
Storage stability was assessed under accelerated stress conditions. Therefore, SM101 samples and 
respective placebos in 2R vials were stored at 25±0.5°C and analyzed after 0, 1, 7, 14 and 28 
days, while samples stored at 40±1°C were analyzed at day 0, 1, 2 and 7. 
2.6.2 Aerosol formulation development 
Surrogate method (Agitation at elevated temperatures) 
2.0 mL or 0.65 mL PP caps (VWR International, West Chester, Cat.# 20170-170 and Cat.# 
20170-293) half-filled with 1.0 mL or 0.325 mL sample respectively were agitated at 1450 rpm on 
a shaker platform (Eppendorf Mixer 5432, Eppendorf AG, Hamburg, Germany), which was 
modified to hold caps horizontally. Shaking was performed inside an incubator. During method 
development (Chapter V.3 for SM101 and Chapter V.4 for LDH and G-CSF) shaking time ranged 
from 5 to 60 minutes while incubator temperatures were set to 25±1°C, 30±1°C, 35±1 or 40±1°C. 
Settings used during surrogate based formulation development for SM101 were 10 minute 
agitation at 30°C. For G-CSF and LDH, agitation times were prolonged to 45 and 60 minutes 
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respectively. Additional experiments involving 60 minute agitation of SM101 and G-CSF at 30°C 
were performed. 
Design of experiment for aerosol formulation candidate selection 
Design and evaluation of the experiments for formulation optimization was done with Modde 9.0 
software (Umetrics, Umeå, Sweden). A central-composite-face centered design (CCF) including 
four factors with three levels each (high, average, low) was used, giving a total of 27 runs a 
centered triplicate included. Investigated factors were SM101 concentration, sodium chloride 
concentration, total sugar content (fixed sucrose:mannitol ratio of 2:1 (w:w)) and polysorbate 
concentration. Turbidity after application of the surrogate method was the response parameter, 
whereby turbidity of equally treated placebo was subtracted as blank. 
2.7 Protein stability 
2.7.1 Size exclusion chromatography (SE-HPLC) 
Size exclusion chromatography (SE-HPLC) was used to determine the extent of soluble protein 
aggregation and monitor changes in protein monomer content. Soluble protein aggregates and 
protein fragment content was calculated from respective peak area under the curve ratios. 
Deviations in protein monomer content were calculated dividing sample monomer peak area by 
monomer peak area of respective unstressed standards. 
Protein samples were diluted to 2.0 mg/mL (Chapter V - SM101 formulation development) or 
1.0 mg/mL protein (all other experiments) with respective formulation buffer. Samples with 
lower protein concentration were analyzed without prior dilution. After 5 minutes centrifugation 
at 18.000g, 100 µL of supernatant was injected onto a SE-HPLC column and eluted. 
SM101 
During parenteral formulation development for SM101 (Chapter V.2), SE-HPLC analytics were 
performed on an Agilent Series 1200 HPLC system by T. Pohl at SuppreMol. All consecutive 
SE-HPLC analyses were performed on a Merck Hitachi LaChrom 7000 HPLC system. Elution 
was monitored over a range of 200-400nm by a diode array detector to discriminate between 
proteinaceous and non-proteinaceous peaks. Calculations based on 280nm chromatogram data. 
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For separation, SM101 samples were injected onto a Superdex 75 300/10GL column (GE 
Healthcare Europe GmbH, Freiburg, Germany) and eluted with 20 mM histidine, 150 mM NaCl, 
pH 6.5 buffer at a flow rate of 0.5 mL/min. The column was calibrated with SM101 reference 
standard at 0.17, 0.39, 0.69, 1.39 and 2.8 mg/mL. 
G-CSF 
G-CSF samples were also separated with a Superdex 75 300/10GL column but 100 mM potassium 
phosphate buffer at pH 6.9 was used for elution at a flow rate of 0.5 mL/min. 
LDH 
LDH samples were injected onto a Superose 12 300/10GL column (GE Healthcare Europe GmbH, 
Freiburg, Germany) and eluted with 50 mM phosphate, 150 mM NaCl, pH 6.9 at 0.8 mL/min. 
IgG 
A Superose 12 column and 50 mM phosphate, 150 mM NaCl, pH 6.9 elution buffer were also 
used for the separation of monoclonal IgG samples at a flow rate of 0.8 mL/min. 
OVA 
OVA samples and mixtures of OVA and SM101 were separated on a Superose 12 column and 
eluted with a 50 mM phosphate, 150 mM NaCl, pH 6.9 buffer at a flow rate of 0.8 mL/min. 
Anti-OVA IgG 
Anti-OVA IgG and mixtures of anti-OVA IgG and SM101 were analyzed on a Dionex HPLC 
System (P680 pump, ASI100 autosampler, UVD170U UV/Vis detector, all Sunnyvale, CA, USA). 
For better results two Superose 12 columns were connected serially and samples eluted with 
50 mM phosphate, 150 mM NaCl, pH 7.0 at a flow rate of 0.8 mL/min. On this HPLC system 
elution was monitored at 215 nm, 254 nm and 280 nm while calculations based on 280 nm 
chromatogram data. 
2.7.2 Reverse phase chromatography (RP-HPLC) 
Chemical degradation of SM101 was analyzed by reverse phase chromatography (RP-HPLC). 
Therefore, samples were run over a Knauer Eurosil Bioselect 300-5 C4 column attached to a 
Dionex HPLC system (see above, SE-HPLC of anti-OVA IgG). The column was equilibrated in 
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2.7.7 Light obscuration 
Light obscuration performed on a PAMAS particle counter (PAMAS SVSS-C, PAMAS GmbH, 
Rutesheim) was used to determine subvisible particle counts in a range of 1 to 200 µm. After 0.5 
mL rinsing volume, three consecutive measurements of 0.3 mL sample were performed. Results 
were averaged and normalized to particle count in 1 mL of sample. Prior to each measurement, 
the system was flushed with ultra clean water until less than a total of 100 particles per milliliter 
and no particle greater 10 µm were observed. 
Samples were measured without dilution except during SM101 parenteral formulation 
development (Chapter V.2) and during investigation of SM101 and anti-OVA IgG stability to 
small volume VM nebulization (Chapter VI.3), where the measurements were performed after 
fivefold or 15-fold dilution with corresponding placebo buffer respectively to yield a total of 
1500 µL. The subvisible particle count in the undiluted sample was calculated by the following 
equation: 
 Equation III-6 
 
 
Particle count data was also used to estimate the mass of protein aggregated in subvisible 
particles. According to Barnard et al. [28], the average bin diameter was used to calculate the 
particle volume for each bin size assuming spherical particles. The density of protein particles 
was reported as 1.43 g/mL. Barnard assumed particles to contain 25% water and 75% protein, 
thus an additional factor is introduced into the equation. Bin particle count, bin volume and 
protein particle density are multiplied to give the particle mass in each size bin, which is 
integrated over the whole particle range to give the total mass of aggregates in the sample. 
Equation III-7 
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2.7.9 Visual inspection 
Visual inspection was performed in front of a white and black background under diffuse and 
direct illumination as outlined in European Pharmacopoeia method 2.9.20. Samples were 
classified according to Deutscher Arzneimittelkodex (DAC 2006). Categories are 0: no visible 
particles; 1: hardly visible particles within 5 seconds of inspection; 2: clearly visible particles 
within 5 seconds of inspection; 10: instantly visible large numbers of particles. 
2.7.10 OVA gel weight determination 
To quantify the extent of OVA gelation, formed gels were collected from container walls and 
transferred into fresh 1.5 mL PP reaction caps. Samples were than centrifuged for 5 minutes at 
18.000 g and the supernatant discarded. The gel pellets were transferred to small aluminum cups 
and dried for 1h at 80°C. Dried pellet weight was determined on a microbalance (Mettler Toledo, 
Gießen, Germany). 
2.8 Protein activity 
SM101 activity determination was performed by Thomas Pohl at the SuppreMol Laboratories in 
Martinsried, Germany. 
2.8.1 SM101 FACS potency assay 
The activity of SM101 after nebulization was measured using a FACS based cellular assay 
according to SuppreMol’s internal protocol. Raji cells (DSMZ # ACC319, human Burkitt 
Lymphoma) were incubated with a constant amount of aggregated human IgG (ligands for 
FcγRIIB) and varying amounts of SM101 (sFcγRIIB). In this setting, the soluble FcγRIIB-
receptor SM101 competes with the cell-bound FcγRIIB receptor, being the sole Fcγ receptor 
expressed on Raji cells, for binding to human aggregated IgG. Cell-bound aggregated IgGs can 
subsequently be detected by means of fluorescence labeled polyclonal secondary antibody binding 
to the heavy and light chain of human IgG. By applying varying amounts of SM101 to a set 
amount of cells and aggregated IgG a progressive inhibition of IgG binding to membrane-bound 
FcγRIIB (being a function of SM101 concentration) can be determined. Parallel control samples 
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with unstained cells and cells incubated with secondary antibody only are used to determine the 
auto-fluorescence of the cells as well as unspecific binding of secondary antibody. FACS-analysis 
was carried out by recording 1x104 gated viable cells on a BD-FACS-Canto-II using BD FACS-
Diva software (BD Biosciences, San Jose, CA, USA). Data was subsequently evaluated using 
FlowJo Software (Treestar Inc., OR, USA). For calculation of the IC50 the logistic function 
(Origin 6.0, Microcal, Northampton, MA, USA) was fitted to the raw data. For calculations, the 
SM101 concentration was determined by UV/Vis spectroscopy. 
2.8.2 LDH activity assay 
LDH enzymatic activity assay was adapted from the method described by Niven et al. [14] to 
work with a microplate reader. Wells were preloaded with 50 µL of diluted LDH sample. 250 µL 
of freshly prepared pyruvate-β-NADH mixture was added and measurement started immediately, 
monitoring the decrease of absorption at 340 nm for at least 60 s. Sample dilution and pyruvate-
β-NADH mixture were done with 1% BSA solution to prevent LDH adsorption to surfaces. Each 
set of simultaneous measurements contained one well 1% BSA as blank and a LDH reference 
standard. LDH activity was calculated from the linear segment of the slope of absorption 
decrease. Remaining LDH activity was calculated as the fraction of activity after nebulization or 
agitation compared to simultaneously determined activity of non-stressed (non-nebulized and 
non-agitated) LDH standard. 
2.8.3 ELISA 
The OVA binding activity of anti-OVA IgG was determined by an ELISA kit (Mybiosource, San 
Diego, CA, USA) in 96 well format according to the instructions. A standard calibration curve 
was recorded with 0.0, 0.5, 1.0, 2.5, 5.0 and 10.0 mg/mL anti-OVA IgG with every measurement.  
2.9 Other in vitro analytics 
2.9.1 pH 
Sample pH was determined with a Mettler Toledo Inlab Micro pH electrode in 100µL sample 
solution. 
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2.9.2 Osmolality measurements 
Formulation osmolality was determined on an automatic semi-micro cryo-osmometer (Knauer, 
Berlin, Germany) with 200 μL of sample. Before each measurement, the device was calibrated 
against standard solutions of 0 mOsm/kg (highly purified water) and 400 mOsm/kg (217 mM 
NaCl) real osmolality, which corresponds to 434 mOsm/kg ideal osmolality. 
2.9.3 Viscosity 
Viscosity of placebo and protein formulations was determined with a cone plate rheometer (Anton 
Paar, Graz, Austria) at 25°C. A fixed shear rate of 100 s-1 was used. 
2.9.4 Surface tension 
Surface tension of placebo and protein formulations was determined with an automatic Wilhelmy 
plate tensiometer (Krüss K100, Hamburg, Germany). The plate and the sample cup were 
thoroughly cleaned prior to each measurement. The surface tension of de-ionized water was 
determined at least once a day as a reference. 
2.9.5 Microscopy / Coomassie staining 
Coomassie staining was used to determine if material deposited on the vibrating mesh was of 
proteinaceous nature. The meshes were covered with premixed coomassie staining solution (Serva 
Electrophoresis GmbH, Heidelberg, Germany) and incubated for 60 minutes on a laboratory 
shaker. The meshes were then rinsed with ultraclean water and agitated in ultraclean water 
overnight. Stained and unstained nebulizer membranes were observed under a digital microscope 
(Keyence, Neu-Isenburg, Germany) at a range of 100 fold to 1000 fold magnification. 
2.10 Statistical evaluation of results 
Significance levels of the results were calculated by one-way Analysis of variance (ANOVA) 
including post-hoc testing by Tukey to calculate individual p-values. The symbols and 
significance levels displayed are listed in Table III-7.  
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The excised lungs were separated into the trachea and the five lobes and analyzed regarding 
deposition and distribution of the fluorescent dye by IVIS imaging and by fluorescence 
spectroscopy of the homogenized lung.  
Lung imaging by IVIS 
The freshly excised lobes and the trachea were placed on a microscope slide, which was placed 
into the imaging chamber and aligned to the field of view of the in vivo imaging system (IVIS 
Lumina, Xenogen Corporation, CA, USA). An excitation wavelength of 745 nm and an emission 
range of 810-875 nm were used for Alexa Fluor® 750. The outline of the lobes as seen in the 
white light images were used to mark the region of interest (ROI) for calculation of the 
fluorescence signal of the single lobes and the entire lung. 
Lung homogenate 
After IVIS imaging, the lung tissue was stored at -20°C for several days until preparation of lung 
homogenates according to an optimized protocol based on MacLoughlin et al. [33]. Lung lobes 
were thawed and the mass was determined gravimetrically. Each lobe was homogenized 
separately. Therefore, 300 µL minus the lobe weight of a formamide-water (1:3) mixture was 
added and the sample was then homogenized with an ultra-turrax homogenizer at level 5-6 (IKA 
T 10 basic, IKA®-Werke GmbH & CO. KG, Staufen, Germany) for 3 minutes at room 
temperature. The homogenizer was rinsed with the solvent mixture and the wash collected and 
pooled with the sample. As a reference 50µL fluorescent dye were added to a pristine lung that 
was treated alike. The homogenized samples were incubated at 60°C for 14-18 h while shaking 
at 300 rpm. Finally, the lysed samples were vortexed. Sample fluorescence was determined with 
a Tecan Safire 2 plate reader (Tecan Group Ltd., Männedorf, Switzerland). Therefore, 50 µL 
aliquots of each sample were loaded into 4 wells of a black, flat bottom 96 well plate. Formamide-
water (1:3) mixture served as a blank and a standard calibration series was recorded with every 
well plate measured. An excitation wavelength of 745 nm and an emission range of 765-799 nm 
was used for Alexa Fluor® 750 and Alexa Fluor® 750 conjugated SM101. The measured 
fluorescence intensity was corrected for dilution with formamide-water during homogenization 
by the factor fdilution (Equation III-8) and extrapolated to the intensity of the entire lobe (Ilobe) 
(Equation III-9). 
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Equation III-8 
 
Equation III-9 
 
Fluorescence intensity of an entire lung (Ilung) was calculated by addition of the intensities of all 
five lobes and the trachea. The relative deposition efficiency for the application method was 
calculated as a percentage of the intensity of the reference lung (Ireference) (Equation III-10). Sample 
homogenization and measurement was not completed in a single day. The fluorescence yield of 
SM101 bound Alexa Fluor® 750 declined during storage, so that the reference values determined 
on the first day were not applicable to later day samples. Therefore, fluorescence data of the 
instilled lungs/lobes homogenized on each day served as the 100% reference value for all other 
application methods. 
Equation III-10 
 
To determine the amount of dye deposited in each lobe, the intensity of 1 µL dye (Idye) was 
calculated from the reference sample. 
Equation III-11 
 
The dye volume (Vdye) deposited in each lobe was then calculated by Equation III-12. 
Equation III-12 
 
Finally, the amount of dye deposited in a lobe was normalized for relative lung mass (Equation 
III-13). 
Equation III-13 
 
Aerosol distribution was judged by inter-lobe variability, which was calculated as the standard 
deviation of Vnormalized between all five lobes of a lung. 
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Chapter IV Characterization of 
vibrating mesh 
nebulization 
1 Introduction 
The initial decision to develop a liquid formulation for the pulmonary delivery of SM101 instead 
of a dry powder aerosol entailed the application of vibrating mesh (VM) nebulization for the 
aerosol generation. VM nebulizers, although originally not designed for proteins, have been 
reported to be promising for protein nebulization for their gentle aerosol generation, efficient 
delivery and improved usability. As explained in the introduction, successful protein nebulization 
relies on a suitable combination of the aerosol generating device and the protein formulation. 
This chapter will approach the objective to evaluate the feasibility of VM nebulization for 
pulmonary protein delivery from the device’s side. Aiming to prepare for efficient protein delivery, 
VM nebulization was investigated and aspects relevant for protein stability or aerosol 
performance were identified and characterized. 
The circumstance that the nebulized solution can influence the aerosol characteristics, depending 
on its physicochemical properties like viscosity or surface tension, has been reported for VM 
nebulizers. Resulting consequences however have only been demonstrated for model excipients 
that are of low relevance for protein formulation like silicon oils, glycerol or alcohol [1]. The 
influence of excipients commonly used for protein formulation on nebulizer performance of three 
different VM nebulizers was investigated. The device capable of the most efficient pulmonary 
delivery was selected, based on comparison under these relevant conditions. Furthermore, the 
effect of proteins aggregation on vibrating mesh functioning was evaluated. 
On the other hand, the impact of VM nebulization on proteins was investigated. To gain a better 
understanding of how VM nebulization affects protein stability, potential stress factors were 
identified and characterized. On this basis, procedures to mitigate these stress factors were 
developed in order to enable advantageous VM nebulization for sensitive proteins. 
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An important prerequisite for the evaluation of protein stability after nebulization is a procedure 
to re-condense the generated aerosol cloud back into a bulk liquid, so standard stability and 
activity analytics may be applied. Different procedures have been mentioned for aerosol collection 
but not all suggested methods may be appropriate for atomized proteins. Therefore, collection 
procedures were evaluated regarding the impact on protein stability, collection efficiency and 
ease of handling with the aim to select a suitable method for subsequent use. 
2 Impact of the formulation on vibrating mesh nebulization 
2.1 Introduction 
Three vibrating mesh nebulizers, which were available as retail including PARI’s eFlow® rapid, 
the Aeroneb® Go (Aerogen) and OMRON’s MicroAIR were compared regarding their aerosol 
performance. Taking into account that the nebulized solution influences these characteristics [1], 
the effects on nebulizer performance were evaluated for two model excipients commonly employed 
in protein formulation and for two model proteins. Sucrose served as an example of a viscosity 
enhancing excipient, which like other sugars or polyols is used to improve protein storage stability 
[2]. Polysorbate 20 (PS20) on the other hand, represented the class of nonionic surfactants often 
added to protect proteins from interfacial stress by surface exclusion, which is concomitant with 
a reduction in surface tension [3]. G-CSF served as a surface-active model protein and an IgG1 
antibody was used to manipulate formulation viscosity. Based on the results for nebulizer 
performance under relevant conditions, the most suitable nebulizer was selected for further 
application. 
During preliminary experiments, prolonged nebulization times were observed when some protein 
solutions were nebulized. Prolongation exceeded a dimension that could be explained by changes 
in physicochemical properties alone, according to literature [1, 4]. Instead, another mechanism is 
suggested. Insufficient stabilization led to protein degradation during nebulization. Subsequently, 
insoluble protein aggregates occluded some of the micron sized holes of the vibrating mesh. 
Obstruction and constriction of the mesh would explain distinct reduction of the output rate 
(OR) and may also affect other aerosol properties like droplet size distribution. To investigate 
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this hypothesis, a model was used that allowed the adjustment of protein stability, while 
maintaining equal physicochemical properties. Therefore narrow pH changes were used to control 
protein stability to nebulization. The formulation remained basically unchanged, so that an 
impact on nebulizer performance could be attributed to protein stability, while formulation 
properties could be ruled out. G-CSF is an ideal model due to its very pH sensitive stability. In 
acidic environment of pH 4.0 or below G-CSF remains stable, whereas above pH 4.5 significant 
G-CSF degradation was observed after interfacial stress [5, 6]. 
Nebulizer performance was judged by the size distribution of the generated aerosol droplets and 
the OR. The OR is a measure of the speed of nebulization. A higher OR results in a shorter 
treatment time, which is desirable since prolonged treatment times may have negative impacts 
on life quality of chronically ill patients and are associated with reduced compliance [7, 8]. The 
aerosol droplet size distribution was determined by laser diffraction, which delivers results that 
are in good agreement to cascade impactor determined values for aqueous aerosols of unit density 
[9]. Droplet size is represented by the volume median diameter (VMD, also d[v,50]), which under 
these conditions concurs with the mass median aerodynamic diameter (MMAD) [10]. The width 
of the distribution is reported as the geometric standard deviation (GSD) or the relative span. 
Equation IV-1 
 
Equation IV-2 
  
The aerosol droplet size distribution affects the fine particle fraction (FPF) of nebulized volume 
within droplets of 1-5 µm diameter. It is considered as a simplistic in vitro measure of the 
respirable fraction of the aerosol [11]. A promising nebulizer would generate aerosols of large 
respirable fractions at a high OR. 
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Both the shrinking droplets and the sloping OR in relation to the extent of G-CSF aggregation 
lead to the reasonable presumption that nebulizer performance is impaired by an obstruction of 
the vibrating mesh with G-CSF aggregate matter. Insoluble aggregates adhere to the mesh and 
constrict the micron sized apertures, so that progressively smaller droplets are extruded. As more 
and more G-CSF molecules degrade with ongoing nebulization, more apertures get clogged 
resulting in reduced OR and cessation of nebulization upon congestion of the entire vibrating 
mesh. 
Presumably occluded meshes were observed under a digital microscope to confirm this hypothesis. 
Therefore, the mesh was rinsed with ultrapure water to rid non adhering protein material and 
stained with coomassie blue to confirm the proteinaceous nature of deposited matter. 
The apertures are conically shaped [29]. On the inner side of the mesh, facing the reservoir, the 
holes have a diameter of approximately 30 µm and are easily visible even at low magnification 
(Figure IV-10 A). While coomassie staining revealed the adsorption of a proteinaceous layer to 
the metal membrane, aperture obstruction is not obvious from the inner side of the mesh (Figure 
IV-10 B). On the outer side, delivering the aerosol, the apertures are approximately 4µm wide. 
After nebulization of instable G-CSF samples (pH 5.0) the microscopic images of the mesh show 
small, white, elevated clusters of aggregated G-CSF evenly distributed over the entire perforated 
region of the membrane (Figure IV-10 D). In contrast, the mesh seemed free of such debris if 
stable G-CSF (pH 3.5) was nebulized (Figure IV-10 C). The clusters could be stained by 
coomassie blue confirming their proteinaceous nature (Figure IV-10 E+F). The regular pattern 
of the aggregate deposition on the mesh resembled the distribution of the apertures. Virtually all 
holes were clogged by aggregate matter that had been extruded from the tiny apertures to form 
elevated shapes. G-CSF seems to have heavily aggregated during its passage through the 
vibrating mesh. 
These illustrative pictures confirm the theory that mesh occlusion by protein aggregates is the 
reason for severe break down of nebulizer performance observed for instable protein samples. 
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Figure IV-10: Inner side of the vibrating mesh at 1000 fold (A) and 100 fold (B) magnification after the nebulization 
of G-CSF at pH 5.0. Outer side of the mesh after nebulization of G-CSF at pH 3.5 (1000 fold magnification) (C) and 
pH 5.0 (500 fold magnification) (D). Coomassie stained GCSF aggregates on the outer side of the mesh after 
nebulization at pH 5.0 at 1000 fold (E) and 100 fold magnification (F). 
2.7 Conclusion 
The presented investigation revealed that nebulizer performance is influenced by both proteins 
and excipients commonly employed in protein formulation, as they alter the physicochemical 
properties of the formulation. A decrease in surface tension led to a slowdown in OR for two 
nebulizers, which is unfavorable for the nebulization of surface active proteins and stabilizing 
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surfactants. Only the PARI eFlow® was not negatively affected. Viscosity, on the other hand, 
had an impact on the OR and droplet size of all tested devices. This has to be considered for 
formulations containing viscosity increasing excipients like sugars or polyols as well as for 
elevated protein concentrations. While the respirable fraction was improved, OR was markedly 
reduced if the formulation viscosity rose above 1.2 mPa*s. Two nebulizers even failed to operate 
at higher viscosities. 
The PARI eFlow® exhibited the best aerosol performance and was therefore selected for further 
application. This also allows to seamlessly switch to the AKITA2 APIXNEB nebulizer (Activaero, 
Gemünden/Wohra, Germany) at a later stages of the project, as it is also powered by the eFlow® 
VM technology.  
The AKITA2 system controls the users breathing pattern, one of the most important factors 
regarding aerosol deposition [7, 30] and thus allows for a more efficient and reproducible aerosol 
delivery [31, 32]. Additionally, treatment compliance can be monitored, which is beneficial during 
clinical trials. 
Aerosol characteristics are not constant but change throughout the duration of one nebulization, 
which can be explained by a gradual increase of the temperature inside the reservoir during 
operation and the temperature dependency of viscosity. This heat up may pose a challenge for 
the nebulization of heat sensitive proteins and has to be investigated further. 
Protein aggregation was demonstrated to disrupt proper VM nebulizer operation by the occlusion 
of the mesh apertures. Even if protein aggregation is effectively prevented, thorough mesh 
cleaning procedures and a regular assessment of mesh function are vital for the reproducible 
generation of protein aerosols with VM nebulizers. The newly developed method for time resolved 
OR data can be used to detect early mesh occlusion and may be a valuable tool for the 
development of suspensions or nanoparticle or liposome formulations for VM nebulization, where 
mesh occlusion is of concern.  
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3 Aerosol cloud collection procedures 
3.1 Introduction 
As is evident from literature, nebulization may inflict significant degradation to sensitive protein 
molecules [33, 34]. In order to assess protein activity and stability after nebulization with common 
analytical methods, it becomes necessary to re-collect the aerosol cloud and condense it into a 
bulk liquid. Such a procedure must not induce protein denaturation by the collection itself, as it 
would be impossible to differentiate it from nebulizer induced protein degradation and thus 
corrupt subsequent stability data. Secondly, a collection procedure should collect the entire 
aerosol population generated by the nebulizer, since theoretically, aerosol deposition and protein 
degradation are affected by droplet diameter and a systemic disregard of certain aerosol 
populations might bias follow up stability analytics. All forces associated with aerosol deposition 
are influenced by droplet diameter (d): inertial impaction (~d2), gravitational sedimentation (~d3) 
and diffusion (~1/d) [30]. Smaller droplets are less affected by these forces and are therefore more 
likely to evade collection. On the other hand, droplet diameter also determines the specific surface 
area (~1/d) and may therefore influence the extent of protein degradation. Smaller droplets 
possess a higher specific surface area, thus protein molecules are more likely to interact with the 
hydrophobic air-liquid interface and suffer from interfacial stress [35]. Protein molecules in 
smaller aerosol droplets may therefore exhibit a different stability profile and lead to potentially 
biased protein stability data if overlooked. Finally, an ideal procedure should be simple to handle 
and not rely on an elaborate setup. 
Aerosol cloud collection has been achieved by a variety of methods described in literature 
including liquid collection in a twin-stage impinger (TSI) [36-39], condensation in a vacuum 
vented reflux condenser (RC) [34, 40], collection in the nebulizer’s aerosol chamber [41] or in test 
tubes [42, 43] of various volume and material. Collection efficiency and impact on protein stability 
were not reported although there is evidence of considerable detrimental influence of at least 
some of the listed procedures like TSI collection. Khatri et al. [39], already mentioned in chapter 
I, found protein collected in the lower TSI stage significantly less active than the fraction collected 
in the upper stage. Khatri et al. attributed this to a remarkable impact of aerosol droplet size on 
protein degradation. An effect of such extent has not been reported elsewhere and it seems more 
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Additionally, the CF concentration increased by 11% after collection, which likely resulted from 
solvent evaporation caused by the vacuum induced air-flow through the collector. After collection 
with a TSI 95.7%, aerosol was recovered in placebo buffer. The simultaneous occurrence of 
dilution, evaporation and unaccounted aerosol losses prevented the calculation of the extent of 
solvent evaporation, which can be assumed to be comparable to RC collection. 
Nebulization without aerosol collection performed as a reference procedure resulted in a 10°C 
increase in reservoir temperature (TRES). A similar extent of reservoir heat up was observed for 
test tube or aerosol chamber collection. In contrast, TSI and RC collection exhibited reservoir 
heat up of about 4-6°C respectively, which can likely be accounted to a cooling effect of the 
observed solvent evaporation. This deviation from normal nebulization conditions may 
significantly alter protein stability of likewise collected samples and thereby generate misleading 
data. 
3.3 Impact of aerosol collection on protein stability 
3.3.1 SM101 
SM101 stability was affected by the collection procedures. After RC or TSI collection, even 
non-nebulized SM101 was degraded, which reveals the detrimental nature of these collection 
procedures. Especially collection with a TSI led to the loss of 20% SM101 according to dilution 
corrected monomer recovery data and was accompanied by the formation of large amounts of 
subvisible particles and high turbidities for non-nebulized controls and collected SM101 aerosols 
alike (Figure IV-11). 
The fraction of condensate that directly drained into a tube below the RC (direct) exhibited low 
subvisible particle and turbidity values. Monomer recovery of aerosol and control were slightly 
above 100% accounting for solvent evaporation and CF correction. A small fraction of condensed 
aerosol did not drain from the RC but was recovered after rinsing the RC with a fixed volume 
of placebo buffer (rinse). This fraction contained a highly increased turbidity and particle count 
compared to the first fraction.  
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The observed impact of aerosol collector size on protein stability was quickly investigated for an 
IgG1 antibody as a second protein. Collector size dependent aggregation propensity was 
confirmed for the IgG1. The increment in subvisible particles and turbidity after nebulization 
was approximately twice as large for aerosols collected in 15 mL PP tubes than for aerosols 
collected in 2mL PP tubes. Monomer recovery was not affected by collector size (Figure IV-12). 
3.4 Conclusion 
Virtually complete aerosol cloud collection can be achieved with various approaches. However, 
the compared procedures differ in respect to ease of handling and their impact on protein 
stability. Collection in test tubes or in the aerosol chamber stands out for easy handling since no 
additional equipment is needed. Neither aerosol concentration nor TRES were altered by this 
approach. In contrast, collection with an RC or a TSI requires special glass ware that needs to 
be thoroughly cleaned before each collection. Both procedures rely on a vacuum induced stream 
of air through the collector. This leads to solvent evaporation and a reduced TRES, which may 
both corrupt protein stability data after nebulization. In the TSI, the aerosol is collected in a 
highly diluted form possibly introducing further sources of error. The TSI was very unsuitable 
for the collection of SM101 aerosols, since the collection procedure alone was very detrimental 
and caused far more SM101 degradation than inflicted by actual nebulization. The observed 
degradation was probably a result of the air bubbling through the collection buffer filled second 
stage, which posed a significant interfacial stress for the collected protein molecules [37, 45]. 
While RC collection seemed less detrimental, resulting stability data for SM101 was not reliable. 
On the one hand, SM101 degradation was induced by the collection procedure itself, probably 
due to a combination of solvent evaporation and deposition on the large glass interface. On the 
other hand, SM101 aggregates were restrained inside the collector and only appeared in the 
washing fraction, thus leading to biased protein stability data.  
Collection of non-nebulized control in test tubes did not cause any SM101 degradation, which is 
reasonable since no detrimental force is introduced by the procedure (unlike air-bubbling or 
evaporation on large interfaces). However, the size of the container used for collection affected 
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The procedure of aerosol collection has a significant impact on subsequently generated protein 
stability data. An unsuitable method may corrupt results, e.g. falsely attribute protein 
degradation to nebulization that actually resulted from the collection process. It is therefore 
crucial to carefully select and exclusively use one collection procedure to obtain meaningful and 
comparable datasets. Aerosol cloud collection in 2 mL PP tubes interfered least with protein 
stability and was therefore chosen as the standard procedure for all further experiments involving 
aerosol cloud collection. 
4 Impact of vibrating mesh nebulization on protein 
stability 
4.1 Introduction 
Previous investigations yielded evidence for a significant rise of the temperature inside the 
reservoir (TRES) of the PARI eFlow® during operation (section 3.2). The temperatures reached 
toward the end of nebulization can be detrimental for thermolabile protein drugs, provoking the 
loss of therapeutic activity and potentially leading to aggregation, which may result in unwanted 
side effects like increased immunogenicity [48, 49]. In contrast, various authors state that heating 
of the drug reservoir inside the VM nebulizer is limited and less pronounced as compared to US 
nebulizers [50, 51]. Therefore, eFlow® operation was investigated with respect to heating and the 
TRES profile within the reservoir was recorded. 
Temperature may not only influence the stability of the nebulized proteins as reported for US 
nebulizers or for vibrating mesh spray drying but also seems to have an effect on the 
characteristics of the generated aerosol via temperature dependent viscosity changes. 
Additionally, degradation of nebulized proteins may have dramatic consequences for the proper 
aerosol generation by VM nebulization due to occlusion of the mesh apertures (section 2.6). The 
prevention of protein degradation is therefore a prerequisite for efficient VM nebulization. 
The relevance of thermal stress for protein degradation during VM nebulization was investigated 
with proteins of different susceptibility to thermal degradation. The contribution of thermal 
stress was discriminated from other stress factors relevant for VM nebulization. This is mainly 
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interfacial stress by the atomization immanent creation of a vast new air/liquid interface [37, 
45], whereas shear or cavitation [52] by the mesh vibration have been ruled out.  
In order to benefit from the advantages of VM nebulization with thermolabile protein drugs, 
different ways to prevent or reduce heating during nebulization were investigated. These 
approaches included simple ‘passive’ procedures to reduce reservoir heat-up, like nebulization of 
pre-cooled solutions, nebulizer pausing to cool down as well as reservoir overloading, i.e. 
nebulization of only a fraction of the loaded volume. Furthermore, active cooling of the nebulizer 
reservoir with a micro Peltier element was tested. All nebulization procedures were evaluated 
with respect to their capability to reduce TRES during operation as well as their impact on 
nebulizer performance. Protein degradation after nebulization and the contribution of thermal 
stress were studied for three different proteins. Lactic dehydrogenase (LDH) served as a model 
protein, due to its sensitivity toward thermal and interfacial stress during nebulization [53, 54] 
and the availability of an activity assay. An IgG1 antibody was employed to investigate the 
effects of cooled nebulization on a more thermostable protein. Finally, the feasibility to protect 
SM101 during nebulization was tested. SM101 is rather sensitive to elevated temperatures, 
wherefore control of TRES during VM nebulization appears highly important. 
4.2 Temperature during operation 
4.2.1 Impact of initial load on temperature profile 
The temperature profile of the PARI eFlow® was measured in dependence of the initial reservoir 
load (IL) (1 mL, 2 mL, 3 mL or 4 mL saline). The IL had a significant impact on the reservoir 
temperature (Figure IV-13 A). Although the OR was constant and smaller volumes were 
nebulized in shorter times, the maximum reservoir temperature (TRES MAX) only slightly increased 
with increased IL. Consequently, the average heating rate is inversely proportional to the IL 
(Figure IV-13 B). Energy dissipated from the circular piezo element heats the metallic substrate 
and the attached membrane to temperatures above 40°C almost immediately upon commencing 
operation and steadily rises with advancing nebulization. While a TRES of 40°C is only reached 
toward the end of nebulization, this temperature stress during nebulization with a VM nebulizer 
may already be detrimental for thermolabile proteins of low Tm. 
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When nebulized in the absence of thermal stress at 15°C, turbidity also initially rose above 50 
mAU, while the further increase throughout nebulization was reduced and reached a maximum 
of only 118 mAU. In contrast, the extent of IgG1 aggregation after nebulization was not altered 
by active cooling (Figure IV-18 B). Regardless of TRES, turbidity immediately increased by 35 
mAU and only slowly increased during further nebulization by a maximum of 76 mAU. The 
initial rise in turbidity was less pronounced for SM101 but with increasing TRES the increase in 
turbidity was very distinct, reaching turbidity values above 400 mAU (Figure IV-18 C). When 
thermal stress was mitigated by active cooling, SM101 aggregation during nebulization was 
almost completely prevented. 
This data suggests that LDH aggregation is promoted by both thermal and interfacial stress of 
VM nebulization. Interfacial stress occurred instantly upon aerosol droplet generation and 
remained constant throughout operation. It is responsible for the immediate jump in turbidity 
and the constant turbidity throughout cooled nebulization. In contrast, the extent of thermal 
aggregation increased with increasing TRES leading to rising turbidity for normal but not for 
cooled nebulization. IgG1 did not suffer from thermal stress during nebulization but exhibited 
constant turbidity values due to aggregation by interfacial stress. On the other hand, interfacial 
stress did not seem to contribute to SM101 aggregation during nebulization. Instead, thermal 
stress was the detrimental force. The susceptibility to thermal degradation and the resulting 
benefit from cooled nebulization can be predicted by the proteins Tm value. The use of Tm to 
predict nebulization stability of proteins was also suggested by Zeles-Hahn et al. [58]. 
Interestingly, thermal degradation of LDH and SM101 occurred at temperatures below their Tm, 
which confirms reports that onset temperatures for protein unfolding are considerably lower at 
the air-liquid interface than for bulk solutions [46]. Thermal and interfacial stress have also been 
reported responsible for LDH degradation during vibrating mesh spray drying, whereas potential 
cavitation by mesh vibration did not cause any harm [59]. 
While protein aggregation by thermal stress was effectively reduced by cooling, interfacial stress 
is usually prevented by the addition of protective excipients like nonionic surfactant that protect 
proteins by surface displacement [3]. The protective capabilities of passive and active cooling 
procedures were compared to the effect of PS20 addition to formulations of LDH and SM101. 
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For SM101, active and passive reduction of TRES are more effective measures to reduce 
aggregation than PS20 addition. Unlike the addition of 0.04% PS20 that did not cause a 
significant reduction of subvisible particle levels, both cooling procedures very effectively 
prevented the formation of subvisible particles (Figure IV-19 C). The extent of turbidity 
reduction by passive cooling was comparable to the effects of 0.04% PS20, while active cooling 
was even more protective (Figure IV-19 B). The combined use of active or passive cooling and 
PS20 most significantly prevented SM101 aggregation during nebulization. Nebulization did not 
result in the formation of soluble protein aggregates or fragments of LDH or SM101 as determined 
by size-exclusion chromatography. 
For both proteins, cooled nebulization and the addition of a protective excipient are a necessity 
for the complete prevention of aggregation. As LDH is more sensitive toward interfacial stress, 
PS20 was very protective, while SM101 benefited more from nebulizer cooling. Active cooling 
and passive cooling strategies are appropriate for this purpose. 
4.5.2 Impact of normal and cooled nebulization on LDH activity 
The contribution of thermal and interfacial stress to LDH activity loss during VM nebulization 
was investigated respectively. Again, LDH was nebulized under normal conditions and at 15°C 
in the absence of thermal stress. The LDH activity in both the collected aerosol and the reservoir 
fluid was compared. In the reservoir fluid, LDH molecules are only exposed to thermal stress. 
When collected after VM nebulization, LDH molecules additionally underwent atomization and 
interaction with the newly created air/liquid interface.  
During normal nebulization more than 25% LDH activity was lost instantly upon nebulization, 
of which 15% was already lost within the reservoir (Figure IV-20 A). With proceeding 
nebulization, LDH activity further deteriorated within the reservoir, which also reduced the 
remaining activity of the collected aerosol. Prevention of reservoir heating preserved the full LDH 
activity inside the reservoir for half of the nebulization process as shown for 15°C (Figure IV-20 
B). Subsequently, LDH activity also decreased in the reservoir. Despite cooling, actual 
nebulization caused an immediate activity loss of 13% which gradually increased as LDH activity 
diminished inside the reservoir fluid. 
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Similar to aggregation, LDH activity loss can be attributed to different factors. Thermal stress 
already occurs inside the reservoir before actual atomization. It increases with ongoing operation 
and rising TRES and led to rising activity losses with advancing nebulization. Interfacial stress 
occurs upon actual nebulization and droplet formation and is responsible for an instantaneous 
but constant activity loss of approximately 13-25%. As witnessed for aggregation, cooling reduces 
thermal stress but cannot prevent interfacial LDH degradation. The contribution of thermal and 
interfacial stress to LDH degradation had already been shown with an US nebulizer [53]. 
The capability to preserve LDH activity during nebulization by passive or active cooling was 
compared to the stabilizing effects of 0.1% PS20. 35% LDH activity was lost after normal 
nebulization (Figure IV-21 A). With passive cooling, this loss was reduced to 29%, which was 
not quite significant due to high variability of remaining activity after normal nebulization. A 
significant protection of LDH activity was achieved with active cooling, which reduced activity 
loss to 22%. The addition of 0.1% PS20 to the LDH formulation on the other hand, resulted in 
very significant protection and reduced activity loss to 10%. Combining passive or active cooling 
with PS20 addition protected an additional 3.9-5.6% LDH activity respectively. Monomer 
recovery values confirmed these observations, indicating that loss of LDH monomers was 
responsible for reduced activity (Figure IV-21 B).  
SM101 was much less affected from monomer loss with 94% recovery after normal nebulization 
(Figure IV-21 C). SM101 monomer loss was reduced below 2% by passive cooling or PS20 
addition and below 1% by active cooling, though none of these effects was statistically significant. 
Confirming the findings for aggregation, partial protection of LDH can be achieved by either 
reduction of TRES or the addition of protective excipients but only a combination of both 
approaches can provide complete protection. Furthermore, the finding that SM101 suffers mostly 
from thermal stress, while LDH is susceptible to both interfacial and thermal stress, is reflected 
by the effectiveness of protein stabilization by either cooling or surfactant addition. 
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capable to prevent protein degradation by the thermal stress of VM nebulization without 
negatively influencing nebulizer performance.  
Overloading the reservoir with pre-cooled solution is simple and easy to integrate into 
nebulization routine. It can significantly improve the stability of nebulized protein drugs by a 
reduction of TRES as demonstrated for LDH and SM101. Peltier based active cooling is far more 
capable as it enables full control over TRES, which offers a range of interesting applications. The 
influence of TRES on aerosol characteristics was investigated. The observed effects can be 
attributed to temperature dependent viscosity changes. As demonstrated, thermal stress can be 
completely eliminated from VM nebulization, a capability that was exploited to investigate the 
contribution of thermal stress to protein degradation during VM nebulization. The relevance of 
thermal exposure during VM nebulization and the respective benefit from cooling, depend on the 
proteins susceptibility to thermal degradation, which can be predicted by its Tm. An IgG1 
antibody of relative thermostability was not degraded by thermal stress and thus did not benefit 
from cooling, whilst the thermolabile SM101 was completely protected from severe aggregation 
by active cooling. LDH on the other hand, was shown to degrade by thermal and interfacial 
stress. While only the interfacial degradation was containable by surfactant addition, thermal 
degradation could be prevented by nebulizer cooling. 
Cooled nebulization can also improve nebulizer performance as demonstrated for LDH. Higher 
remaining protein activity and an increased respirable aerosol fraction can reduce API 
consumption by up to 39%, while maintaining treatment times, an advantage that even stable 
but valuable drugs may benefit from. PC-OL cooling is readily applicable by any patient/user 
without additional requirements. The prototype setup for Peltier cooling is feasible for laboratory 
use and offers several opportunities for optimization, which would allow a more general 
application. The curved shape of the device reservoir did not allow direct attachment of a Peltier 
element but required the use of a bulky heat transducer. Better integration of the Peltier element 
into the reservoir design would allow a much more compact cooler setup. This would improve 
TRES control, reduce energy consumption and heat dissipation. The already oversized fan cooled 
heat sink could be replaced by a smaller, passive one further reducing the complexity of the 
setup. The use of the presented procedures is recommended for the nebulization of thermolabile 
protein drugs.  
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5 Summary 
The investigations summarized in this chapter aimed to thoroughly characterize vibrating mesh 
nebulization to provide the necessary prerequisites for efficient nebulization of stable protein 
solutions. As a result of these investigations, the PARI eFlow® was selected for nebulization, as 
it generates aerosols of the highest respirable fraction at the highest output rate among the tested 
devices. It was shown that both proteins and commonly employed excipients may influence the 
aerosol characteristics when applied in concentrations that markedly alter formulation viscosity. 
This can potentially improve the delivery efficiency at the cost of a reduced output rate. The 
temperature dependence of viscosity can explain a comparable impact of the reservoir 
temperature on nebulizer performance. 
Thermal and interfacial stress were identified as the main detrimental factors in vibrating mesh 
nebulization. The significant temperature rise observed for the PARI eFlow® can prove very 
detrimental for nebulized proteins, depending on their susceptibility to thermal degradation. 
Protein unfolding temperatures are a suitable indicator to predict the thread of thermal 
degradation during vibrating mesh nebulization. In this context, the thermolability of SM101 
was confirmed.  
While interfacial stress can be controlled by the addition of stabilizing excipients like nonionic 
surfactants, procedures for the mitigation of thermal stress were proposed. Overloading the 
reservoir with pre-cooled solution is simple, effective and readily available without further 
requirements. Alternatively, Peltier based active cooling offers full control over reservoir 
temperatures and is capable of completely eliminating thermal stress from vibrating mesh 
nebulization. Use of these methods is recommended for the nebulization of heat sensitive proteins 
with the PARI eFlow®. 
Failing to do so may entail extensive protein aggregation which can disrupt proper nebulizer 
operation. The responsible mesh occlusion can be detected early with a newly developed method, 
providing time resolved output rate data. This tool may be useful in the development of 
suspensions, nanoparticle or liposome formulations for vibrating mesh nebulizers, where 
obstruction of the membrane is also of concern. 
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The induction of protein degradation was also observed as a result of several procedures of aerosol 
cloud collection. While aerosol cloud re-condensation is mandatory for subsequent protein 
stability analytics, associated protein degradation must be avoided to obtain meaningful stability 
data. Based on according experiments, aerosol collection in 2 mL polypropylene test tubes was 
the most appropriate approach for this purpose. 
Important prerequisites for protein nebulization have been clarified, so that the specific 
requirements for the development of inhalable protein formulation may be examined in the 
following chapter.  
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Chapter V Formulation development 
for vibrating mesh 
nebulization of 
pharmaceutical proteins 
1 Introduction 
The development of protein formulations for the purpose of pulmonary delivery involves some 
special aspects and limitations to consider. Like any formulation, inhalable protein formulations 
have to maintain protein stability during production, shelf live and handling. Additionally, 
proteins have to be protected from the detrimental forces occurring during aerosol generation, in 
case of vibrating mesh (VM) nebulization this is mainly thermal and interfacial stress (Chapter 
IV). As observed in chapter IV, stabilization may be achieved by stabilizing excipients and 
control of the nebulization conditions. Inhalative formulations underlie some restrictions. The pH 
must be in a range of pH 3.5-8.0 [1] and should ideally be above pH 5.0 [2]. Osmolality in the 
range of 150-549 mOsmol was well tolerated but isotonicity of pulmonary formulations has been 
recommended [2]. This limits the maximum concentration of osmotically active excipients often 
used for protein stabilization (e.g. salts, sugars, polyols) in a formulation. The influence of the 
formulation on aerosol properties (Chapter IV) has to be considered as well to maintain an 
efficient aerosol generation. Complicating matters, the range of excipients currently approved for 
pulmonary delivery is very limited (FDA inactive ingredient database for approved drugs, [3]). 
In this chapter, aerosol formulation development is demonstrated at the example of SM101. 
Initially, a parenteral formulation of highly concentrated SM101 was developed and also tested 
for nebulization. In a second stage, a method for accelerated testing of nebulizer stress on protein 
stability was developed and its feasibility evaluated for different proteins. Aerosol formulation 
development based on this surrogate method was conducted for SM101. Finally the selected lead 
candidate formulations were tested against VM and jet nebulization.  
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2 Development of a highly concentrated parenteral formulation 
for SM101 
2.1 Rationale for the optimization of the parenteral formulation 
The current parenteral formulation of SM101 has been successfully employed during early phase 
Ib/IIa clinical trials of Primary Immune Thrombocytopenia (ITP) treatment, yet an increase in 
SM101 concentration seemed a reasonable approach to satisfy the growing demand of SM101 
during upcoming clinical studies. Handling and patient treatment would be facilitated if the 
required SM101 doses could be delivered in smaller infusion volumes. Additionally, an improved 
production process for SM101 bulk material has been developed. Direct manufacturing of SM101 
bulk material into the parenteral formulation is intended to improve bulk material stability. 
Therefore, the previous parenteral formulation had to be modified to increase SM101 
concentration and provide sufficient freeze/thaw (F/T) stability for storage and shipment in 
frozen form. 
Phosphate buffers, as found in the current formulation, may undergo significant pH shift during 
freezing [4], which can seriously compromise protein stability [5]. For histidine, buffering at the 
desired pH of 6.5, much less temperature dependent pH shift was reported [6]. Accordingly, 
histidine was chosen to replace the phosphate buffer in the formulation. Non-crystallizing 
cryoprotectants can reduce protein degradation during phase transition between the liquid and 
the frozen state [6]. The incorporated mannitol partially crystallizes during freezing [7] and may 
therefore not provide optimum SM101 F/T protection. Sucrose seemed to be a more appropriate 
excipient for cryoprotection and has already proven SM101 stabilizing potential during early 
formulation studies. 
At the site of SuppreMol (Martinsried, Germany) in cooperation with Thomas Pohl, three 
formulation candidates were prepared at 10 and 20 mg/mL SM101 and evaluated regarding F/T 
stabilization and accelerated stability studies at 25°C and 40°C. Based on the current 
formulation, containing a phosphate buffer, 150 mM NaCl, 2% mannitol and 0.005% polysorbate 
20 (PS20), formulation candidate A replaced the phosphate buffer by 20 mM histidine, pH 6.5 
while the rest of the composition remained unchanged. Additional incorporation of 2% sucrose 
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Figure V-3 A: Light-microscopic image of SM101 crystals formed in formulation C at 20 mg/mL SM101. B: SDS-
PAGE of soluble and insoluble fraction: lane 1: molecular weight standard, lane 2: 4 µg SM101 reference, lanes 
3+5: isolated and washed precipitate from formulation C, lanes 4+6: supernatant from formulation C. Pictures 
provided by Thomas Pohl (SuppreMol). 
2.3 Storage stability 
Formulation candidate C was not included into further testing due to the insufficient solubility 
of SM101. Accelerated storage stability testing was performed for the formulation candidates A 
and B. Samples were incubated for up to four weeks at 25°C and analyzed after 0, 1, 7, 14 or 28 
days. During a one week storage at 40°C, samples were analyzed after 0, 1, 2, or 7 days. 
SM101 concentration was analyzed with UV/Vis photometry and confirmed by SE-HPLC 
monomer recovery. Chemical degradation was assessed with RP-HPLC and charge variants were 
detected by CEX-HPLC. Soluble aggregates were detected with SE-HPLC, while insoluble 
aggregates were assessed with light obscuration and visual inspection.  
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Figure V-6: RP-HPLC chromatogram overlays for samples of formulation candidate B at 20 mg/mL SM101 stored 
for 0 days (blue), 1 day (green), 2 days ( yellow), 7 days (purple), 14 days (red) or 28 days (orange) at 25°C (A) or 
40°C (B). 
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formulation screening with nebulizers is a time consuming task. Additionally, API consumption 
may be too high in early development considering limited availability and the high manufacturing 
costs of the protein bulk drug substance. This framework may significantly limit the number of 
formulation parameters tested during development. Nebulization stress testing could be 
accelerated, while consuming less API material if the main stress factors occurring during 
nebulization were mimicked in a controllable manner by a surrogate method allowing generation 
of multiple samples in parallel. Such an accelerated stress test may be used to predict stabilizing 
formulation conditions allowing the selection of few promising formulation candidates, which are 
then thoroughly tested employing the real nebulizer in question. 
As observed during characterization of the PARI eFlow® (Chapter IV), generation of air-liquid 
interface and heat are the main stress forces contributing to protein degradation during 
nebulization. In an effort to design a surrogate stress method for this nebulizer in order to 
accelerate formulation development with reduced protein consumption, the generation of 
comparable stress conditions by simple controllable means was pursued. 
Air-liquid interfacial stress is classically generated by sample agitation via shaking or vortexing 
[9, 10]. Generated air-liquid interface is maximized when using half-filled reaction tubes [11] 
placed horizontally. Alternatively, bubbling of gas through liquid has been employed [12, 13] but 
involves a more complex setup. Agitation in an incubator at defined elevated temperatures may 
be used to emulate nebulizer heat up. In this study we aimed to develop a method based on 
vigorous agitation at elevated temperatures to imitate nebulization conditions in a simple and 
controllable manner, able to predict the stabilizing potential of different excipient classes allowing 
higher throughput stress testing. The surrogate method was initially developed for SM101. 
Formulation development for SM101 was demonstrated based on this technique, comprising an 
excipient screening and formulation optimization based on the surrogate method and statistical 
design. Two formulation candidates were created and ultimately challenged by real nebulization 
experiments to verify and evaluate the results attained by the surrogate method. Finally, we 
investigated if the proposed surrogate method is applicable for the formulation development of 
other protein drugs. For this purpose, lactic dehydrogenase (LDH) and granulocyte-colony 
stimulating factor (G-CSF) were chosen, exhibiting distinctly different protein characteristics 
than SM101 and a history in nebulization [14, 15]. 
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3.2 Development of a surrogate method to simulate nebulization stress 
In order to save both time and valuable SM101 material, a surrogate method allowing stress 
testing without nebulization was to be developed based on generation of multiple samples in 
parallel by agitation at elevated temperatures. The surrogate conditions should render similar 
protein degradation as nebulization. Therefore, a test set of three SM101 formulations and the 
model excipient PS20 were first nebulized and later used to identify suitable agitation conditions. 
PS20 was chosen as a model excipient for its potential to stabilize proteins during nebulization 
by occupation of the air-liquid interface [16]. All formulations contained 5 mg/mL SM101 in 
HBS, pH 6.5 but varying amounts of PS20, assuming that the formulation without PS20 would 
show marked instability, whereas the one with 0.05% PS20, above the critical micelle 
concentration, would be well stabilized and the third formulation including 0.005% PS20 would 
be in between. This setup enabled a three-point calibration of the surrogate method settings, 
which are agitation time and incubation temperature, while agitation speed was fixed at 1450rpm. 
The initial test settings for shaking time and incubation temperature were inspired by the 
conditions observed during nebulizer operation, which typically took approximately 5 minutes 
resulting in average reservoir temperatures of 30-35°C (Chapter IV). 
Subvisible particle (r2=0.9996) and turbidity (r2=0.912) values after nebulization are well met 
when a 1 mL sample is agitated for ten minutes at 30°C in 2.0 mL PP caps (Figure V-10 A+B). 
To further reduce the sample volume, 0.65 mL PP caps requiring only 325 µL sample were tested 
and consequently light obscuration analysis was dropped due to its high sample demand per 
analysis (>1.2 mL) and its low throughput. Turbidity after nebulization also correlated for 
samples agitated in 0.65 mL PP caps (Figure V-10 C). Analogous to 2.0 ml PP caps, shaking at 
30°C for 10 min resulted in the best correlation (r2=0.973) to nebulization data. When shaking 
was performed at 35°C, matching values (r2=0.924) were reached already after 5 min, while at 
25°C, 15 min shaking was required (r2=0.9027). As implied by nebulization of the parenteral 
formulation (Table V-4), SEC data did not reveal significant changes in monomer or soluble 
aggregate content for both nebulized and agitated samples. Interestingly, SM101 degradation 
behavior after nebulization was very well matched with surrogate method settings closely 
resembling conditions found during nebulization, suggesting that the developed surrogate stress 
method is able to generate a comparable amount of stress at the air-liquid interface and by heat. 
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hydration of proteins by steric exclusion of the PEG molecules from native proteins [21, 22]. 
Furthermore, it has been suggested that PEG sterically hinders monomer to monomer 
interactions at the air-water interface thus preventing further aggregation [16]. Although the 
amino acid arginine is frequently used during protein refolding and for suppression of aggregation 
the stabilizing mechanism is still object of discussion and research. Proposed theories include 
suppression or deceleration of protein interactions [23, 24]. 
The surrogate results accurately predict nebulization induced SM101 degradation for all tested 
excipients (Figure V-11) except for the concentration dependent effect of arginine on SM101. 
Upon nebulization, 2% arginine caused drastic SM101 aggregation while 8% arginine increased 
SM101 stability, which was both correctly predicted by the surrogate. The addition of 5% 
arginine however was predicted to stabilize SM101 (21 mAU) but instead led to increased 
aggregation (99 mAU) upon nebulization. Such arginine-protein ratio dependent stabilizing and 
destabilizing effects of arginine have been reported before [25]. Despite this discrepancy, the 
observed correlation between surrogate and nebulization was excellent (R2=0.9725). The 
formulations containing 0.35% or 3.5% HPβCD and 0.05% PS20 or 1.0% PEG 8000 are the most 
stabilizing. 
 
Figure V-11: Correlation of turbidity after nebulization (n=5 for drug substance and PS20 formulations, mean ± 
SD; n=1 for other excipients) and surrogate method (n=3 for all formulations, mean ± SD) for PS20 ( blue circle), 
HP-β-CD ( orange square), PEG8000 ( green triangle), L-arginine ( yellow diamond) and without added 
excipient ( grey diamond) (R² = 0.9725).  
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3.3 Surrogate based formulation development for SM101 
Consequently, we developed a formulation for nebulization of SM101 based on the new surrogate 
method by screening for stabilizing excipients followed by formulation optimization via the 
surrogate method and statistical experimental design. Based on these results, two formulation 
candidates were selected, which were tested with an advanced vibrating mesh nebulizer based on 
PARI eFlow® technology  the AKITA2 APIXNEB. Additionally an AKITA jet nebulizer was 
used as an alternative and SM101 stability compared after the nebulization with either device. 
3.3.1 Single excipient screening 
To identify excipients that protect SM101 during nebulization, formulations with a single 
excipient added were treated with the surrogate method. Additionally, excipients that may 
preserve SM101 stability during quiescent storage were tested for their effects during 
nebulization. Solution turbidity was used as read out after subtracting the turbidity values of 
equally treated corresponding placebo formulations. The parenteral SM101 formulation and 
SM101 in HBS without any excipient added served as references. While finally aiming at a SM101 
concentration of approx. 20 mg/mL, screening was performed at 2 mg/mL and 8 mg/ml due to 
limited SM101 availability which saved valuable protein but enables a statement on protein 
concentration effects and an outlook toward the intended concentration range. 
Non-formulated SM101 in HBS served as a reference. Additionally the excipient effects were 
compared to the SM101 parenteral formulation that contains 0.005% PS20, 2% sucrose and 1% 
mannitol to identify conditions outperforming it in regard to SM101 stabilization. 
At 2 mg/mL non-formulated SM101 exhibited a turbidity of 40 mAU which was reduced to 12 
mAU by the parenteral formulation. All tested excipients provided equal or even better 
protection of SM101 (Figure V-12 A). At 8 mg/mL non-formulated SM101 exhibited a turbidity 
of 119 mAU (Figure V-12 B). The parenteral formulation partially protected SM101 and reduced 
the turbidity to 26 mAU. PS80 or PS20 at 0.005% reduced the turbidity compared to non-
formulated SM101 but did not outperform the parenteral formulation. Better protection of SM101 
was achieved by higher concentrations of PS80 and PS20 with turbidity values as low as 9 mAU 
and 8 mAU respectively. Comparable protection was also achieved with HPβCD and PEG 8000. 
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Addition of sugars, polyols or amino acids to 8 mg/mL SM101 mostly resulted in reduction of 
turbidity compared to non-formulated SM101 (Figure V-12 C). The level of protection granted 
by the PS20 containing parenteral formulation was not achieved though. Interestingly, the tested 
sugars and polyols seem to exhibit a concentration dependent effect on SM101 stability, where 
high or low concentrations result in less turbidity than the intermediate concentration. 
Accordingly, mannitol and sucrose were not protective at 2% but at 1% and 5%. The addition 
of glycine had inconsiderable effects. 
Comparing different excipients to the parenteral formulation of SM101 revealed that nonionic 
surfactants but also HPβCD and PEG 8000 are potent protectors of SM101 against the interfacial 
stress during surrogate screening. For improved SM101 stabilization, there is no need to 
substitute the excipients of the starting formulation if excipient concentrations are adjusted to 
suitable values. None of the tested excipients outperformed 0.02%-0.05% PS20 regarding SM101 
stabilization. Adjusting of sucrose and mannitol content may also be beneficial for improved 
SM101 protection. 
 
Figure V-12: Turbidity of formulations containing 2 mg/mL (A, n=2, mean ± SD) or 8 mg/mL (B, n=2, mean ± SD 
and C, n=1) SM101 with one excipient added at the concentration indicated. SM101 in HBS (n=3) or the new 
parenteral formulation (n=3) served as references and their respective turbidity values are indicated with dotted 
lines for easier distinction of stabilizing from non-stabilizing formulations. 
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screening of sugars and polyols (Figure V-12 C), i.e. low and high levels of “sugar” led to less 
turbidity than intermediate levels, is indicated by SUGAR2. Since linear fitting of the “sugar” 
data points would result in a flat line of no apparent slope, the linear SUGAR factor is 
insignificant and the effect of sucrose:mannitol content in the formulation is only revealed after 
the introduction of this quadratic term (Figure V-14 B). Sodium chloride (SALT) content did 
not have a significant effect on turbidity after stressing but manipulated how “sugar” addition 
affected turbidity. When sodium chloride content was low, increasing the “sugar” concentration 
was protective but in the presence of the high sodium chloride concentration rising the “sugar” 
concentration would increase turbidity, though the overall magnitude of this effect was small 
compared to the influence of PS20 and SM101. The SALT:SUGAR interaction factor (Figure 
V-14 C) accounts for this antagonistic interaction. 
The response surface of the main impact factors SM101 and PS20 concentration (Figure V-15) 
visualizes the described effects and demonstrated that the composition of the parenteral 
formulation is not optimal regarding the stabilization of SM101 during surrogate stressing. Based 
on this data, two formulation candidates were identified that have a much better stabilization 
potential. Their formulation is summarized in Table V-1. PS20 concentration was set to the 
optimum at 0.04% in candidate 1, for an easily implementable but significant improvement of 
SM101 protection. Since SM101 concentration was retained at 20 mg/mL, the formulation 
remained hyperosmolar with 424 mOsmol. Candidate 2 was selected as a compromise between 
best possible stabilization by adjusting both PS20 and SM101 content but maintaining an 
acceptably high SM101 concentration of 10mg/mL. Additionally, candidate 2 exhibits near 
isotonic osmolality of 324 mOsmol, which was achieved by cutting sodium chloride content to 
half and instead increasing SUGAR concentration to 4.0%, which should also further improve 
SM101 stability (SALT:SUGAR antagonism, Figure V-14C). 
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was reduced to 60% of a non-nebulized reference. Interestingly, this is not caused by SM101 
monomer loss as only a minor decline of 3.4% was detected by SE-HPLC analysis, indicating 
that this monomeric population must also be severely damaged or that the degraded protein 
interferes with the assay. During nebulization, SM101 heavily aggregated, forming a very milky 
solution with large visible particles, making light obscuration analysis essentially impossible. 
Aerosol generation ceased prematurely after nebulization of only 1.5 mL as the vibrating mesh 
increasingly occluded by large aggregates (see Chapter IV.2.6).  
Both formulation candidates showed a major improvement regarding SM101 stability and 
delivered clear solutions free of visible particles after aerosol re-condensation. Light obscuration 
and turbidity revealed some degree of aggregation for candidate 1 and only very little aggregation 
for candidate 2. Both candidates would even comply with Ph. Eur. demands regarding subvisible 
particles ≥ 10µm and ≥ 25 µm for parenterals. SE-HPLC showed no formation of soluble 
aggregates and no loss in SM101 monomer concentration for the two candidate formulations. 
Regarding biologic potency, nebulization of candidate 1 resulted in a slight reduction of activity 
by 14% but is safely within internal specification (67-200% activity). Candidate 2 maintained 
full SM101 potency after nebulization (106%). 
As predicted by DoE surrogate data (Figure V-15), formulation candidate 2 slightly outperformed 
candidate 1 regarding protection of SM101 during nebulization. Unlike the parenteral 
formulation, both developed formulation candidates deliver stable and active SM101 to the 
nebulizer mouthpiece. The predictions made on the basis of the DoE surrogate approach were 
confirmed by the real nebulization results. According to the DoE results, enhanced stabilization 
is mainly caused by increasing PS20 content and SM101 concentration reduction. To investigate 
if the minor improvements in SM101 stability predicted for salt and sucrose:mannitol content 
(Figure V-14) also contribute to the better performance of candidate 2 over candidate 1, both 
candidate formulations were also nebulized containing only 10 mg/mL SM101 with the PARI 
eFlow® nebulizer.  
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3.5 Conclusion 
This study demonstrates how the newly developed surrogate method can be used to replace 
laborious nebulization and thereby accelerate the development process for inhalable protein 
formulations and drastically reduce material demand (4mL nebulization versus 0.35mL 
surrogate). As was demonstrated for vibrating mesh nebulizers relying on PARI eFlow® 
technology (PARI eFlow® and AKITA2) and the protein SM101, a method mimicking nebulizer 
related stress factors by agitation at elevated temperatures is feasible and allows predictions 
about the stabilizing potential of various excipients and in doing so can predict their necessary 
concentration for protein stabilization. 
It is generally advisable to use more than one analytical method to investigate different aspects 
of protein degradation like loss of protein content, aggregation, structural changes or loss of 
biologic activity. Based on this surrogate stress method, the successful development of a 
formulation dedicated to nebulization of SM101 was demonstrated. Its high quality of correlation 
enabled prediction of stability influencing factors by means of statistical design. All predictions 
made were confirmed by nebulization with an AKITA2 vibrating mesh nebulizer.  
Especially aerosol formulation candidate 2 preserves the activity and stability of SM101 after 
nebulization, which fulfills a major requirement for future in vivo studies. It could also be 
demonstrated that VM nebulization was less detrimental than jet nebulization of SM101 with 
the tested formulation candidates. Nevertheless, with candidate 1, a formulation providing 
sufficient stability during jet nebulization is also available in case jet nebulization of SM101 
should become necessary. 
Within the scope of this study, the general applicability of the suggested procedure for other 
nebulizers was not evaluated. Therefore any such extrapolation should be accompanied by further 
testing, which may be accomplished by following the procedures presented in this section. For 
other vibrating mesh nebulizer models, we expect the adaption of the surrogate method to be 
straight forward as principle of operation, generated droplet size and therefore encountered stress 
upon nebulization should be similar. The incubation temperature may need to be adjusted based 
upon temperatures measured inside the device reservoir during operation. Transfer to ultrasonic 
(US) nebulizers might also be possible, as comparable stress factors - namely reservoir heating 
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and interface generation - occur. Otherwise, protein stability threatening effects of excessive 
recirculation and evaporation, which are not modeled by the surrogate method may cause a 
significantly altered protein degradation pattern. The latter is especially applicable to jet 
nebulizers, which may hence not be well simulated by the proposed surrogate method. 
Caution toward extrapolation is also advised regarding the applicability of surrogate screening 
to other proteins, which was therefore further evaluated for two additional proteins. 
4 Feasibility of the surrogate screening method for other 
proteins 
4.1 Selection of model proteins to test with the surrogate method 
The power of the surrogate method for formulation development was successfully demonstrated 
for SM101. Therefore, two further model proteins lactic dehydrogenase (LDH) and 
granulocyte-colony stimulating factor (G-CSF) were selected to examine a wider applicability of 
the surrogate method for protein stability prediction during VM nebulization. Both proteins 
exhibit distinctly different characteristics compared to SM101 (Table V-7).  
As suggested in chapter IV and by Zeles-Hahn et al., Tm may be used to evaluate protein stability 
to atomization [31]. All selected proteins exhibit a Tm below 60°C but onset of melting (see Table 
V-7) occurs at a higher temperatures for G-CSF compared to LDH and especially SM101. G-CSF 
is of comparable molecular weight but mainly helical structure compared to the mostly beta-
strand structure of SM101. Unlike SM101 or G-CSF, LDH is a tetrameric protein of 140 kDa of 
the alpha and beta protein folding class [32]. LDH is often used as a model for interfacial stress 
(lyophilization, spray drying, nebulization) and has a history of nebulization [14, 15], where it 
was proven highly susceptible to degradation by jet or US nebulization. While nebulization at 
ambient temperatures is already detrimental, additional heat during US nebulization acts 
synergistically, whereas heating alone is not problematic up to 45°C [33]. Comparable behavior 
was observed for VM spray drying [34]. A tendency of G-CSF to degrade during jet nebulization 
is also described in literature [15].  
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As was to be expected, SM101 turbidity after 60 minute agitation was more than tenfold higher 
compared to nebulization. Nevertheless, both sets of turbidity values followed a common trend 
(R3=0.9744) (Figure V-24). Additionally, monomer recovery data also revealed formulation 
dependent SM101 stability, as extensive agitation caused monomer loss that inversely correlated 
to turbidity after nebulization (R2=0.9935). A rough approximation of G-CSF stability after 
nebulization was possible by combining the results of turbidity and monomer recovery after 
agitation (Figure V-25). Using this standard surrogate method results in inferior prediction 
accuracy but allows a fast, rough assessment of expected formulation stability toward 
nebulization. 
4.5 Conclusion 
Applicability of the surrogate screening method previously developed for SM101 was evaluated 
for the model proteins G-CSF and LDH. The results reveal, that the surrogate approach is also 
feasible for these proteins. The best correlation was achieved after protein specific adjustment of 
the surrogate settings. In the case of G-CSF and LDH, prolonging the agitation time was more 
expedient than altering incubation temperature. Protein specific adjustment can be skipped when 
a set of standard settings for the surrogate method is used, allowing a fast and rough assessment 
of expected formulation stability upon nebulization.  
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5 Summary 
This chapter deals with the importance of a dedicated development of nebulized protein 
formulations. The example of SM101 clearly demonstrated that the nebulization procedure has 
to be an integral part of formulation development. As elucidated in chapter IV, vibrating mesh 
nebulization, as well as other nebulization techniques, induces significant stress that differs in its 
extent and factor combination from regular conditions experienced by parenteral formulations. 
It is therefore not covered by the range of standard stress testing. Conducting thorough 
nebulizations for the testing of excipients and formulation may evolve into an excessive task if 
several candidates shall be tested, due to long nebulization times, limited possibilities for 
automation or parallelization and high API consumption. A solution to these issues has been 
demonstrated with the surrogate method proposed in this chapter. Based on the simulation of 
the two major stress factors of vibrating mesh nebulization  interface and heat  by simple and 
controllable means, it allows the high throughput screening of excipient and formulation 
candidates. Application of the surrogate screening to three different proteins revealed that 
predictions could be improved with protein specific sets of surrogate screening parameters. On 
the other hand, universal test parameters were defined, which allowed the rapid screening of all 
tested proteins without the need of prior parameter optimization.  
Concerning SM101, an optimized parenteral formulation with improved handling was developed 
for upcoming clinical trials. Based on the surrogate screening, a dedicated aerosol formulation 
was developed that enables the efficient vibrating mesh nebulization of 10 mg/mL SM101 without 
loss of activity or aggregation. This formulation will be used during in vivo studies of SM101 
efficacy in mice.  
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Chapter VI SM101 in vivo efficacy 
study 
1 Introduction 
After successful development of a formulation allowing efficient pulmonary delivery of SM101 via 
nebulization (Chapter V), the ultimate stage of the thesis aimed at the demonstration of in vivo 
efficacy of pulmonary delivered SM101. Preparations for in vivo efficacy testing comprised the 
choice of a disease model adequate to demonstrate SM101 efficacy in mice and the 
characterization of different pulmonary administration procedures suitable for such small 
animals. 
All in vivo experiments were performed by Otmar Schmid and his group at the Comprehensive 
Center of Pulmonology (Neuherberg, Germany). Lung deposition and distribution investigation 
described in 2.3 are part of the master thesis of Juliane Freitag [1]. In vitro evaluation of protein 
stability and aerosol characteristics was performed by Sebastian Hertel at the department of 
Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilian-University in Munich, 
Germany. 
Skokowa et al. had used a version of sFcγRIIB essentially equal to SM101 to examine its effect 
on a type III hypersensitivity reaction, also known as Arthus reaction, provoked in the lungs of 
mice [2]. The Arthus reaction is initiated by the binding of immune complexes (IC) by Fc-
receptors on the surface of immune competent cells [3] and is therefore applicable for SM101 
efficacy testing. The used mouse model relied on the induction of the immune reaction by 
intratracheal instillation (i.t.) of anti-OVA IgG antibody immediately followed by i.v. injection 
of ovalbumin (OVA) antigen. Skokowa et al. reported that i.t. administered sFCγRIIB can 
prevent the inflammatory cascade in the lungs of mice. It was shown that the IC resulting from 
antibody-antigen binding, initially activated alveolar macrophages (AM) eliciting an 
inflammatory response. If sFcγRIIB was administered to the lungs immediately after antibody 
and antigen administration, no inflammatory response occurred. Skokowa suggested that 
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sFCγRIIB bound IC by their Fc part and prevented Fc receptor mediated activation of AM or 
other Fc receptor bearing immune competent cells. 
While the so called reverse passive Arthus reaction [4, 5] is a common model to induce IC-
triggered hypersensitivity (type III) [6], the suggested setup may be not suitable to evaluate the 
efficacy of SM101 in vivo. Skokowa et al. delivered both antibody and antigen in an opposite to 
physiologic manner. Antigen was administered via i.v. injection while it is naturally inhaled in 
pulmonary Arthus type reactions like the Farmer’s lung disease. Antibodies, on the other hand, 
are naturally secreted by plasma cells and infiltrate the site of immune reactions from the 
systemic circulation. But in the study, they were administered through the lungs. This 
interchange has serious consequence for the model. The delivery of both antibody and sFcγRIIB 
through the lungs increases the possibility of direct binding of sFCγRIIB to the Fc part of the 
IgG before encounter of antibody and antigen, i.e. in the lung lining fluid. So, instead of formation 
of IC as the initial step triggering the Arthus reaction, antigen-antibody binding does not occur 
and the entire disease model is interrupted. The condition to be treated with sFcγRIIB would 
not be induced in the first place. This may falsely be mistaken as therapeutic efficacy of SM101. 
It was therefore necessary to modify the protocol used by Skokowa et al. to a non-reverse Arthus 
reaction to enable a meaningful evaluation of SM101 efficacy in vivo.  
A second need for optimization originates from the importance of homogeneous distribution of 
the pulmonary delivered agents in this disease model. The spatial distribution of drug delivered 
into the lungs by i.t. instillation is non-uniform and patchy and is confined to central lung regions 
[7, 8]. As a consequence, an immune response to OVA antigen  the foundation of this disease 
model  will only be provoked in those patches of lung tissue to which OVA antigen (in case of 
a non-reverse Arthus reaction) or anti-OVA antibody (in case of a reverse Arthus reaction) has 
been delivered. Brain et al. [9] could show that the non-uniformity of i.t. instillation is mostly 
random, meaning that a subsequent instillation may not cover the same lung patches as the 
previous one. Therefore, after subsequent delivery of antibody, antigen and the treatment 
(SM101) three situations may occur: A patch of lung tissue, e.g. an alveolus, received both the 
trigger (antigen or antibody) and treatment fluids as intended. An alveolus received only the 
treatment fluid but no trigger, which is merely ineffective. Finally, the delivery of only the 
triggering fluid while missing the treatment may be problematic. In such regions, an 
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inflammatory cascade will be triggered even if SM101 was efficacious. Due to the averaging of 
the inflammatory response indicators over the entire lung by bronchoalveolar lavage fluid 
(BALF) collection and analysis, this would result in significant noise and attenuate SM101 
efficacy results. Therefore different methods of pulmonary drug delivery to mice were compared 
regarding efficiency and reproducibility of aerosol deposition and the homogeneity of spatial 
distribution in the lungs. Ultimately, the stability of SM101 as well as antigen and antibody 
towards the respective administration methods was examined. 
2 Small animal aerosol delivery with a pneumatic 
MicroSprayer® 
2.1 Introduction  
Aerosol delivery to small laboratory animals like mice is a complicated endeavor. Most of these 
animals are nose-breathers which together with the small size of their airways results in poor 
delivery efficiency to the lungs [9]. Aerosol delivery with common nebulization techniques requires 
the use of special equipment like exposure chambers, where a large fraction of the aerosol may 
not be inhaled but deposits on the skin or pelt and may be ingested during grooming [9]. The 
actual dose deposited in the lungs depends on the breathing pattern, aerosol droplet size and 
airway and alveolar dimensions [9]. The exact dose is therefore not easily assessed and may lack 
reproducibility.  
Therefore, instead of inhalation, pulmonary delivery to small animals is often accomplished by 
oro-tracheal (o.t.) instillation of a liquid. This approach is considerably simpler and does not 
require special equipment like inhalers and exposure chambers. Dose delivery is very efficient and 
the administered dose can be precisely controlled and calculated. Large doses can be administered 
in a short timeframe. Instillation can therefore be considered time and material saving. Accidental 
drug ingestion or topical exposure is ruled out. On the other hand, i.t. instillation is non-
physiological and as mentioned above results in non-uniform and patchy drug distribution, which 
is confined to central lung regions [7, 8]. Delivery of large volumes may lead to pooling of liquid  
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Figure VI-1. Differences in particle distribution following an instillation or inhalation exposure, illustrating the 
decreased homogeneity of an instilled dose. Taken from [10]. 
in lung parenchyma [11]. Inhalation is associated with a wider and more homogeneous spatial 
distribution to central and peripheral regions [9] as illustrated in Figure VI-1 [10]. 
An alternative approach to small animal aerosol delivery is i.t. aerosolization. The 
MicroSprayer®, a high pressure syringe with a special needle that generates an aerosol from its 
tip, uses the pressure of manual actuation to creates a coarse aerosol of 15  30µm [12] directly 
in the trachea. This method combines some of the advantages of instillation with those of 
inhalation. Since it involves intubation, a skilled operator is required but otherwise no special 
equipment is necessary. Dosing is reproducible and the precise delivered dose is known. The 
spatial distribution is expected to be more homogeneous compared to instillation but may depend 
on the operator. No detailed investigation of lung deposition and distribution in comparison with 
instillation or nebulization has been reported. Aiming to improve the reproducibility of aerosol 
application and to eliminate the influence of the individual operator, a pneumatic actuator for 
automatic operation of the MicroSprayer® has been developed by the group of O. Schmid (CPC). 
The newly developed actuator is customizable regarding the preset sprayed volume and the 
pneumatic actuation pressure. Additionally, the tip of the MicroSprayer® is held in a fixed 
position during spraying which can reduce the risk of injuring intubated animals by accidental 
movements during actuation. In a first stage, the pneumatic actuator was compared to manual 
operation of the MicroSprayer® in vitro with regard to the aerosol droplet size distribution. In 
subsequent experiments, in vivo lung deposition and spatial distribution were compared after 
instillation, MicroSprayer® aerosolization and vibrating mesh (VM) nebulization. 
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Droplet size profiles after pneumatic actuation did not exhibit the initial decrease observed for 
manual operation but instead generated droplets of very constant diameter throughout the entire 
spraying duration (Figure VI-2 B). The d[v,50] was very reproducible and inversely proportional 
to the pneumatic actuation pressure (Figure VI-2 C). Increasing actuation pressure also shortened 
spray times. Increasing the actuation pressure in steps of 1 bar in a range of 2-8 bar resulted in 
a continuous decrease in VMD from 32µm to 16µm. The observed impact of actuation pressure 
on droplet size may also explain the observed variability of manual actuation, since the manual 
pressure applied is dependent on the operator. The speed and force of pneumatic actuation had 
to be accounted for when setting the actuation distance of the piston, in order to prevent a bold 
collision between the piston and the syringe barrel. This resulted in a volume of 67 µL remaining 
in the MicroSprayer® after pneumatic actuation compared to only 13 µL residual volume after 
manual operation, so that the charged volume had to be adapted accordingly. During manual 
actuation however, the last fraction of loaded solution left the MicroSprayer® as 1-2 large droplets 
instead of an aerosol spray which did not occur with pneumatic actuation.  
According to these in vitro data, the newly designed pneumatic actuator improves the uniformity 
and reproducibility of MicroSprayer® generated aerosols and mitigates individual operator 
impact. It can further be utilized to control the droplet size in a range of 16-32 µm. 
2.3 Impact of the application method on lung distribution and 
deposition in mice 
If and how the effect of pneumatic actuation pressure influences aerosol deposition in vivo was 
subject of the following investigation. Fluorescently labelled SM101 was administered to 
CL57/B6 mice by either i.t. instillation, vented intubated nebulization (IVN) with an Aeroneb® 
Pro VM nebulizer or pneumatically actuated MicroSprayer® (MS) aerosolization, while the latter 
was performed with actuation pressures of either 2.2 or 4.0 bar. Immediately after administration, 
mice were sacrificed, the lungs excised and examined with respect to the deposited lung dose and 
spatial distribution of the administered drug between the lung lobes. Fluorescence detection for 
the five lobes and the trachea was initially performed with an IVIS 100 CCD imaging system. 
To confirm IVIS results, the same lung lobes were subsequently homogenized and the contained 
amount of fluorescent dye determined from the supernatant. Alexa Fluor® 750 was used as a 
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2.3.2 Lobes distribution 
 
For information about the spatial distribution of the administered SM101-Alexa750, the lobes 
were segregated and fluorescence intensity assessed for each lobe individually. Values were 
normalized for lobe mass and the coefficient of variation among the five lobes of each lung 
calculated (Figure VI-4). Unlike lung deposition, the inter-lobal distribution was influenced by 
the actuation pressure of the pneumatic MicroSprayer®. Actuation at 4 bar resulted in a non-
uniform aerosol distribution among the lobes comparable to the situation found for instillation 
with inter-lobe variability in a range of 80-110%. MicroSprayer® actuation at 2.2 bar, on the 
other hand, cut inter-lobe variability by more than half to approximately 40% as consistently 
determined by IVIS and in the homogenate. Inter-lobe variability after IVN was comparable to 
i.t. instillation.  
IVIS scans (Figure VI-5) and individual lobe data after homogenization (Figure VI-6) reveal that 
the high variation coefficients for instillation, 4 bar microspraying and IVN mainly resulted from 
non-uniform distribution in some lungs (Figure VI-6: instillation lung 4; MS 4 bar lungs 1 and 3; 
IVN lungs 2 and 4). In these lungs SM101-Alexa750 was only delivered into the left or the right 
bronchus. As visible in Figure VI-7, the murine lung consists of 5 lobes whereas lobe 1 is the only 
lobe attached to the left bronchus, while lobes 2 to 5 are attached to the right bronchus. IVIS 
scans of lung 3 of MS 4.0 bar and lung 4 of IVN (Figure VI-5 C and D) clearly demonstrate this 
observation. Only lobe 1 exhibited notable fluorescence signals, while lobes 2-5 did not receive 
significant amounts of the dye. These results were confirmed by the distribution data calculated 
from lung homogenate measurements (Figure VI-6). IVIS scans and homogenate data reveal that 
pneumatic microspraying at 2.2 bar resulted in the most homogeneous inter lobe distribution of 
fluorescence intensity of all measured lung samples. 
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translates to droplet velocity. The probability of droplet impaction, the predominant deposition 
mechanism in the prevalent droplet size range, increases with rising velocity (inertial Impaction 
~ d2 * v). High aerosol velocity in combination with a suboptimal, angled position of the MS 
aerosolizer tip inside the trachea could force all aerosol into only one bronchus, resulting in one-
sided distribution as observed for high pressure MS administration. 
After completion of the experiment, malfunctioning of the Aeroneb® Pro nebulizer utilized for 
IVN was noted. The median droplet size was found to range above 8 µm instead of the 5.0 µm 
determined for functioning devices. A significant impact on lung deposition is to be expected, 
since aerosol deposition in the ventilation tubes connecting the nebulizer to the lung will be 
increased for an increased droplet size and less aerosol will leave the distal end of the intubation 
tube and enter the lung. The deposition data determined for IVN in the course of this study are 
therefore considered as too low. In fact, while a deposition of approximately 2% was found (Figure 
VI-3) in this study, experiments with another Aeroneb® Pro resulted in a deposition range of 
10-20% (O. Schmid 2014, personal communication). 
 
Figure VI-7: Allocation of the five lobes of a murine lung into one left lobe and four right lobes. 
2.4 Conclusion 
The comparison of i.t. aerosolization with a MicroSprayer® against plain i.t. instillation showed 
that the MicroSprayer® allows an equally high dosing efficiency, with slightly improved dosing 
reproducibility. Furthermore, the inter-lobe distribution is more uniform after MicroSprayer® 
administration if the actuation pressure is kept below 4 bar. Actuation at 4 bar diminished 
uniformity of distribution to a level found after instillation. Precise control of MS actuation is 
not possible during manual use but can only be ascertained with the newly developed pneumatic 
actuator. Otherwise, no evidence was found of any favorable in vivo effect of droplet size 
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reduction from approximately 32 µm to 20 µm by increasing pneumatic actuation pressure. 
Instead, advantageous distribution after low pressure actuation may be a consequence of the 
resulting slow aerosol velocity.  
Due to malfunctioning of the Aeroneb® Pro used for IVN, the obtained results are no basis for 
valid assumption on the deposition and distribution characteristics of this pulmonary application 
method in murine lungs. A problem observed for i.t. instillation, high pressure microspraying and 
IVN was undesired one-sided drug deposition. It is therefore very important to place the 
intubation tube and the tip of the cannula or aerosolizer in an optimum position in the trachea 
to avoid one-sided pulmonary delivery. The MicroSprayer® is a suitable tool for pulmonary 
administration of liquids, where the exact dosing of instillation and the uniform distribution of 
nebulization have to be combined. 
IVIS results for lung deposition and lobe distribution were essentially identical to the data 
obtained from the lung homogenate. It is an attractive orthogonal method, allowing fast 
generation of pulmonary deposition and distribution data without the need of laborious sample 
preparation that may be a potential source of artifacts, e.g. through deterioration of sensitive 
fluorescent dyes. More research seems vindicated to fully exploit the full potential of the IVIS 
for ex vivo or in vivo imaging of small animal pulmonary drug delivery. 
3 Stability of proteins toward microspraying and low 
volume vibrating mesh nebulization 
3.1 Introduction  
As demonstrated in chapter IV, atomization can cause proteins to denature depending on its 
sensitivity to the encountered stress. It was therefore a necessity to investigate the different 
methods for pulmonary application in mice regarding their impact on the stability of the 
employed proteins. 
For the Arthus disease model, stability after pulmonary delivery has to be assured not only for 
the treatment protein SM101 but also for anti-OVA IgG antibody or OVA antigen in the case 
SM101 in vivo efficacy study 
185 
of the reverse or non-reverse (direct) passive Arthus model respectively. Insufficient stability of 
OVA or anti-OVA IgG may lead to a failure of the disease model. SM101 degradation on the 
other hand, would impact on the results of treatment efficacy. As demonstrated for VM nebulizers 
in chapter IV, protein aggregation may also lead to a failure of the atomization device. 
Analogously, protein aggregates and adsorption may impair proper function of the small orifice 
of the MS.  
While plain i.t. instillation was assumed to cause no significant protein degradation, the 
MicroSprayer® may impact protein stability by detrimental forces like interfacial stress or shear 
stress during mechanical atomization in the aerosol tip and was therefore object of investigation. 
The setup available for aerosol delivery relies on vented intubated nebulization (IVN) and was 
originally built around an Aeroneb® Pro nebulizer but may be customized to integrate different 
VM nebulizers. Three different models were therefore characterized regarding nebulizer 
performance under the operating conditions intended for the in vivo study. The nebulization 
conditions differ in respect to charged volume and nebulization procedure. Instead of reservoir 
overloading and the nebulization of 3-4 mL, volumes as small as 100 µL were charged into the 
reservoir and nebulized completely. Based on aerosol performance, a suitable nebulizer was 
selected to be used for stability testing of SM101, OVA and anti-OVA IgG under these 
nebulization conditions. 
3.2 Choice of a nebulizer for vented intubated nebulization during in 
vivo studies 
Comparison of aerosol characteristics with placebo aerosol formulation showed that VM nebulizer 
models of different manufactures exhibit significantly different aerosol performance, an 
observation already made during previous investigations (Chapter IV). The PARI eFlow® 
generated aerosol at the highest output rate that was more than double that of the Aeroneb® 
Pro or Solo model (Figure VI-8 A). The PARI eFlow® also outperformed the Aeroneb models 
concerning fine particle fraction (FPF), although the difference was less marked (Figure VI-8 B). 
As already elaborated on in chapter IV, the superior aerosol performance of the PARI eFlow® is 
accompanied by significant heating inside the medication reservoir. Heating was less distinct or 
insignificant for the Aeroneb® Pro and Solo respectively (Figure VI-8 C). 
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strength are used instead of PBS. Simply reducing salt content to lower the ionic strength is not 
a viable option though, since salts, in this case sodium chloride, are also important for tonicity 
adjustment. Pulmonary formulations should be isosmotic to avoid airway irritation [18], which 
is especially important considering the large volume of solution delivered to the small murine 
lung. Plain reduction of salt content would render the formulation hypotonic though. A reduction 
of ionic strength must therefore be compensated by tonicity regulation with non-ionic tonicity 
modifiers like sugars or polyols. Alternatively, pulmonary delivery of OVA may easily be achieved 
by i.t. instillation or MS atomization instead of VM nebulization. 
As a consequence, OVA and SM101 may not be used in the same formulation and formulations 
must not be mixed prior to administration since the higher ionic strength (Chapter V.2) and the 
polysorbate 20 content (Chapter V.3) required for SM101 stabilization would provoke OVA 
instability. 
4 In vivo studies of SM101 efficacy 
Based on this preparative work, the feasibility of SM101 efficacy testing with a non-reverse 
pulmonary Arthus disease model was evaluated by O. Schmid and his group at the 
Comprehensive Pneumology Center (CPC, Neuherberg, Germany). The model was based on the 
protocol employed by Skokowa et al. [2] but the delivery route for antigen and antibody were 
interchanged. OVA antigen was administered to the lungs via i.t. instillation, while anti-OVA 
antibody was given systemically via the tail vein. In a preliminary experiment, reverse and non-
reverse Arthus reaction were induced and the impact compared. Therefore, the BALF was 
characterized in terms of total cell number and differential cell count of neutrophils, macrophages 
and lymphocytes as inflammation markers and red blood cell (RBC) counts to determine 
hemorrhage. 
The differential cell count showed a distinct increase in neutrophils content in the BALF for the 
reverse and the non-reverse (direct) disease model (Figure VI-15). The lymphocyte population 
was not affected and the macrophage count was slightly increased after the reversed but not the 
direct model. According to RBC data, both models induce hemorrhage. While the RBC of the 
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Treatment and control group response was assessed from differential cell count of the BALF. As 
in the previous experiment, inflammation was monitored by total cell, macrophage and 
neutrophils cell count and hemorrhage was determined from erythrocyte numbers (Figure VI-16). 
The “positive control” group exhibited an increase in the total cell (TC) count, which was 
significant in respect to the “lung control” but not compared to the “OVA control” group since 
TC was slightly but not significantly increased compared to the home cage control (HCC) and 
lung control (LC) groups. Macrophage count in the “positive control” and the “OVA control” 
group were slightly increased above HCC and LC levels but differences between the groups were 
not significant. In the negative control groups, the vast majority of TC are macrophages as 
expected in normal BALF. The differential neutrophil count was significantly increased for the 
“positive control” group. In the OVA control group a slight yet insignificant rise was observable. 
Confirming the preliminary experiment, an inflammatory response was induced by the immune 
complex in the positive control group. The slight neutrophils increase for the OVA control group 
may indicate some inflammation caused by OVA alone but the fact that endotoxin free OVA 
was used and no neutrophil rise was observable after OVA application in the LC group do not 
support this assumption. SM101 inhalation reduced neutrophil numbers and macrophage counts 
to levels equal or below negative control groups. 
The erythrocyte count suggests that no hemorrhage was induced in the positive control group, 
contradicting findings of the preliminary experiments (Figure VI-15). Instead, the erythrocyte 
count was significantly increased in the treatment group. Notably, no rise in erythrocytes was 
found for the lung control group that received the same dose of SM101 nor in any of the groups 
receiving placebo formulation by IVN. Furthermore, no hemorrhage occurred after reverse Arthus 
reaction treatment with sFcγRIIB by Skokowa et al. The erythrocyte count observed for the 
treatment group was comparable to the number found in the positive control group during an 
antigen and antibody dose finding experiment (Figure VI-17). Due to these observations, 
hemorrhage does not seem to stem from SM101 or the placebo formulation alone. One possibility 
may be tissue rupture related to IVN or subsequent animal preparation. The occurrence and 
accumulation merely in mice of the treatment group would be improbable though or linked to a 
yet unapparent circumstance. In combination with the failed positive control, no statement about 
the effect of SM101 on hemorrhage is legitimate. 
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While the total cell count may represent reasonable relations between the groups, the differential 
neutrophils count in the positive and negative control groups clearly shows that induction of the 
direct pulmonary Arthus reaction failed (Figure VI-18). Neutrophil count in the OVA control 
and especially the lung control group were distinctly increased. In contrast, neutrophils count in 
the positive control group was markedly lower than in these two negative control groups, where 
only an insignificant rise in neutrophils, as observed in the first iteration of the study, was 
expected. Notably though, in absolute numbers the positive control closely matches the results 
of the first experiment. Erythrocyte counts for the positive control and both treatment groups 
were one to two orders of magnitude higher compared to the first experiment. Even the lung 
control group exhibited an erythrocyte count well above the highest count observed in the first 
set of experiments.  
4.1 Conclusion 
Upon evaluation of these results, it had to be concluded that deduction of statements about 
SM101 efficacy or safety were not legitimate with the current data. The proposed protocol failed 
to induce a direct pulmonary Arthus reaction in mice in a reproducible manner. While 
preliminary experiments resulted in the infliction of inflammatory and hemorrhagic response as 
expected for a type III hypersensitivity reaction, in the subsequent study conducted with 
treatment groups, respective controls signaled a failure of either hemorrhagic response (first 
experiment) or inflammation (second experiment). The reasons for failure remain to be 
elucidated. To improve the robustness and reliability of the direct pulmonary Arthus reaction 
model, a detailed characterization of the influence of the different application regimes in direct 
and reverse pulmonary Arthus reaction on physiological processes should be considered in future 
research. 
The apparent difficulties to reproducibly induce a direct pulmonary Arthus reaction may be a 
reason why only one study utilized a comparable direct pulmonary model on rabbits [19], while 
the reverse Arthus reaction, as used by Skokowa et al., is a standard model for pulmonary type 
III hypersensitivity reactions. Alternatively a disease model relying on active sensitization by 
repeated antigen exposure instead of passive sensitization by antibody administration may be 
established for in vivo efficacy testing of SM101.  
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5 Summary 
Work related to SM101 efficacy testing in vivo is presented in this chapter. This included efforts 
to establish an animal disease model suitable for this purpose and the characterization of 
pulmonary delivery methods that may be used for small laboratory animals. 
Comparison of pulmonary application methods demonstrated the benefit a MicroSprayer® can 
offer in small animal studies by combining the efficient delivery of an exact dose of i.t. instillation 
and the uniform aerosol distribution within the lung that more realistically resembles inhalation. 
This merging however, relies on actuation by a well-defined and constant pressure as 
accomplished by the developed pneumatic actuator. 
SM101 efficacy may be studied by treatment of an immune complex (IC) mediated 
hypersensitivity reaction (type III). The pulmonary model of a reverse passive Arthus reaction 
is commonly used to induce such a reaction and has previously been employed to demonstrate 
sFcγRIIB efficacy to prevent inflammation and hemorrhage. However, the setup of the reverse 
model is considered futile in the case of SM101. Due to its mechanism of binding IC by the 
antibodies Fc-part, the rapid consecutive delivery of both the sensitizing antibody and SM101 
by the pulmonary route may lead to premature SM101-IgG binding before IC were formed and 
a hypersensitivity reaction was induced. Therefore, a protocol to induce a more physiologically 
correct, direct (non-reverse) pulmonary Arhus disease in mice was developed. SM101 delivery 
remained by pulmonary route while the antibody was delivered systemically. The stability of 
antigen, antibody and SM101 to the pulmonary delivery procedures employed by either reverse 
or direct Arthus reaction was tested and ascertained. Yet, while inflammation and hemorrhage 
developed as expected in positive control groups during preliminary trials, the disease model 
failed to reliably induce a type III hypersensitivity reaction during consecutive and repeated 
attempts of SM101 efficacy investigation. The study results therefore do not support a legitimate 
statement on SM101 efficacy. The question of SM101 efficacy to treat pulmonary IC mediated 
hypersensitivity reactions could therefore not be conclusively settled within this work. 
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Chapter VII Conclusion and Outlook 
The overall objective of this thesis (Chapter I) was to investigate the suitability of vibrating 
mesh (VM) nebulization for the pulmonary delivery of sensitive pharmaceutical proteins. 
Emphasis was put on the interaction of protein, formulation and device regarding protein 
stability and nebulizer performance. 
This issue derived from literature reports of advantageous properties of VM nebulization for the 
pulmonary delivery of small molecular drugs and the assumption that biopharmaceuticals may 
especially benefit from these improvements. Promising results, however, were so far only available 
for a handful of stable biopharmaceuticals and no comprehensive investigation about the impact 
of VM nebulization on protein stability had been carried out (Chapter II). 
Basic stimulus and motivation for this work was to prove the feasibility of pulmonary delivery 
of stable and active SM101 (a soluble FcγRIIB) by VM nebulization, the development of a 
respective liquid formulation and in vivo efficacy testing. The presented solutions to issues raised 
throughout this quest are also applicable to the nebulization of biopharmaceuticals in general. 
The work conducted in this thesis is therefore a valuable contribution to the field of pulmonary 
protein delivery. 
Materials and methods employed throughout the entire thesis are summarized in Chapter III. 
Chapter IV summarizes work conducted to establish prerequisite tools necessary for a thorough 
investigation of VM nebulization, meaningful protein stability assessment after nebulization and 
the efficient pulmonary delivery of delicate biopharmaceuticals.  
Initially, different VM nebulizers were tested regarding aerosol performance and found that the 
PARI eFlow® outperformed other models in generating aerosols of high respirable fraction at the 
highest output rate. Additionally, the PARI eFlow® did not suffer any performance losses upon 
decreasing surface tension, which was observed for the other tested nebulizers. This is of special 
importance, accounting for the surface activity of many protein molecules and of surfactants  
the most important group of excipients in liquid aerosol formulations. It could be shown that the 
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performance altering impact of viscosity, previously reported for various fluids of less importance 
in protein formulation, does also occur for commonly employed excipients and proteins 
themselves and must be considered in formulation design. 
Besides aerosol performance, protein stability after nebulization is the most critical issue for 
successful pulmonary protein delivery. Since analytical methods rely on a bulk liquid, aerosol 
condensation and collection is a requirement. A comparison of collection methods mentioned in 
literature revealed that essentially all methods have the potential to alter protein stability. 
Protein degradation by collection may thereby be significantly greater than damage by actual 
nebulization. The investigation showed that aerosol collection in small volume reaction caps was 
related to the least protein degradation. It is very important to evaluate the impact of the 
planned collection procedure on protein stability before commencing with a study. 
Significant heating was observed in the medication reservoir during PARI eFlow® operation. The 
resulting thermal stress was shown to be a major cause for the degradation of proteins during 
nebulization. The second major detrimental force identified was interfacial stress by atomization. 
The contribution of thermal degradation was investigated through nebulization at defined 
temperatures, which was accomplished with a newly developed prototype of a micro Peltier 
cooled nebulizer. These investigations also revealed a significant impact of nebulization 
temperature on key aerosol characteristics like droplet size and respirable fraction as well as 
output rate, which is related to the temperature dependence of viscosity. While a shrinking 
droplet size with reduced temperature is advantageous in terms of an increased respirable 
fraction, it is also accompanied by a decrease in output rate. Overall these contrary effects 
compensate, so that a defined drug dose could be delivered to the lungs in a comparable time 
frame but requiring less nominal dose if the nebulization temperature was lowered. Controlling 
the temperature in the medication reservoir is thus not only mandatory for maintaining the 
stability and activity of delicate proteins during VM nebulization, as demonstrated for LDH and 
SM101, but may also pose an attractive approach to improve the efficiency of pulmonary delivery. 
It may be worth to foster the development of the current prototype towards a VM nebulizer with 
fully integrated Peltier cooling. 
Besides the powerful yet elaborate application of Peltier cooling, the temperature in the 
medication reservoir can also be managed by simple and readily available procedures. A 
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combination of overloading the medication reservoir and pre-cooling the solution efficiently 
reduced the reservoir temperature and protected heat sensitive SM101 during VM nebulization. 
This procedure is therefore highly recommended for VM nebulization of sensitive 
biopharmaceuticals. 
Observed throughout this thesis and also reported in literature, protein nebulization often results 
in higher order aggregation. The impact of subvisible proteinaceous particles on the functionality 
of the micron-sized mesh was therefore assessed. A newly developed gravimetrical method for 
time resolved output rate measurement revealed how mesh occlusion by insufficiently stabilized 
proteins impairs nebulizer operation. This emphasizes the importance to assess and reduce protein 
aggregation during VM nebulization by means of formulation and reservoir temperature 
management. Time resolved output rate determination is a valuable tool for early detection of 
beginning mesh occlusion which may also be of interest for the development of particulate 
formulations for VM nebulization. 
Based on the accomplished foundation, development of a liquid protein formulation for VM 
nebulization by a nebulizer specific high-throughput method was explored in Chapter V.  
Initially, a parenteral formulation of SM101 was optimized to contain a fourfold increased protein 
concentration of 20 mg/mL. The failure of this formulation to protect SM101 during VM 
nebulization illustrated that integration of the nebulization process into formulation development 
is an essential requirement. To avoid laborious nebulization trials and conserve valuable 
resources, a high throughput screening method was developed that simulates the stress factors 
of VM nebulization identified in chapter IV. Thermal and interfacial stress was simply generated 
by vigorous agitation in half-filled reaction caps, while incubated at elevated temperatures. 
Agitation time and incubation temperature served to control the amount of stress generated. For 
SM101, settings remarkably resembling actual nebulization conditions allowed the precise 
prediction of the protective properties of a broad range of excipients with various stabilizing 
mechanisms. Notably, a direct match of screening results and actual nebulization required protein 
specific adjustment of screening method parameters. Therefore, universal method parameters 
were proposed that enabled a rapid screening for the three model proteins SM101, LDH and 
G-CSF.  
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The development of a dedicated aerosol formulation for VM nebulization of SM101 was entirely 
based on the newly developed screening method in conjunction with statistical experimental 
design. The main formulation factors determining SM101 stability were the concentrations of the 
surfactant PS20 and of the protein in the formulation. Hence, two lead formulation candidates 
were identified: One candidate (C1) contained the optimum amount of PS20 but conserved 
SM101 concentration to 20 mg/mL, while the other candidate (C2) contained the ideal PS20 
concentration and a reduced SM101 content of 10 mg/mL. Both candidates were finally 
submitted to VM nebulization and the results of the screening thereby fully confirmed. Both 
candidates are a significant improvement compared to the parenteral formulation, whereas C2 
was slightly more stable than C1, enabling efficient nebulization of SM101 without loss of activity 
or aggregation. Despite its reduced SM101 concentration, C2 was therefore designated to be used 
for all further testing of SM101. 
In parallel, SM101 stability in both formulation candidates was also assessed after jet 
nebulization. Despite the absence of thermal stress, the recovered SM101 was less active after jet 
nebulization, emphasizing the eligibility of VM nebulization for sensitive biopharmaceuticals. 
Work related to in vivo testing of SM101 efficacy is summarized in Chapter VI, which included 
efforts to establish an animal disease model suitable for this purpose and the characterization of 
pulmonary delivery methods applicable to small laboratory animals. 
Comparison of pulmonary application methods demonstrated the benefit a MicroSprayer® can 
offer in small animal studies by combining the efficient delivery of an exact dose as by i.t. 
instillation and the uniform aerosol distribution within the lung that more realistically resembles 
inhalation. This merging however relies on actuation by a well-defined and constant pressure as 
accomplished by the developed pneumatic actuator. 
SM101 efficacy may be studied by treatment of an immune complex (IC) mediated 
hypersensitivity reaction (type III). The pulmonary model of a reverse passive Arthus reaction 
is commonly used to induce such a reaction. It has previously been employed to demonstrate 
sFcγRIIB efficacy to prevent inflammation and hemorrhage. However, the setup of the reverse 
model was considered futile in the case of SM101. Due to its mechanism of binding IC by the 
antibodies Fc-part, the rapid consecutive delivery of both the sensitizing antibody and SM101 
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by the pulmonary route may lead to premature SM101-IgG binding, before IC were formed and 
a hypersensitivity reaction was induced. Therefore, a protocol to induce a more physiologically 
correct, direct (non-reverse) pulmonary Arhus reaction in mice was developed. SM101 delivery 
remained by pulmonary route while the antibody was delivered systemically. The stability of 
antigen, antibody and SM101 to the pulmonary delivery procedures employed by either reverse 
or direct Arthus reaction was tested and ascertained. Yet, while inflammation and hemorrhage 
developed as expected in positive control groups during preliminary trials, the disease model 
failed to reliably induce a type III hypersensitivity reaction during consecutive and repeated 
attempts of SM101 efficacy investigation. Therefore, the study results do not support a legitimate 
statement on SM101 efficacy.  
To put it in a nutshell (conclusion), VM nebulization can be considered the preferential means 
of aerosol generation for liquid biopharmaceutical formulations. VM nebulizers have a low impact 
on protein stability and can be recommended for the pulmonary delivery of delicate 
biopharmaceuticals, provided that measures for temperature management inside the medication 
reservoir are adopted where necessary. Furthermore, they allow efficient and fast pulmonary 
delivery of large drug doses, especially when the latest device generation of highly efficient and 
reproducible breath-controlling VM nebulizers are employed.  
While the applicability of VM nebulization for pulmonary delivery of SM101 was demonstrated, 
the question of SM101 efficacy to treat pulmonary IC mediated hypersensitivity reactions could 
not be conclusively settled within the frame of this work and should be the subject of further 
research. Emphasize should be put on the establishment of a robust animal model of a pulmonary 
type III hypersensitivity reaction. While further optimization of the non-reverse passive Arthus 
reaction protocol is an option worth pursuing, an alternative may be the induction of a 
hypersensitivity reaction by active sensitization through repeated antigen exposure.  
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